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CHAPTER 1: INTRODUCTION
1.1

Drug metabolism in the liver and intestine

The liver and the intestines are among the major organs that determine the bioavailability of
xenobiotics and maintain the homeostasis of many endogenous molecules that play important
roles in cell signaling and metabolic pathways. A large portion of the hepatic and intestinal
metabolic capacity is mediated by xenobiotic-metabolizing enzymes that are capable of
detoxifying foreign substances by converting them into hydrophilic metabolites that are excreted
through urine or bile, converting drugs into their pharmacologically active forms, bioactivating
procarcinogens,

and

regulating

physiological

pathways.

The

process

of

drug

metabolism/transport is generally divided into three phases: (1) phase I reactions that introduce
a functional group into their substrates; (2) phase II reactions that conjugate endogenous
molecules onto foreign and endogenous compounds; and (3) phase III reactions that facilitate the
uptake of molecules into cells and efflux of metabolites through drug transporters.
Phase I reactions are mediated by several families of drug-metabolizing enzymes, including
cytochrome P450s (CYPs). CYPs are a major superfamily of phase I drug-metabolizing enzymes
and they are abundantly expressed in the endoplasmic reticulum of the liver and intestines. In
addition to metabolizing a vast number of drugs and environmental chemicals, CYPs can
metabolize a broad range of endogenous molecules, such as steroids (Wang et al., 1997; Lee et
al., 2003) and fatty acids (Capdevila et al., 1981; Schwarz et al., 2004).
Phase II reactions are catalyzed by transferases that are classified into six major families of
conjugation enzymes: (1) UDP glucuronosyltransferases (UGTs), a superfamily of enzymes that
catalyze the transfer of a glucuronic acid molecule from UDP-glucuronic acid to their substrates;
(2) N-acetyltransferases (NATs), a multi-gene family of enzymes that catalyze the transfer of an
acetyl group from acetyl co-enzyme A to their substrates; (3) glutathione S-transferases (GSTs),
a superfamily of enzymes responsible for the transfer of a glutathione molecule from the tripeptide
glutathione to its target molecules; (4) thiopurine S-methyltransferases (TPMTs), an enzyme
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responsible for the transfer of a methyl group from S-adenosylmethionine (SAM) to its target
molecules; (5) catechol O-methyltransferases (COMTs), a class of enzymes that catalyze the
transfer of a methyl group from SAM to its substrates; and (6) cytosolic sulfotransferases (SULTs),
a superfamily of enzymes that catalyze the transfer of a sulfonate group (-SO3) from 3’phosphoadenosine-5’-phosphosulfate (PAPS) to their substrates. Conjugation enzymes are
widely expressed in human tissues, including liver and intestine, and many of these enzymes
exhibit tissue-specific expression patterns (Jancova et al., 2010).
Phase III drug transporters play an essential role in drug absorption, distribution, and excretion.
Drug transporters, including P-glycoprotein (Thiebaut et al., 1987), multidrug resistance proteins
(Mayer et al., 1995; Konig et al., 1999; Fromm et al., 2000), and organic anion transporting
polypeptide 2 (Lu et al., 1996; Abe et al., 1999), are expressed in the liver and intestine and they
act as a barrier that regulates drug influx and efflux, thus providing a path for drugs to be
eliminated.
The liver is thought to be the major contributor to the first pass metabolism because of its
greater weight and CYP microsomal content, compared to the intestine (Lin et al., 1999; Doherty
and Charman, 2002). The hepatocytes are the liver’s major cell type and they are responsible for
90% of hepatic drug disposition. Expression of drug metabolism is heterogeneously distributed
among hepatocytes. The compartmented gene expression results in phenotypic differences
among the cells and the metabolic zonation of the liver. Most genes that are expressed in the liver
have zone-specific expression patterns, which reflects their function in the liver. CYPs are
primarily expressed in the centrilobular zone, whereas phase II enzymes, including UGTs, SULTs,
and GSTs, are expressed in the periportal as well as centrilobular region, suggesting that these
enzymes play an important role in endogenous metabolism (Gebhardt, 1992; Lindros, 1997).
The intestines which are the site of entry for orally ingested nutrients and xenobiotics,
significantly contributes to the first pass metabolism of many of the exogenous molecules that
enter the intestine before reaching the liver, thus preventing the uptake of many of these
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molecules. A variety of enzymes involved in drug metabolism are expressed in the different
segments of the intestine (Ilett et al., 1990; Labroo et al., 1997; Shen et al., 1997; Beyerle et al.,
2015). The expression of phase I and II enzymes is mainly localized in the intestinal mucosal
epithelial cells that are located in the villous tips of the upper small intestine, the duodenum and
jejenum (Ilett et al., 1990). These enzymes are also expressed in the crypts and the lower small
intestine (ileum) and colon, but at a lower concentration (de Waziers et al., 1990).
1.2

Characteristics of human SULT genes

SULTs are ubiquitously expressed in mammalian and other eukaryotic organisms (Coughtrie,
2002). They conjugate a sulfonate group to a wide variety of alcohol, phenol, amine, N-oxide, and
N-hydroxyl substrates, including cholesterol, hormones, neurotransmitters, drugs, and
environmental chemicals (Table 1.1). PAPS, which is the sulfonate donor, is synthesized from an
inorganic sulfate and ATP in a two-step process that is catalyzed by the PAPS synthase enzymes,
PAPSS1 and PAPSS2 (Klaassen and Boles, 1997).
The SULT superfamily contains 13 human genes that are classified into four families based on
their amino acid sequence similarity; SULT1, SULT2, SULT4, and SULT6; and each family is
further divided into subfamilies (Fig. 1.1A) (Blanchard et al., 2004). SULT1 and SULT2 are the
best characterized families in terms of their substrates, tissue-specific expression, and regulation.
The nomenclature and classification of the SULT genes is based on amino acid sequence
similarity, whereby SULTs that share 45% and 60% amino acid sequence are classified into the
same family and subfamily, respectively. However, clustering analysis of global sequence
similarity, local sequence of the substrate-binding site, and catalytic activity profiles demonstrated
that enzymes that are closely related in terms of amino acid sequence do not necessarily have
similar substrate binding sites or substrate specificity, as shown in Fig. 1.1 (Tibbs et al., 2015).
While SULTs within the same family have overlapping substrate specificities, they display
markedly different preferences toward exogenous and endogenous compounds. For example,
although SULT1A1 and SULT1A3 can sulfonate thyroid hormones, SULT1A1 sulfonation capacity
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towards thyroid hormones was greater than that of SULT1A3 (Richard et al., 2001). SULTs can
also have distinct substrate profiles (Table 1.1). Numerous single nucleotide polymorphisms
(SNPs) were detected in the promoter and coding regions of the SULT genes (Iida et al., 2001;
Nowell and Falany, 2006). This is exemplified by the SNPs found in the SULT1A1 gene that were
associated with a lower enzymatic activity and increased risk of breast and colon cancer (Bamber
et al., 2001; Ning et al., 2005; Shatalova et al., 2006). SNPs were also identified in the SULT2A1
gene and they have been implicated with a decrease in the levels of dehydroepiandrosterone
(DHEA) and DHEA-sulfate that could be associated with an increased risk of prostate cancer
knowing that the latter is a precursor for the synthesis of androgens and estrogens (Wilborn et
al., 2006).
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* **

*

**

*

**

Figure 1.1: Relationship between human SULTs.
Clustering analysis of the human SULTs based on (A) global sequence similarity, (B) local
sequence of the substrate binding site, and (C) catalytic activity profiles. * and ** referred to as
SULT1C2 and SULT1C4 throughout the dissertation, respectively.
Figure taken with permission shown in Appendix A (Tibbs et al., 2015).
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Table 1.1: Endogenous and exogenous substrates of human SULT enzymes
Substrates
SULT
gene
Endogenous
Xenobiotics
SULT1A1 Iodothyronines (Kester et al., 1999), 4-methyl
Drugs, chemicals, and dietary compounds:
phenol (Allali-Hassani et al., 2007), estradiol,

p-nitrophenol, m-nitrophenol, p-ethylphenol, p-

catecholestrogens (Adjei and Weinshilboum,

cresol (Wilborn et al., 1993; Brix et al., 1999),

2002; Hui et al., 2008)

oxymorphone, acetominophen, minoxidil
(Tibbs et al., 2015), nalbuphine, nalorphine,
naltrexone (Kurogi et al., 2014)
Procarcinogens: 2,4-dinitrobenzylalcohol, 2acetylamino-4 hydroxylaminotoluene, Nhydroxy-2- acetylamino-3-methyl-5phenylpyridine, 2-hydroxylamino-1-methyl-6phenylimidazo[4,5-b]pyridine (N-OH-PhIP), 2-nitropropane (Glatt,
2000), 2-hydroxymethylcholanthrene
(Banoglu, 2000)

SULT1A2

Estradiol and catecholestrogens (Adjei and

Drugs, chemicals, and dietary compounds:

Weinshilboum, 2002; Hui et al., 2008)

p-nitrophenol (Zhu et al., 1996), naloxone
(Kurogi et al., 2012a), minoxidil, β-naphthol
(Sundaram et al., 1989)
Procarcinogens: N-hydroxy-2acetylaminofluorene (Glatt, 2000)

SULT1A3

Dopamine, norepinephrine (Dajani et al., 1999),

Drugs, chemicals, and dietary compounds:

tyramine (Brix et al., 1999), Iodothyronines

Curcumin, demethoxycurcumin (Lu et al.,

(Kester et al., 1999)

2015)
troglitazone (Honma et al., 2002), morphine,
hydromorphone (Kurogi et al., 2014), Odesmethyltramadol (Rasool et al., 2017)
Procarcinogens: Oxamniquine (Glatt, 2000)

7
SULT1B1

Iodothyronines (Fujita et al., 1999)

Drugs, chemicals, and dietary compounds:
Curcumin (Lu et al., 2015), 3hydroxybenzo[a]pyrene (Wang et al., 2004), 1naphthol (Wang et al., 1998)
Procarcinogens: 6-hydroxymethylbenzo[a]pyrene, 4-hydroxycyclopenta[def ]chrysene
(Glatt, 2000)

SULT1C2

Iodothyronines (Li et al., 2000), Epinephrine,

Drugs, chemicals, and dietary compounds:

norepinephrine, 2-hydroxyestradiol, estrone

p-nitrophenol, 4-nitrophenol, 1-naphthol, 2-

(Allali-Hassani et al., 2007)

naphthol, 4-ethylphenol, 2-n-propylphenol, 2sec-butylphenol, vanillin, resveratrol (AllaliHassani et al., 2007)
Procarcinogens: N-hydroxy-2acetylaminofluorene (Sakakibara et al., 1998)

SULT1C3

Lithocholic acid, a-Zearalenol (Allali-Hassani et

Drugs, chemicals, and dietary compounds:

al., 2007)

1-naphthol, 4-nitrophenol, 2-ethylphenol, 2-npropylphenol, 2-sec-butylphenol, a-zearalenol,
vanillin (Allali-Hassani et al., 2007), 1,2,3,4
tetrahydro 1-naphthol, tolvaptan (Fang JL,
2016)
Procarcinogens: 1-hydroxymethylpyrene,
(+)-1-(a-hydroxyethyl)pyrene, (-)-1-(ahydroxyethyl)pyrene, 6hydroxymethylbenzo[a]pyrene,
6-hydroxymethylanthanthrene, 10hydroxysafrole (Meinl et al., 2008a)
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SULT1C4

Estradiol, estrogen, catechol estrogens (Hui et

Drugs, chemicals, and dietary compounds:

al., 2008), dopamine (Pai et al., 2002), a-

Genistein, daidzein, apigenin, chrysin, 6,4′-

zearalenol, T3, p-Cresol, tyramine, cholesterol,

dihydroxyflavone, BPA (Guidry et al., 2017), 1-

epinephrine, norepinephrine (Allali-Hassani et

naphthol, 2-naphthol, 2-ethylphenol, 4-

al., 2007)

ethylphenol, 4-aminophenol, 2-n-propylphenol,
2-sec-butylphenol, 4-octylphenol, 4-nnonylphenol, vanillin, acetominophen,
resveratrol (Allali-Hassani et al., 2007), Odesmethyltramadol (Rasool et al., 2017),
clioquinol , iodoquinol (Yamamoto et al.,
2016), doxorubicin, epirubicin (Luo et al.,
2016b), Tapentadol (Bairam et al., 2017),
ethanol (Kurogi et al., 2012b), acetaminophen
(Yamamoto et al., 2015)
Procarcinogens: N-hydroxy-2acetylaminofluorene, 2-hydroxylamino-3methyl-9H-pyrido[2,3-b]indole, cigarette
smoke extract components, 5hydroxymethylfurfural, 2,5(bishydroxymethyl)furan, furfuryl alcohol, 5methylfurfuryl alcohol, (+)-10Hydroxymethyleugenol, (-)-10hydroxymethyleugenol, (E)-30hydroxymethylisoeugenol (Runge-Morris and
Kocarek, 2013)
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SULT1E1

Estradiol, estrone, catecholestrogens (Adjei and

Drugs, chemicals, and dietary compounds:

Weinshilboum, 2002), Iodothyronines (Kester et

troglitazone (Honma et al., 2002)

al., 1999), dehydroepiandrosterone,

Procarcinogens: (−)-1-(a-

pregnenolone, ethinylestradiol, and 1-naphthol

Hydroxyethyl)pyrene [(−)-1-HEP], (+)-1-(a-

(Falany et al., 1995)

hydroxyethyl)pyrene[(+)-1-HEP], 1acetylpyrene (Glatt, 2000), 7-OH-7,8,9,10tetrahydrobenzo[a]pyrene, 10-OH-7,8,9,10tetrahydrobenzo[a]pyrene, 1hydroxymethylpyrene,
S-(-)-1-hydroxyethylpyrene (Banoglu, 2000)

SULT2A1

DHEA, bile acids (Falany et al., 1989), Estrone,

Drugs, chemicals, and dietary compounds:

Estradiol, and catecholestrogens (Adjei and

Butorphanol , levorphanol (Kurogi et al.,

Weinshilboum, 2002; Hui et al., 2008)

2014), tibolone (Falany et al., 2004),
budesonide (Meloche et al., 2002), quinolone
drugs (Senggunprai et al., 2009)
Procarcinogens: Hycanthone (Glatt, 2000),
6-hydroxymethylbenzo[a]-pyrene, (R)-(+)-1hydroxyethylpyrene (Banoglu, 2000)

SULT2B1

DHEA (Meloche and Falany, 2001), 25-

None reported

hydroxycholesterol (Bai et al., 2011), estradiol
and catecholestrogens (Adjei and
Weinshilboum, 2002; Hui et al., 2008)
SULT4A1

None reported

None reported

SULT6B1

None reported

None reported
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Table 1.2: Tissue distribution of human SULT mRNA and protein
hSULT
SULT1A1

mRNA

Adult: Skin, kidney, liver, colon, ovary, brain

Protein
Fetal: Liver, lung, kidney, adrenal, small
intestine, brain (Richard et al., 2001; Stanley et
al., 2005)
Adult: Stomach, small intestine, colon, liver,

(Dooley et al., 2000)

lung, kidney, placenta (Stanley et al., 2005;

Fetal: N/A

Teubner et al., 2007; Riches et al., 2009)
SULT1A2

Fetal: N/A

Fetal: N/A

Adult: Liver, ovary, lung, kidney, intestine

Adult: Liver (Teubner et al., 2007)

(Dooley et al., 2000)
SULT1A3

Fetal: N/A

Fetal: Lung, liver, kidney, small intestine, brain
(Richard et al., 2001; Stanley et al., 2005)

Adult: Skin, oral mucosa, liver, lung, ovary,

Adult: Liver, lung, kidney, placenta, stomach,

colon, brain, prostate (Dooley et al., 2000;

small intestine, colon (Richard et al., 2001;

Yalcin et al., 2013)

Stanley et al., 2005; Teubner et al., 2007;
Riches et al., 2009)

SULT1B1

SULT1C2

Fetal: N/A

Fetal: Small intestine (Stanley et al., 2005)

Adult: Liver, kidney, ovary, stomach, small

Adult: Stomach, small intestine, colon, liver,

intestine, colon, brain, blood leukocytes, spleen

lung, kidney, blood leukocytes (Wang et al.,

leukocytes (Wang et al., 1998; Dooley et al.,

1998; Stanley et al., 2005; Teubner et al.,

2000)

2007; Riches et al., 2009)

Fetal: Kidney, liver (Her et al., 1997)

Fetal: Kidney, liver, lung, small intestine (Her et
al., 1997; Stanley et al., 2005)

Adult: Kidney, stomach, thyroid, duodenum,

Adult: Stomach, kidney, thyroid (Her et al.,

colon, rectum, liver, ovary, brain (Dooley et al.,

1997; Teubner et al., 2007)

2000; Bourgine et al., 2012; Hardwick et al.,
2013)
SULT1C3

Fetal: N/A

Fetal: N/A

Adult: Small intestine, colon, rectum (Bourgine

Adult: N/A

et al., 2012; Duniec-Dmuchowski et al., 2014)
SULT1C4

Fetal: Lung, kidney, and heart (Sakakibara et
al., 1998)

Fetal: N/A

11
Adult: Kidney, ovary, spinal cord, colon, and

Adult: N/A

liver (Sakakibara et al., 1998; Bourgine et al.,
2012; Hardwick et al., 2013)
SULT1E1

SULT2A1

Fetal: Liver, thyroid, adrenal gland, lung, kidney,

Fetal: Liver, kidney, lung, thyroid, brain

heart, intestine (Miki et al., 2002)

(Stanley et al., 2005; Duanmu et al., 2006)

Adult: Liver, kidney, brain, stomach, adrenal,

Adult: Liver, lung, colon, small intestine, breast,

lung, intestine, estrogen responsive tissues

endometrium, prostate, testis (Falany et al.,

(Falany et al., 1998; Dooley et al., 2000; Miki et

1998; Miki et al., 2002; Stanley et al., 2005;

al., 2002)

Teubner et al., 2007; Riches et al., 2009)

Fetal: Adrenal (Forbes et al., 1995)

Fetal: Liver and adrenal (Barker et al., 1994;
Stanley et al., 2005; Duanmu et al., 2006)

Adult: Liver, adrenal gland, small intestine

Adult: Adrenal gland, small intestine, liver, lung

(Dooley et al., 2000)

(Tashiro et al., 2000; Teubner et al., 2007;
Riches et al., 2009)

SULT2B1

Fetal: Brain (Falany and Rohn-Glowacki, 2013)

Fetal: Brain (Falany and Rohn-Glowacki, 2013)

Adult: Skin, oral mucosa, prostate, colorectal,

Adult: Prostate, placenta, skin, lung, brain,

placenta, lung, trachea, brain (Her et al., 1998;

breast, endometrium, platelets (He et al., 2005;

Meloche and Falany, 2001; He et al., 2005;

Falany and Rohn-Glowacki, 2013)

Falany and Rohn-Glowacki, 2013)
SULT4A1

Adult: Brain (Liyou et al., 2003)

N/A

SULT6B1

Adult: Testis (Allali-Hassani et al., 2007)

N/A

N/A: stands for not available
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1.2.1 SULT1 family
The SULT1 family includes 9 human SULTs, which are known to sulfonate phenolic compounds.
Members of the SULT1 family have been shown to detoxify a myriad of xenobiotics (Table 1.1).
SULT1A
The SULT1A subfamily contains 4 genes, SULT1A1, SULT1A2, SULT1A3, and SULT1A4,
which are clustered on chromosome 16 (Blanchard et al., 2004). SULT1A1 was the first member
of the subfamily to be identified (Wilborn et al., 1993), and was shown to be one of the most
abundant SULT proteins in the liver and the major SULT1A protein in the human body (Riches et
al., 2009). There are five SULT1A1 transcript variants (TVs) that are indexed in the NCBI
database (to be discussed in chapter 2) that encode two SULT1A1 isoforms: isoform a, which is
made up of 295 amino acids, encoded by TVs 1 to 4; and isoform b, which is made up of 217
amino acids, encoded by TV5. SULT1A1 has a hydrophobic substrate-binding pocket that prefers
to bind uncharged phenolic compounds, especially simple ones like p-nitrophenol. SULT1A1 is
the only SULT1A that is expressed in species other than higher primates, including rodents. This
gene has at least fifteen allelic variants that encode four allozymes, which were detected in the
human population (Raftogianis et al., 1997; Raftogianis et al., 1999).
SULT1A2 was first cloned from a human liver library and was not detected in any other species
(Ozawa et al., 1995). Although SULT1A2 shares more than 93% of its coding sequence with
SULT1A1 and SULT1A3, its sulfonation activity towards some of the preferred SULT1A1 and
SULT1A3 substrates is variable. SULT1A2 has thirteen allelic variants that encode six allozymes,
three of which (allozymes 1 to 3) have different biochemical and physical properties (Raftogianis
et al., 1999).
SULT1A3 and SULT1A4, which were generated by a gene duplication event on chromosome
16, are very closely related genes. SULT1A3/4 genes were only found in humans and other higher
primates and they encode an identical protein that is made up of 295 amino acids despite some
sequence variation at the DNA level. SULT1A3 is primarily expressed in the human intestine and

13
fetal, but not adult, liver (Stanley et al., 2005; Teubner et al., 2007; Riches et al., 2009). The
SULT1A3 substrate-binding site contains acidic residues, and thus prefers positively charged
molecules such as dopamine and other monoamines. SULT1A3 has at least eleven allelic
variants that encode two allozymes (Thomae et al., 2003).
SULT1B
SULT1B1 was first isolated from a human liver library and was classified into the SULT1B
family because of its similarity to rat sult1b1 (74% in the amino acid sequence). SULT1B1, which
is located on chromosome 4, is the major SULT in the small intestine (Riches et al., 2009). Its
coding sequence encodes a protein that is made up of 296 amino acids.
SULT1C
SULT1C subfamily consist of three members; SULT1C2, SULT1C3, and SULT1C4, as well as
a pseudogene, SULT1C2P1; that are located in a cluster on chromosome 2q12 (Freimuth et al.,
2004). In earlier studies SULT1C2 and SULT1C4 were referred to as SULT1C1 and SULT1C2,
respectively (Blanchard et al., 2004). Although SULT1C mRNA was detected in adult tissues, the
expression of these genes is higher in fetal tissues (Her et al., 1997; Sakakibara et al., 1998;
Stanley et al., 2005).
SULT1C2 is the first human member of the SULT1C family to be cloned (Her et al., 1997). It
has two splice variants that encode two full length proteins, SULT1C2a and SULT1C2b, that are
made up of 296 and 307 amino acids, respectively. Although the two SULT1C2 isoforms are 91%
identical, the differences, which are in the intermediate amino acid sequences, could have an
impact on the proteins’ functionality.
There is very little known about the expression, regulation, and substrate specificity of
SULT1C3 enzyme, which was identified through computational analysis of the human genome
and was predicted to have exon duplications that could theoretically produce four splice variants;
SULT1C3a, b, c, and d (Freimuth et al., 2004; Allali-Hassani et al., 2007). Previous studies
screening for the splice variant encoding the “SULT1C3d” isoform containing exons 7b/8b failed
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to detect this transcript in human tissues (Freimuth et al., 2004; Meinl et al., 2008a). However,
SULT1C3a containing exon 7a/8a was detected in human intestinal tissues and LS180 colorectal
adenocarcinoma cells (Duniec-Dmuchowski et al., 2014; Rondini et al., 2014).
The full-length SULT1C4 cDNA was originally cloned and characterized from human fetal lung
(Sakakibara et al., 1998; Freimuth et al., 2000). SULT1C4 has two transcript variants that are
indexed in the GenBank database. The full-length transcript (TV1) encodes SULT1C4 isoform a
that is made up of 302 amino acids, and TV2 encodes isoform b that is made up of 227 amino
acids. The substrate-binding site of SULT1C4 is similar to that of SULT1A1 and SULT1B1, and
thus these three SULTs share many of the same substrates (Dong et al., 2012).
SULT1E1
The SULT1E1 gene is located on chromosome 4 and is only expressed in mammals. Unlike
other SULT1 members, SULT1E1 is primarily involved in sulfonation of endogenous compounds,
especially estrogens (Kester et al., 1999; Adjei and Weinshilboum, 2002; Hui et al., 2008). The
inactivation of estrogen by SULT1E1 reduces the mitogenic effect of estrogen in breast epithelial
cells (Falany et al., 1995) and promotes adipocyte differentiation (Wada et al., 2011). SULT1E1
expression is induced in the homozygous cystic fibrosis transmembrane receptor (CFTR) knockout mouse model as well as a human cholangiocyte–hepatocyte co-culture model, where the
knockdown of the CFTR in the cholangiocytes induced SULT1E1 expression in hepatocytes
(Falany et al., 2009). The only known SULT1E1 transcript encodes a protein that is made up of
294 amino acids.
1.2.2 SULT2 family
This SULT family includes two human genes, SULT2A1 and SULT2B1, that primarily sulfonate
hydroxysteroids and are responsible for regulating cellular functions. Although these two genes
are classified into two subfamilies, they are located in the same region of chromosome 19
suggesting that they are a result of a gene duplication.
SULT2A1
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SULT2A1 was first identified and characterized in adult liver and it was found to be highly active
towards dehydroepiandrosterone (Falany et al., 1989). It is expressed throughout development
and is thought to be involved in steroid biosynthesis during fetal stages (Barker et al., 1994;
Stanley et al., 2005; Duanmu et al., 2006). There is only one SULT2A1 transcript that encodes a
285 amino acid-long protein.
SULT2B1
Two SULT2B1 transcripts, SULT2B1a and SULT2B1b, that are derived from a single gene
were identified and characterized using placental and prostate cDNA (Her et al., 1998). The two
transcript variants, which are generated by alternate splicing of the first exon, encode two isoforms
that are 350 and 365 amino acids long, respectively (Meloche and Falany, 2001). SULT2B1a and
b mRNA is expressed in several human tissues with SULT2B1b mRNA being more abundant
than that of SULT2B1a, but only SULT2B1b protein was detected in human tissues (Falany et al.,
2006). SULT2B1b is involved in regulating various physiological processes in extrahepatic
tissues, where it is predominantly expressed. For example, cholesterol sulfate, which is produced
by SULT2B1b, promotes keratinocyte differentiation (Higashi et al., 2004).
1.2.3 Other SULT families
SULT4A1, the only member of the SULT4 family, is a brain-specific SULT and the most highly
conserved SULT in vertebrates (Falany et al., 2000). Although SULT4A1 was cloned and
characterized in rat, mouse, and human brain almost two decades ago, there are still no known
substrates for this enzyme (Falany et al., 2000; Sakakibara et al., 2002). Several studies linked
SULT4A1 polymorphisms and deletion to neurological disorders, such as schizophrenia (Brennan
and Condra, 2005; Meltzer et al., 2008). SULT4A1 is thought to play a role in neuronal
development because its expression is localized in the neurons and knocking out this gene in
mice resulted in severe neurological symptoms, including tremor, rigidity, seizures, and death
between postnatal days 21 – 25 (Garcia et al., 2018; Hashiguchi et al., 2018). The SULT6B1
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gene, which is located on chromosome 2, was first identified by computational analysis, and
expression profiling studies detected SULT6B1 mRNA in human testis (Freimuth et al., 2004).
1.3

Consequences of sulfonate conjugation in human liver and intestine
Many SULTs are abundantly expressed in the liver and small intestine, and to a lesser extent

in the colon (Teubner et al., 2007; Riches et al., 2009). In these tissues, SULTs can detoxify or
bioactivate their target substrates, modulate the activity of endogenous compounds, or regulate
the biosynthesis of hormones. There is relatively little information about zonal expression of
SULTs in human liver, but in rat liver a SULT that most likely corresponds to SULT1A1 (termed
ASTIV) was highest in centrilobular hepatocytes, where most of the enzymes involved in drug
biotransformation are expressed (Chen et al., 1995). However, STa (corresponding to a SULT2A
protein) expression was highest in periportal hepatocytes (Chen et al., 1995), where a majority of
the expressed genes are involved in cellular metabolism (Lindros, 1997), suggesting that this
protein is primarily involved in the regulation of metabolic pathways. Although SULTs are
considered to be an important line of defense that protects organisms from chemical exposures,
these enzymes can contribute to initiation of carcinogenesis and other diseases by bioactivating
promutagens (Banoglu, 2000).
1.3.1 Detoxification of exogenous molecules
Out of all thirteen SULTs, SULT1A1 and SULT1B1 are the two most active SULTs in hepatic
metabolism of exogenous molecules because of their broad substrate specificities and high
expression levels, together accounting for ~70% of SULT protein content (Coughtrie, 2016).
Although SULT1A1 and SULT1B1 have overlapping substrates, the sulfonation capacity of the
former is greater than the latter. Although SULT1C enzymes have not been studied extensively,
the available information about the substrates of the three SULT1C enzymes indicates that
SULT1C4 has the highest activity towards xenobiotics, and thus this enzyme plays an important
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role in drug and environmental chemical metabolism (Yasuda et al., 2007; Hui et al., 2015;
Yamamoto et al., 2015; Luo et al., 2016a; Luo et al., 2016b).
In the small intestine and colon, SULT1B1 and SULT1A3 are the most abundant SULTs
(Teubner et al., 2007; Riches et al., 2009). SULT1A1 protein is also present at relatively high
levels, but lower than that of SULT1A3 (Teubner et al., 2007). The expression of SULTs in the
intestine was highest in the ileum, compared to the other intestinal segments, and was localized
in the differentiated enterocytes implicating these enzymes in the elimination of bioactive foodborne ingredients (Teubner et al., 2007).
1.3.2 Regulation of physiological metabolism
SULTs regulate the activity and homeostasis of a wide range of small endogenous substrates,
including cholesterol, bile acids, steroids, neurotransmitters, and thyroid hormone. Sulfonated
molecules act as signaling molecules or reservoirs that can regulate biological processes in
various tissues. For example, DHEA-sulfate that is synthesized in the brain is involved in brain
development and functions (Baulieu, 1998; Maninger et al., 2009), whereas the sulfonation of
DHEA in the adrenal gland plays an important role in steroid biosynthesis (Rainey et al., 2002).
Contrary to SULTs, sulfatases are enzymes that hydrolyze the ester bonds to release the
sulfonate group. These enzymes are required to maintain the homeostasis of endogenous
molecules, which are substrates of the SULT enzymes. Since the focus of this dissertation is on
the role of SULTs in liver and intestine, the following are a few examples of endogenous molecules
that are metabolized by SULTs expressed in these tissues:
a. Sulfonation of thyroid hormones
Thyroid hormone is required for normal development and is a major regulator of
metabolism in adults (Mullur et al., 2014). Sulfonation is an important pathway through
which 3,5,3′,5′-tetraiodo-l-thyronine (T4) is irreversibly inactivated by stimulation of inner
ring deiodination (Visser, 1994). However, sulfonated 3,5,3’-triiodothyronine (T3) is a
reservoir for T3 hormone that can be hydrolyzed by tissue sulfatases as needed (Visser,
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1996). The T4 metabolite 3,3′-diiodothyronine (3, 3′-T2), is also extensively metabolized by
SULT enzymes (Richard et al., 2001). SULT1A1, SULT1A3, SULT1B1, SULT1C2, and
SULT1E1, which are expressed in the liver, have been implicated in the sulfonation of
thyroid hormones, including T3 and T4 (Wang et al., 1998; Kester et al., 1999; Li et al.,
2000).
b. Sulfonation of steroids and bile acids
Estrogens play essential roles in regulating cellular metabolism and growth but can also
contribute to carcinogenesis in hormone-sensitive tissues, such as breast and uterus (Zhu
and Conney, 1998; Mauvais-Jarvis et al., 2013). The activity of the estrogen hormone
forms, including the two most biologically active forms, estrone (E1) and 17b-estradiol
(E2), is mediated through the estrogen receptor (ER). The sulfonated estrogens cannot
bind to the ER, and thus they are rendered inactive. Although estrogen sulfonation in
human tissues can be catalyzed by several SULTs, SULT1E1 is the primary enzyme that
can sulfonate estrogens at nanomolar concentrations (Falany et al., 1995). Other steroids,
including DHEA, androgens, and cholesterol, are primarily metabolized by SULT2A1 and
SULT2B1 enzymes that have high sulfonation capacity towards DHEA and cholesterol,
respectively. Since SULT2B1 expression is low in the hepatic and intestinal tissues
(Meloche and Falany, 2001), SULT2A1 is the major enzyme that can conjugate steroids
and bile acids in these tissues, and thus facilitate their excretion through bile (Teubner et
al., 2007; Riches et al., 2009).
1.3.3 Bioactivation of promutagens
The conjugation of a sulfonate provides a good leaving group that generates reactive
intermediates that can interact with DNA, RNA, and protein, inducing cancer and other diseases
(Banoglu, 2000). Watabe et al. was the first study that reported the bioactivation of a
procarcinogen (i.e., 7-hydroxymethyl-12-methylbenz[a]anthracene) by sulfonation (Watabe et al.,
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1982). SULT1 and SULT2 enzymes can bioactivate a wide range of promutagens that include
drugs (e.g., tamoxifen), environmental contaminants (e.g., hydroxymethyl polycyclic aromatic
hydrocarbons and N-hydroxy arylamines), and food-derived procarcinogens (Chou et al., 1995;
Banoglu and King, 2002; Yasuda et al., 2007; Srivastava et al., 2010; Beyerle et al., 2015). For
example, human SULT1A1 and SULT1A2 can bioactivate N-OH-PhIP, which is a very mutagenic
compound that forms while cooking meat (Ozawa et al., 1994). Additionally, SULT1C enzymes
are also capable of bioactivating various phenols, drugs, and procarcinogens, such as N-hydroxy2- acetylaminofluorene (N-OH AAF) and large benzylic alcohols derived from alkylated polycyclic
hydrocarbons (Her et al., 1998; Sakakibara et al., 1998; Meinl et al., 2008a).
1.4

The role of SULTs during liver development

The liver is the largest internal organ, and it performs vital metabolic, endocrine, and exocrine
functions. The xenobiotic-metabolizing capacity of the human liver varies throughout
development. There are xenobiotic-metabolizing enzymes that are expressed during early life and
these likely influence the susceptibility of the developing human to the effects of drugs and
environmental chemicals (Barker et al., 1994; Miki et al., 2002; Duanmu et al., 2006; Hines, 2007;
Sadler et al., 2016) and regulate biological processes, such as steroid biosynthesis and estrogen
and thyroid hormone homeostasis, which are essential during development.
1.4.1 Liver development
The process of liver development is evolutionarily conserved, and it begins during
embryogenesis, when the endoderm and mesoderm layers emerge from a primitive streak. The
endoderm is an uncommitted germ layer that gives rise to a primitive gut tube that is patterned
into three domains: foregut, midgut, and hindgut. Hepatogenesis is initiated in the foregut domain,
where the inhibition of the Wnt and fibroblast growth factor 4 (FGF4) pathways is required to
establish its identity and progenitors. The hepatic mesenchyme, which originates from the
mesoderm, secretes various transcription factors and signaling molecules that promote liver
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development. The secretion of FGFs and bone morphogenetic proteins (BMPs) occurs from the
heart and septum transversum mesenchyme (STM), respectively, and induces hepatic
specification in the ventral foregut endoderm. The hepatic endoderm cells, known as
hepatoblasts, are bipotent progenitor cells that differentiate into two cell types: (1) the
parenchymal cells that are the major cell type (70-80%) in the liver, known as hepatocytes, and
(2) the cells that are localized near the portal vein and are involved in the ductal plate remodeling,
known as biliary epithelial cells (BECs) or cholangiocytes. The hepatoblasts migrate from the
endoderm and invade the STM, thereby triggering liver bud formation. During liver bud growth,
the hepatoblasts begin to differentiate into hepatocytes or BECs, and both cell types differentiate
further during fetal development to reach maturity during the perinatal period. The other liver cell
types, including stromal cells, stellate cells, and Kupffer cells are derived the from mesoderm
(Zorn, 2008).
The expression of xenobiotic-metabolizing enzymes in the fetal liver is localized in the
hematopoietic stem cells (HSCs) and embryonic hepatocytes. Several CYPs, including CYP1A1
and CYP3A5, are expressed at low levels in the HSCs whereas the expression of multiple GSTs,
including GSTM1, M2, M4, and GSTP1, and SULT1A1 was reported to be much higher in the
HSCs (Richard et al., 2001; Shao et al., 2007). However, the expression of many xenobioticmetabolizing enzymes, such as CYP3A7, CYP1A2, and SULT2A1, seems to be restricted to the
fetal hepatocytes (Barker et al., 1994; Shao et al., 2007).
1.4.2 SULT expression profiles during liver development
Experimental and epidemiological studies suggest that exposures to environmental stressors
during prenatal periods can increase the risk for developing diseases, such as cancer and
metabolic syndrome, later in life (Murray et al., 2007; Drake et al., 2010; La Merrill et al., 2013;
Merlo et al., 2014; Shen et al., 2014). The impact of xenobiotic exposures on the developing fetus
is modulated by the detoxification enzymes that are expressed in mother and fetus. Because
many of the xenobiotic-metabolizing enzymes are differentially expressed during liver maturation,
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the metabolic capacity of the fetal liver is different from that of the adult liver. Previous studies
established that xenobiotic-metabolizing enzymes and transporters are differentially expressed
throughout development, and three major patterns of hepatic expression have been described:
(1) class I, where expression is highest in prenatal liver, (2) class II, where expression is relatively
constant from prenatal to adult life, and (3) class III, where expression is highest in adult liver
(Hines, 2013).
The presence of xenobiotic-metabolizing enzymes was detected starting from the first
trimester. For example, CYP3A5 and CYP3A7 protein and activity as well as flavin
monooxygenase 1 (FMO 1) protein were detected starting from week 8 of gestation (Yang et al.,
1994; Lacroix et al., 1997; Koukouritaki et al., 2002; Stevens et al., 2003). However, the
expression of many enzymes involved in xenobiotic metabolism is not well-developed in the
prenatal period compared to the postnatal period (Hines, 2008).
Unlike other families of xenobiotic-metabolizing enzymes, SULTs are widely expressed in
human tissues during development and, therefore, more likely to be responsible for modulating
the effects of chemical exposures and regulating cellular processes in human fetuses. Previous
studies detected SULT expression in the developing liver and demonstrated that some of these
enzymes are preferentially expressed in the fetal stage (Barker et al., 1994; Richard et al., 2001;
Stanley et al., 2005; Duanmu et al., 2006). Using a panel of 235 human liver cytosols prepared
from donors ranging in age from early gestation to 18 years, our lab previously reported that
SULT1E1, 1A1, and 2A1 proteins are expressed with class I, II, and III developmental patterns,
respectively (Duanmu et al., 2006). Additional evidence indicated that SULT1A3, SULT1C2, and
SULT1C4 are also preferentially expressed in fetal liver (Cappiello et al., 1991; Her et al., 1997;
Sakakibara et al., 1998; Stanley et al., 2005). While SULT1B1 appears to be primarily expressed
in adult tissues, SULT1B1 mRNA was detected in several fetal tissues, including small intestine
and liver, and its protein was identified in fetal small intestine only (Stanley et al., 2005; Riches et
al., 2009).
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1.4.3 The beneficial and harmful effects of SULTs in the immature liver
Exposure to environmental stressors during fetal life can cause genomic and/or epigenomic
alterations that lead to disease later in life. The expression of SULTs during vulnerable life stages,
especially early developmental periods, positions these enzymes to be one of the major defense
systems that protect the fetus from xenobiotic exposures by promoting their excretion. However,
many molecules can interact with SULTs as substrates or inhibitors, altering the metabolic
capability of the fetal liver, increasing the mutagenicity of the parent compounds, or perturbing
homeostasis by interfering with the metabolism of endogenous molecules. For example, cigarette
compounds, such as β-naphthylamine, catechol, and caffeic acid, which are sulfonated by
SULT1A1, SULT1A2, SULT1A3, and SULT1C4, reduced the sulfonation capacity of SULT1A1
towards 17b estradiol, thereby disrupting estrogen homeostasis (Yasuda et al., 2007). Sulfonation
of cigarette compounds was also shown to increase the mutagenicity of these compounds, which
could contribute to the initiation of carcinogenesis (Banoglu, 2000; Wang and James, 2006). An
example of a SULT inhibitor is 2,6-dichloro-4-nitrophenol, which can inhibit the activity of
SULT1E1, affecting the state of estrogen and thyroid hormone equilibrium (Wang and James,
2006).
SULTs expressed in fetal liver can metabolize endogenous molecules that have critical
developmental functions. DHEA sulfate, which is generated by SULT2A1 in the fetal liver and
adrenal gland, circulates in the blood and is desulfonated by the sulfatases that are expressed in
the placenta to be used as a precursor for estrogen biosynthesis, indicating that sulfonated DHEA
plays an essential role in regulating estrogen biosynthesis during the prenatal stages (Barker et
al., 1994). Another critical hormone that is regulated by SULTs during fetal development is thyroid
hormone, which is sulfonated by hepatic SULT2A1 (Strott, 2002).
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1.5

Regulation of SULTs by lipid- and xenobiotic-sensing transcription factors in

hepatic and intestinal tissues
Nuclear receptors, which are a superfamily of transcription factors, are known regulators of
genes that play essential roles in regulating cellular processes and xenobiotic metabolism
(Mangelsdorf and Evans, 1995; Urquhart et al., 2007; Runge-Morris and Kocarek, 2009). These
transcription factors can bind as homo- or heterodimers to specific consensus sequences, also
known as response elements, and they are classified into four classes based on their mechanism
of action (Fig. 1.2). Many nuclear receptors are activated by endogenous (e.g., oxysterols, bile
acids, and estrogen) and exogenous compounds (e.g., drugs and environmental toxicants).
Constitutive androstane receptor (CAR), farnesoid X receptor (FXR), liver X receptor (LXR),
peroxisome proliferator-activated receptor alpha, delta, and gamma (PPARa, d, and g), pregnane
X receptor (PXR), and vitamin D receptor (VDR) are lipid- and xenobiotic-sensing nuclear
receptors that form heterodimers with retinoid X receptor (RXR). They were identified as
regulators of many detoxification enzyme systems, including SULTs, in human and rodent tissues
(Runge-Morris, 1997; Assem et al., 2004; Jiang et al., 2005; Alnouti and Klaassen, 2008;
Sueyoshi et al., 2011; Runge-Morris et al., 2013). These nuclear receptors are expressed in
various tissues, including liver and intestine, and they regulate expression of SULTs in a species, tissue-, and gender- (in case of rodents) specific manner (examples will be provided throughout
this section). The mechanisms underlying the regulation of several human SULTs in hepatic and
intestinal cells by CAR, FXR, PPARa, PXR, and VDR were detailed by a number of studies using
animal and human experimental models.
CAR was initially identified as a regulator of CYP2B expression in mouse and human liver
(Honkakoski and Negishi, 1998; Honkakoski et al., 1998; Sueyoshi et al., 1999). Assem et al.
demonstrated that CAR can co-regulate MRP4, an ABC transporter, and SULT2A1 in mouse liver
and human hepatic HepG2 cells (Assem et al., 2004). CAR can regulate murine SULT2A1
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transcription by binding to a FXR, LXR, and PXR response element, which is only found in the 5’flanking region of the rodent SULT2A1 genes (Saini et al., 2004). More recent studies found that
CAR activators induced the expression of several SULTs, including SULT1E1, in rodent, but not
in human, liver (Ding et al., 2006; Alnouti and Klaassen, 2008; Radovic et al., 2010; Ghose et al.,
2011; Sueyoshi et al., 2011; Aleksunes et al., 2012). In colon adenocarcinoma Caco-2 cells,
activated CAR induced SULT2A1 mRNA (Echchgadda et al., 2007). Using chromatin
immunoprecipitation (ChIP) and DNase I footprinting analyses, a composite cis-acting response
element located at nt -131 to -155 and nt -167 to -190 relative to the SULT2A1 transcription start
site that can bind to CAR and a proximal hepatocyte nuclear factor 4α (HNF4α)-binding site
between nt -63 to -35 was identified (Echchgadda et al., 2007).
FXR is a lipid-sensing nuclear receptor that is activated by endogenous molecules, such
as bile acids, and can regulate genes involved in maintaining cholesterol and bile acid
homeostasis (Makishima et al., 1999; Sinal et al., 2000). FXR activation induced the expression
of rat SULT2A1 by binding to a response element located in the 5’-flanking region of the gene,
between nucleotides -169 and -193 (Song et al., 2001). However, chenodeoxycholic (CDCA)mediated FXR activation suppressed SULT2A1 expression in mouse liver and HepG2 cells
(Miyata et al., 2006). FXR was also recently reported to suppress SULT1E1 expression in HepG2
cells by inhibiting the binding of PPARγ coactivator 1α to HNF4α (Wang et al., 2017).
Like FXR, LXR is activated by lipid molecules, primarily sterols, and can regulate similar
physiological functions (Kalaany and Mangelsdorf, 2006). Uppal et al. reported that LXR can
induce SULT2A1 expression in mouse liver by binding to the same FXR and CAR response
element described above, thereby preventing lithocholic acid (LCA) toxicity. LXR activation
induced SULT2A1 expression in primary human hepatocytes and SULT1E1 expression in mouse
liver and HepG2 cells (Gong et al., 2007; Uppal et al., 2007; Falany et al., 2009; Li et al., 2009).
In colorectal adenocarcinoma LS180 cells, ligand-activated LXR upregulated the expression of
SULT1C2 and 1C3 (Rondini et al., 2014).
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The three PPARs, PPARα, PPARδ (also called PPARβ), and PPARγ, regulate essential
cellular pathways, including energy metabolism, lipid metabolism, and inflammation (Seedorf and
Aberle, 2007; Su et al., 2007; Pawlak et al., 2015). While PPARa has been established as a
regulator of xenobiotic-metabolizing enzymes, little is known about the role of PPARδ and PPARγ
in xenobiotic metabolism (Waxman, 1999; Runge-Morris and Kocarek, 2009; Runge-Morris et al.,
2013; Thomas et al., 2013). Rat SULT1E1 protein was decreased in rats fed with PPARa
activators (Fan et al., 2004). Injecting mice intraperitoneally with ciprofibrate (PPARa activator)
suppressed SULT1E1, SULT2A, and SULT1C mRNA in female mice only, but these effects were
not observed in female mice with nullified PPARa expression (Alnouti and Klaassen, 2008;
Aleksunes et al., 2012). We previously reported that PPARa upregulates human, but not rat,
SULT2A1 transcription through a peroxisome proliferator response element (PPRE) in the distal
5’-flanking region of the SULT2A1 gene (Fang et al., 2005). Our recent analysis indicated that
activation of PPARα and PPARγ increased SULT1C3 mRNA in LS180 cells (Rondini et al., 2014).
PXR was initially identified as a xenobiotic-sensing transcription factor that plays an essential
role in the regulation of xenobiotic detoxification enzymes, such as CYP3A4 (Lehmann et al.,
1998). Later studies demonstrated that ligand-activated PXR can also control endogenous
metabolic pathways in the liver (Dussault et al., 2003; Ihunnah et al., 2011). PXR is activated by
secondary bile acids and sterols as well as a variety of exogenous compounds, such as rifampicin
and hyperforin (Lehmann et al., 1998; Moore et al., 2000). Echchgadda et al. initially determined
that PXR activated the transcription of Sult2a1 in mouse livers that were injected intraperitoneally
with pregnenolone 16 α-carbonitrile (PCN), a rodent PXR activator (Echchgadda et al., 2004a).
While feeding mice with LCA suppressed Sult2a1 expression in a PXR-independent manner,
intraperitoneal administration of LCA, which bypasses the gut, induced Sult2a1 through the
activation of PXR (Owen et al., 2010). In human hepatocytes, we identified two PXR-responsive
elements in the SULT2A1 promoter region that are bound by HNFa in the absence of a PXR
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activator (Fang et al., 2007). However, treatment of human primary hepatocytes with rifampicin
suppressed SULT2A1 mRNA by interfering with the positive effect of HNF4a on SULT2A1
transcription (Fang et al., 2007). PXR was also established as a regulator of SULT1E1
transcription in primary human hepatocytes and the hepatocellular carcinoma cell line Huh7
(Kodama et al., 2011). This study revealed that HNF4a enhances the expression of SULT1E1 by
binding to a distal enhancer sequence located between nt -1000 and -901 relative to the
transcription start site of the gene and that ligand-activated PXR targets HNF4a to decrease its
binding to the enhancer sequence, thereby repressing SULT1E1 expression (Kodama et al.,
2011). In contrast, SULT2A1 expression was upregulated by PXR activation in Caco-2 cells, and
this effect was mediated by a response element that can bind PXR and CAR (as mentioned earlier
in this section), located in the SULT2A1 promoter region (Echchgadda et al., 2007). Treatment of
intestinal LS180 cells with rifampicin induced SULT1C2 mRNA and protein and SULT1C3 mRNA
(Rondini et al., 2014).
VDR is involved in the maintenance of calcium and phosphate homeostasis and it also plays
a role in regulating key cellular pathways, including differentiation, proliferation, and inflammation
(Lin and White, 2004). It is activated by the hormone form of vitamin D3 (1α,25-dihydroxyvitamin
D3), secondary bile acids (e.g., LCA), and dietary compounds such as curcumin (Makishima et
al., 2002). The involvement of VDR in regulation of detoxification enzymes was initially
established by multiple studies that identified VDR as a regulator of CYP2 and CYP3 expression
(Schmiedlin-Ren et al., 2001; Thummel et al., 2001; Drocourt et al., 2002; Thompson et al., 2002).
Ligand-activated VDR was also reported to induce the expression of mouse, rat, and human
SULT2A1 in HepG2 and Caco-2 cells and mouse hepatocytes (Echchgadda et al., 2004b). VDR
activation induced rodent Sult2a1 expression by binding to the same response element that is
recognized by CAR, PXR, and FXR (Echchgadda et al., 2004b). In 2006, Song et al. located a
composite response element in the 5’-flanking region of human SULT2A1 that consists of
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VDR/RXR and CAAT/enhancer binding protein (C/EBP) binding sites that mediate the induction
of SULT2A1 by VDR in Caco-2 cells (Song et al., 2006). Rondini et al. recently reported that
SULT1C2 transcription is induced by VDR activation in LS180 cells (Rondini et al., 2014). Barrett
et al. then demonstrated that the inducible effect of VDR on SULT1C2 mRNA is mediated through
a cis-acting VDR response element found ~5 kb upstream of the transcription start site of the
SULT1C2 gene that was identified by computational analysis and was predicted to be a PXRbinding site (Barrett et al., 2016).
Aryl hydrocarbon receptor (AhR) is a xenobiotic-sensing transcription factor that belongs to the
Per Arnt Sim (PAS) domain family and is responsible for activating a battery of genes that control
a broad range of functions, including xenobiotic detoxification as well as cellular proliferation,
differentiation, and apoptosis (Marlowe and Puga, 2005). AhR is activated by exogenous
compounds, most notably halogenated and aromatic compounds such as 2,3,7,8tetrachlorodibenzo-p-dioxin (TCDD) and benzo[a]pyrene, and endogenous molecules, such as
tryptophan metabolites and low-density lipoprotein (McMillan and Bradfield, 2007b; McMillan and
Bradfield, 2007a). In the canonical pathway, AhR forms a complex with the aryl hydrocarbon
receptor nuclear translocator (ARNT) and together they bind to consensus sequences located in
the promoter region of their target genes, such as CYP1A1 (Reyes et al., 1992). AhR activation
was reported to have a suppressive effect on SULT1A1 expression in rat and mouse primary
hepatocytes, and suppressed SULT2A expression in rat hepatocytes only (Runge-Morris and
Kocarek, 2005). TCDD treatment of HepG2 cells and female mice suppressed SULT1E1 mRNA
(Puga et al., 2000).
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Figure 1.2: Mechanisms of action of nuclear receptors.
There are four types of nuclear receptors that are classified based on their mechanism of action.
Type I nuclear receptors (e.g., estrogen receptor) reside in the cytoplasm and/or nucleus and
are associated with chaperone proteins, including heat shock protein 90. The binding of a ligand
(e.g., estrogen) triggers the translocation of the protein complex to the nucleus, where the
chaperone proteins are released and the homodimer is formed. The homodimer will bind to a
specific consensus sequence to induce or suppress the transcription of target genes. Type II
receptors (e.g., thyroid hormone receptor; TR) are found in the nucleus bound to their DNA
consensus sequences as heterodimers with RXR. While some unliganded type II receptors
have no impact on the transcription of their target genes, several others (e.g., TR) can suppress
transcription of target genes by interacting with corepressors (e.g., NCoR and SMRT). After the
binding of a ligand, type II nuclear receptors induce the transcription of the target genes by
interacting with coactivators that have intrinsic histone acetyltransferase activity, such as cyclic
AMP response element binding protein binding protein (CBP) and p300. Type III and type IV
receptors function relatively in the same way as type I receptors. However, type III receptors
recognize a different type of response element (direct instead of inverted repeat) and type IV
receptors (not shown in the figure) bind as monomers to half-site response element.
Figure taken with permission from (Sever and Glass, 2013).

29
1.6

Models of human liver development

Differences in the metabolic capacity of the liver between species have been well-documented,
and these variations are mostly because of differences in the expression and sequences of
xenobiotic-metabolizing enzymes, including SULTs (Honma et al., 2001; Shiratani et al., 2008;
Choughule et al., 2015) . For example, mouse and rat SULT1B1 are very homologous, sharing
87.6% of their amino acid sequence, but human SULT1B1 shares only 72.3% and 74% with the
mouse and rat proteins, respectively (Saeki et al., 1998; Wang et al., 1998). In terms of
expression, rodent SULT1B1 is primarily expressed in the liver, whereas in humans its role
appears to be more prominent in the intestine (Dunn and Klaassen, 1998; Saeki et al., 1998;
Riches et al., 2009). SULT1Cs also exhibit variations in their sequences across species. While,
SULT1C2 shares greater than 90% sequence similarity with its apparent mouse, rat, and rabbit
orthologs human SULT1C3 and SULT1C4 share less than 80% amino acid sequence similarity
with any of the known SULT1C proteins in the three animal species (Runge-Morris and Kocarek,
2013). Inter-species variation in SULT sequences are reflected in differences in the orthologs’
substrate specificities. This is exemplified by SULT1A1, where human SULT1A1 and its
presumed mouse, rat, and rabbit orthologs share 79-85% amino acid sequence similarity and a
preference for sulfonation of phenolic substrates. However, human SULT1A1 has much higher
activity than the animal enzymes toward troglitazone and 2-amino-4’-hydroxy-1-methyl-6henylimidazo[4,5-b]pyridine (Honma et al., 2001). Therefore, the use of human in vitro models
and biospecimens is necessary to understand the role of SULTs in the human liver.
In vitro models have been utilized to study chemical metabolism, mechanisms of toxicity, and
enzyme kinetics (Iwatsubo et al., 1997; Soldatow et al., 2013). These models were also used to
study physiological functions (e.g., proliferation and differentiation of liver cells) and
pathophysiological conditions (e.g., non-alcoholic fatty liver disease) of the liver (Hino et al., 1999;
Rumin et al., 1999; Yalcin et al., 2013). In this dissertation we used hepatic HepaRG cells and
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primary cultures of fetal hepatocytes to examine SULT expression and regulation in immature
and differentiated liver cells.
HepaRG is a widely used human cell line that was derived from an Edmonson grade I
differentiated hepatocellular carcinoma (Martins-Filho et al., 2017). These cells function
essentially as bipotent hepatic progenitor cells that can be differentiated in culture into mature
hepatocyte-like and cholangiocyte-like cells, and they express many of the xenobioticmetabolizing enzymes, transporters, and nuclear receptors that are expressed in normal human
hepatocytes (Aninat et al., 2006; Hoekstra et al., 2013; Laurent et al., 2013). Differentiated
HepaRG cells exhibit characteristics and gene expression profiles similar to those of adult
hepatocytes, whereas proliferating and confluent HepaRG cells behave more like fetal
hepatocytes. For example, CYP3A7 and pyruvate kinase muscle isozyme, which are abundantly
expressed in fetal hepatocytes, are more abundantly expressed in undifferentiated HepaRG cells
while CYP3A4 and CYP2E1, which are preferentially expressed in adult hepatocytes, are more
highly expressed in differentiated HepaRG cells (Tsuji et al., 2014; Bucher et al., 2016). These
cells have been used to study hepatocellular differentiation, xenobiotic metabolism and toxicity,
and development of liver diseases (Sharanek et al., 2015; Nunn et al., 2016; Rodrigues et al.,
2016; Sayyed et al., 2016; Xia et al., 2016).
Cultured fetal hepatocytes are another useful model to examine physiological processes and
xenobiotic metabolism during prenatal periods because they can maintain hepatocyte-like traits,
such as morphology of the cells and gene expression patterns (Carpenter et al., 1996; Lazaro et
al., 2003; Chinnici et al., 2015; Tobita et al., 2016). Several studies demonstrated that xenobioticmetabolizing enzymes that are expressed in the fetal liver, including CYP3A7, CYP3A5, CYP3A4
and CYP2E1, were detected in human and rodent primary fetal hepatocytes (Kremers et al., 1981;
Mathis et al., 1986; Carpenter et al., 1996; Chinnici et al., 2015).
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1.7

Objective of dissertation, hypothesis, and specific aims

The overall objective of this dissertation is to improve our understanding of the physiological
roles of the SULT1 and SULT2 family members in the developing liver as well as adult intestines.
Previous findings published by our lab and other groups indicated that several of the SULTs are
preferentially expressed in prenatal periods and that SULT expression is modulated by lipid- and
xenobiotic-sensing pathways. Based on these reports, we hypothesize that: (1) SULT1 and
SULT2 enzymes have markedly different developmental expression profiles and several of these
enzymes are preferentially expressed in the early stages of human liver development and the
undifferentiated HepaRG cells; (2) SULT1 and SULT2 expression is regulated by lipid- and
xenobiotic-sensing transcription factors in confluent and differentiating HepaRG as well as
primary cultures of fetal hepatocytes; (3) the expression of the SULT1C4 transcript variants varies
throughout human liver development; and (4) SULT1C3 transcription is regulated by PPARg in
human LS180 intestinal cells, and its effect is mediated by a functional PPRE located in the 5’flanking region of the SULT1C3 gene. These hypotheses will be tested by the following specific
aims:
Specific aim 1: Determine the developmental expression patterns of SULT mRNA and protein in
the developing liver.
Specific aim 2: Identify the SULT1C4 transcript variants that are expressed in developing liver.
Specific aim 3: Examine the temporal expression profile of SULT mRNA and protein in confluent
and differentiated HepaRG cells and evaluate the role of lipid- and xenobiotic-sensing
transcription factors in the regulation of SULT mRNA in these two stages.
Specific aim 4: Determine the mechanism underlying the transcriptional regulation of SULT1C3
by PPARg.
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CHAPTER 2: REGULATION OF CYTOSOLIC SULFOTRANSFERASES IN MODELS OF
HUMAN HEPATOCYTE DEVELOPMENT
2.1

Introduction
Cytosolic sulfotransferases (SULTs) are expressed during early life and, therefore,

metabolize endogenous and xenobiotic chemicals during development. Several human SULTs,
including SULT1A1, SULT1A3, SULT1C2, SULT1E1, and SULT2A1, were found to be abundantly
expressed in the early stages of development (Cappiello et al., 1991; Barker et al., 1994; Stanley
et al., 2005; Duanmu et al., 2006; Ekstrom and Rane, 2015), but little is currently known about
the regulation of individual SULTs in the developing human liver. Previous studies demonstrated
that the expression of SULT1 and SULT2 enzymes is regulated by lipid- and xenobiotic-sensing
transcription factors (discussed in chapter 1.4). In this study we (1) examined the expression of
SULT1 and SULT2 enzymes in primary cultures of human fetal hepatocytes and the HepaRG
model of liver cell differentiation, (2) investigated the role of AhR, CAR, FXR, LXR, PPARa,
PPARg, PXR, and VDR in the regulation of the SULT1 and SULT2 mRNA in human fetal
hepatocytes as well as confluent and differentiating HepaRG cells, (3) studied the role of AhR
signaling in regulating the expression of SULT1C2, SULT1C4, SULT1E1, SULT2A1, CYP3A4,
and CYP3A7 during hepatocyte differentiation, (4) examined the mechanism underlying the
regulation of SULT1C4 by LXR, PXR, and VDR.
2.2

Materials and Methods

Materials: Cell culture media and supplements (except insulin) and Lipofectamine 2000 were
purchased from Invitrogen (Carlsbad, CA). Human recombinant insulin (Novolin R) was
purchased from Novo Nordisk Pharmaceuticals, Inc. (Princeton, NJ). 3-[2-[2-Chloro-4-[[3-(2,6dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl]ethenyl]benzoic acid (GW4064,
purity ³ 97%) and 2-[[4-[2-[[(cyclohexylamino)carbonyl](4 cyclohexylbutyl)amino]ethyl]phenyl]
thio]-2-methylpropanoic acid (GW7647, purity ³ 99%) were purchased from Tocris Biosciences
(Minneapolis, MN). Chenodeoxycholate (CDCA, purity ³ 97%), 6-(4-chlorophenyl)imidazo[2,1-
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b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime (CITCO, purity ³ 98%), rosiglitazone
(purity ³ 98%), rifampicin (purity ³ 97%), 1α,25-dihydroxyvitamin D3 (VitD3, purity ³ 99%), 3-[3[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]

benzeneacetic

acid hydrochloride (GW3965, purity ³ 98%), and dimethyl sulfoxide (DMSO) were purchased from
Sigma-Aldrich (St. Louis, MO), and 2,3,7,8- tetrachlorodibenzo-p-dioxin (TCDD, purity ~98%) was
purchased from Midwest Research Institute (Kansas City, MO). Targets of these drugs is listed in
Appendix E. Oligonucleotides were purchased from Integrated DNA Technologies (IDT,
Coralville, IA). Other materials were obtained from the sources indicated below.
HepaRG culture and treatments: HepaRG cells were obtained from Biopredic International under
a Material Transfer Agreement with INSERM-Transfert (Paris, France). Cells were plated into 6well plates at a density of 250,000 cells/well in growth medium consisting of Williams’ Medium E
(WME) supplemented with 10% fetal bovine serum (FBS), 5 μg/ml insulin, 0.1 µM triamcinolone
acetonide, 100 U/ml penicillin, and 100 μg/ml streptomycin. Fourteen days after plating, the
medium was changed to differentiation medium, consisting of growth medium with 2% DMSO,
and the cells were incubated for 14 more days, with medium replenishment every 2-3 days.
Differentiated HepaRG cells were then incubated in treatment medium, consisting of growth
medium with 2% FBS but without DMSO, 72 hours prior to treatment. Confluent (10 days postplating) and differentiated (after 72-hour incubation with treatment medium) HepaRG cells were
treated with vehicle (0.1% DMSO or 0.1% ethanol) or a transcription factor activator for 48 hours
at the concentrations indicated in the figure legends (treatments were renewed after 24 hours).
The concentrations used for the various agonists were selected based on previous
demonstrations that these concentrations produce optimal regulation of known target genes as
well as some of the SULTs (Fang et al., 2007; Rondini et al., 2014; Barrett et al., 2016; Dubaisi
et al., 2016).
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AhR knockout (KO) HepaRG cells were purchased from Sigma-Aldrich. Around 250,000
AhR KO cells were plated in 6-well plates and maintained in the same media used with the wildtype (WT) HepaRG cells.
Primary human fetal hepatocyte culture and treatments: Experiments with human fetal
hepatocytes were done in collaboration with Dr. Alejandro Soto-Gutierrez from the University of
Pittsburgh. De-identified tissues were obtained from Magee Women’s Hospital (Pittsburgh, PA)
and the University of Washington Department of Pediatrics, Division of Genetic Medicine,
Laboratory of Developmental Biology (Seattle, WA) after obtaining written informed consent by a
protocol approved by the Human Research Review Committee of the University of Pittsburgh
(Honest broker approval number HB015 and HB000836). Human fetal hepatocytes were isolated
from fetal livers obtained after the termination of pregnancy performed at 12–22 weeks of
gestation (Appendix D). Primary human fetal hepatocytes were isolated by digesting the tissue in
Eagle’s Minimum Essential Medium (Lonza, Walkersville, MD) containing 0.5 mg/ml of
collagenase (Type XI, Sigma-Aldrich) on a laboratory shaker for 40 minutes. Viability was
assessed by trypan blue exclusion and was routinely >85%. Hepatocytes were plated at a density
of 130,000 cells/cm2 on type I rat tail collagen-coated 12-well plates (Corning, Corning, NY). Cells
were cultured overnight with Dulbecco’s Modified Eagle Medium (Life Technologies, Carlsbad,
CA) containing 100 U/ml penicillin, 100 μg/ml streptomycin, 0.1 µM insulin (Sigma-Aldrich), and
5% bovine serum albumin (Life Technologies). Hepatocytes were then treated with vehicle (0.1%
DMSO or 0.1% ethanol) or a transcription factor activator for 48 hours as indicated in the legend
to Fig. 2.3 (treatments were renewed after 24 hours).
Human intestinal organoids (HIOs): These organoids were generated from pluripotent stem cells
as described previously (McCracken et al., 2011). Briefly, H9 embryonic stem cells (ESCs; Wicell
International Stem Cell Bank, Wicell Research Institute) were grown in feeder free conditions on
hESC-qualified, matrigel-coated nunclon delta surface 6-well plates and incubated at 5% CO2 and
37°C. Cells were passaged onto new plates every 4–5 days using dispase (1mg/mL) and treated
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with Activin A (R&D Systems) for 3 days to generate endoderm. To promote the patterning of the
endoderm into CDX2+ that spontaneously form floating, 3-dimensional aggregates called
spheroids, FGF4 (R&D Systems) and Chir99021 (STEMGENT), a Wnt agonist used in place of
recombinant Wnt3a, were added to the medium. Spheroids were collected and plated into
droplets of Matrigel (BD Biosciences/Corning), a laminin-rich basement membrane complex.
Spheroids were cultured in media containing EGF (100ng/mL, R&D Systems), R-Spondin 2, and
Noggin (100ng/mL, R&D Systems) for 1 week and then in media containing only EGF and RSpondin 2 as they grew into HIOs.
RNA isolation and analysis: Total RNA was isolated from HepaRG cells, freshly isolated and
cultured human fetal hepatocytes using the Purelink RNA Mini Kit (Life Technologies). RNA was
also isolated from the ESCs, definitive endoderms (DE), hindgut (HG; treated with FGF for 4 and
6 days), and HIOs using the same kit. RNA levels were quantified using the TaqMan Gene
Expression Assays (listed in Appendix F) from Life Technologies. In each PCR reaction a 2 μl of
diluted cDNA (1:2), a TaqMan probe with a FAM or VIC dye label on the 5’ end and minor groove
binder (MGB), and Universal PCR Master Mix (Applied Biosystems, Foster City, CA). The reaction
was performed using the StepOnePlus Real-Time PCR System (Applied Biosystems). Standard
thermocycling parameters were 94°C for 10 minutes, and 40 cycles of 95°C for 15 seconds and
60°C for 1 minute. Data were normalized to a reference gene (indicated in the legend of each
figure) and to the mean ΔCT of the control (both are indicated in the figure legends) to calculate
ΔCT and ΔΔCT, respectively, and then the 2−ΔΔCT method was used to quantify the relative
changes in gene expression (Livak and Schmittgen, 2001).
Western blot analysis: HepaRG cells were plated into 6-well plates at a density of 250,000 cells
per well and harvested after 5, 9, 14, 19, 26, or 30 days for preparation of whole cell lysates, as
previously described (Rondini et al., 2014). Protein concentrations were determined using the
BCA Protein Assay Kit (ThermoFisher Scientific, Waltham, MA). Proteins (20-30 μg) were
resolved on 12.5% sodium dodecyl sulfate-polyacrylamide gels, transferred onto polyvinylidene
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difluoride membranes, and incubated for one hour with blocking buffer [2.5% non-fat dry milk in
Tris-buffered saline with 0.1% Tween 20 (Sigma-Aldrich)]. The membranes were then incubated
overnight at 4°C with mouse monoclonal anti-SULT1C2 (clone OTI5A4; Origene, Rockville, MD)
diluted 1:5,000, anti-SULT1E1 (clone E-12; Santa Cruz Biotechnology, Dallas, TX) diluted
1:2,000, or anti-SULT2A1 (clone OTI4D7; Origene) diluted 1:5,000. SULT1C2 and SULT2A1
antibodies detect only the human SULTs whereas SULT1E1 antibody can detect the human,
mouse, and rat SULTs. Membranes were then incubated with horseradish peroxidase-conjugated
goat anti-mouse IgG (sc-2005; Santa Cruz Biotechnology) diluted 1:20,000 (for membranes
probed with anti-SULT1E1 or anti-SULT2A1) or 1:25,000 (for membranes probed with antiSULT1C2). Enhanced chemiluminescence and a FluorChem E detection system (ProteinSimple,
San Jose, CA) were used to visualize the immunoreactive bands. The blots were then incubated
in stripping buffer (60 mM Tris-HCl, 70 mM sodium dodecyl sulfate, and 100 mM βmercaptoethanol) at 37°C to remove the antibodies and re-probed with b-actin antibody (clone
AC15; Sigma-Aldrich) diluted 1:40,000 followed by horseradish peroxidase-conjugated goat antimouse IgG diluted 1:100,000. Band densities were quantified with ImageJ32 software (Schneider
et al., 2012).
RACE analysis: This analysis was performed using the SMARTer RACE 5’/3’ kit (Takara Bio USA
Inc., Mountain View, CA) and RACE-ready cDNA that was prepared from RNA of Caco-2 and
HepaRG cells. A SULT1C4-specific reverse primer was designed for the 5’-RACE analysis
(Appendix G). The PCR reactions were run on a 0.8% agarose gel and the bands were recovered
and ligated into the pGEM-T Easy plasmid (Promega Corporation, Madison, WI). Individual clones
were sequenced at the Wayne State University Applied Genomics Technology Center.
Preparation of SULT1C4 reporter plasmids: Genomic DNA was isolated from MCF10A human
breast epithelial cells using the DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA). Genomic
DNA (100 ng), primer sets predicted to amplify ~2.2 Kb (nucleotides -1890:+350) and ~0.3 Kb
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(nucleotides -290:+53) fragments containing the core promoter, and the HotStarTaq DNA
polymerase from Qiagen were used to PCR amplify two fragments from the SULT1C4 5’-flanking
region. These fragments were ligated into the XhoI and HindIII site of the promoterless
pGL4.10[luc2] firefly luciferase reporter plasmid (Promega Corporation, Madison, WI). The
reporter plasmid containing the 0.3 Kb fragment was used as the backbone to prepare a series
of reporters (A through I) that each contain ~ 2 Kb (A, B, E, F, G, H, I) or ~ 1 Kb (C and D)
fragments from the SULT1C4 5’-flanking region starting from nt -1630 up until nt -15,174 (a
schematic representation of these fragments is shown in Fig 2.11A). The fragments were
amplified by PCR from genomic DNA and inserted into the KpnI and XhoI sites upstream of
SULT1C4 core-promoter fragment in the pGL4.10 vector using the In-Fusion HD Cloning Kit
(Clonetech, Mountain View, CA). All primer sequences are listed in Appendix G. The sequences
of all SULT1C4 clones were confirmed using the services of the Applied Genomics Technology
Center at Wayne State University.
HepG2 culture: HepG2 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin,
and non-essential amino acid mix (all purchased from Life Technologies, Grand Island, NY). Cells
were incubated in a humidified atmosphere of 95% air, 5% CO2 at 37°C.
Transient transfection analysis and treatments: Approximately 100,000 HepaRG cells/ well were
plated in 12-well plates and maintained in 1 ml of supplemented WME. At day 9 post-seeding
cells were transfected with a complex containing 4μl Lipofectamine 2000, 1.6μg of a firefly
luciferase reporter containing one of SULT1C4 fragments (shown in Fig. 2.11A), and 1ng pRLCMV (Promega) per well diluted in 400μl Opti-MEM (Life Technologies). To transiently transfect
HepG2 cells, around 250,000 cells were plated in 12-well plates and maintained in 1 ml of
supplemented DMEM. 24-48 hours post-plating, cells were transfected with the same complex
used when transfecting HepaRG cells. 1 ng of PXR-pSG5 (provided by Dr. Steven Kliewer,
University of Texas Southwestern, Dallas, TX) or VDR-pcDNA3.1 (Barrett et al., 2016) expression
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plasmids were cotransfected into HepG2 cells when evaluating the effect of PXR or VDR,
respectively, on SULT1C4 transcription. Luciferase reporters containing LXR-responsive element
(LXRE) , PXR-responsive regions (referred to as xenobiotic-responsive enhancer module, XREM;
provided by Dr. Bryan Goodwin, GlaxoSmithKline, Research Triangle Park, NC), or VDRresponsive element (VDRE) that are located in the promoter region of SREBP1c (Barrett et al.,
2013), CYP3A4 (Goodwin et al., 1999), or SULT1C2 gene (Barrett et al., 2016), respectively,
were used as positive controls. 24 Hours after transfection of HepaRG and HepG2 cells, fresh
supplemented medium was added containing either DMSO (0.1% final concentration), GW3965
(10 µM), rifampicin (10 µM), or VitD3 (0.1 µM). Treatment medium was changed after 24 hours.
Cells were lysed and collected after 48 hours of treatment, and firefly and Renilla luciferase
activities were measured using the Dual-Luciferase Reporter Assay System (Promega) and a
Glomax Luminometer (Promega). For each sample, the firefly luciferase value was normalized to
the corresponding Renilla luciferase value.
Statistical analysis: All experiments, except where indicated in the figure legends, were repeated
at least three times. Gene expression data are presented as means ± SEM (with three or more
independent experiments) or range (with two independent experiments) relative to control.
Statistical analyses were performed using Prism (version 6; GraphPad, La Jolla, CA). Data were
analyzed using two-tailed unpaired t-tests or one- or two-way analysis of variance followed by
Tukey’s post hoc test, with p<0.05 considered significantly different.
2.3
2.3.1

Results
Expression and regulation of SULTs in primary cultures of human fetal hepatocytes. To

study the regulation of SULTs in a model of human fetal liver, hepatocytes were isolated from five
fetal livers, placed into primary culture, and then treated for 48 hours with a vehicle (0.1% DMSO
or 0.1% ethanol) or panel of nuclear receptor activators. SULT mRNA levels were then measured,
together with CYP3A7 and CYP3A4 for comparison, since these genes are well-known to be
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predominantly expressed in fetal or adult liver, respectively. Because several SULT1A1 transcript
variants (TVs) have been described (5 confirmed mRNAs, NCBI SULT1A1 UniGene Hs.567342),
we used two different TaqMan Gene Expression Assays to measure TV1 separately, since this
variant is described as being most abundant, and TV5 separately, since the transcription start site
of this variant is distinct from that of TVs 1-4 (i.e., more than 10 Kb upstream). The mRNA levels
measured in the DMSO-treated hepatocytes were considered as estimates of basal expression.
As expected, CYP3A7 was highly expressed [as estimated by cycle threshold (Ct) values] in the
cultured fetal hepatocytes (Ct= 23.6) while CYP3A4 expression was minimal (Ct= 32.7) (Fig. 2.1).
Of the SULTs, SULT1C4 was most highly expressed (Ct= 25.9), followed by SULT1E1 (Ct= 26.4),
while SULT1A1 TV1 (Ct= 28.2), SULT2A1 (Ct= 28.4), and SULT1C2 (Ct= 28.6) mRNA levels were
somewhat lower but still readily detectable. SULT1A1 TV5 (Ct= 35.8), SULT1B1 (Ct= 30.7),
SULT1C3 (Ct= 36.6), and SULT2B1 (Ct= 32.6) mRNA levels were low or barely detectable (Fig.
2.1). To evaluate the impact of placing freshly isolated human fetal hepatocytes into primary
culture on SULT expression, the ratios of the mRNA levels in cultured relative to freshly isolated
hepatocytes were calculated. Culturing the fetal hepatocytes reduced the expression of SULT1C2
(by 82%), SULT1E1 (92%), and SULT2A1 (94%) but increased the expression of SULT1A1-TV5
(3-fold), SULT1B1 (14-fold), and SULT2B1 (6-fold) (Fig. 2.2). CYP3A7 and CYP3A4 expression
was also decreased by primary culture, by approximately 91% and 38%, respectively (Fig. 2.2).
Treatment of the human fetal hepatocyte cultures with a panel of nuclear receptor
activators produced several effects that were reproducibly seen across the five preparations.
Treatment with the LXR agonist GW3965 (10 μM) significantly increased the amount of SULT1A1
TV5 by an average of 7.2-fold (relative to DMSO-treated control) and treatment with the VDR
agonist VitD3 (0.1 μM) significantly increased SULT1C2 and SULT2B1 mRNA content by an
average of 2.2-fold and 2.0-fold, respectively (relative to ethanol-treated control). VitD3 treatment
also increased CYP3A4 and CYP3A7 mRNA levels (by 2.7- and 2.9-fold, respectively). While not
significant, treatment with the PPARα agonist GW7647 (10 μM) or PPARγ agonist rosiglitazone
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(1 μM) increased the amount of SULT2A1 mRNA by 1.9-fold, while treatment with the FXR agonist
GW4064 (10 μM) decreased SULT2A1, CYP3A4, and CYP3A7 mRNA levels (by 78 to 85%).
None of the treatments produced clear changes in the levels of SULT1A1 TV1, SULT1B1,
SULT1C4, or SULT1E1 mRNA (Fig 2.3).
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Figure 2.1: SULT, CYP3A4, and CYP3A7 expression in primary cultured human fetal
hepatocytes.
Freshly isolated hepatocytes from five fetal livers were incubated in medium containing 0.1%
DMSO for 48 hr, after which the cells were harvested and SULT, CYP3A4, CYP3A7, and
GAPDH (used as normalization gene) mRNA levels were measured using TaqMan Gene
Expression Assays. Each bar represents the mean relative mRNA level ± SEM for the five
independent experiments compared to SULT1C4, which had the highest expression of the
SULTs. Relative CYP3A4 and 3A7 mRNA levels are shown for comparison.
Figure taken with permission from (Dubaisi et al., 2018).
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Figure 2.2: Effects of placing freshly isolated human fetal hepatocytes into primary
culture on SULT, CYP3A4, and CYP3A7 expression.
mRNA levels from three preparations of freshly isolated fetal hepatocytes and the
corresponding DMSO-treated primary cultured fetal hepatocytes were measured using TaqMan
Gene Expression Assays. mRNA levels were normalized to 18S RNA and are expressed as
ratios of the mRNA levels in cultured to uncultured hepatocytes.
Figure taken with permission from (Dubaisi et al., 2018).
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Figure 2.3: Effects of nuclear receptor agonists on SULT, CYP3A4, and CYP3A7
expression in primary cultured human fetal hepatocytes.
Freshly isolated hepatocytes from five fetal livers were incubated in medium containing 0.1%
DMSO, 0.1% ethanol (EtOH), 10 μM rifampicin (Rif), 10 μM GW3965, 10 μM GW4064, 10 μM
GW7647, 1 μM rosiglitazone (Rosi), or 0.1 μM VitD3 for 48 hr, after which the cells were
harvested and SULT, CYP3A4, CYP3A7, and GAPDH (used as normalization gene) mRNA
levels were measured. Each bar represents the mean relative mRNA level ± SEM compared to
control (0.1% ethanol for VitD3; 0.1% DMSO for other agonists) for the five independent
experiments. *Significantly different from control, p< 0.05.
Figure taken with permission from (Dubaisi et al., 2018).
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2.3.2 Temporal expression of SULTs in HepaRG cells. The approximately one-month protocol for
converting proliferating cultures of HepaRG cells into a mixed population of hepatocyte-like and
cholangiocyte-like cells consists of growing the cells to confluency, maintaining them at
confluency for several more days, and then incubating them in DMSO-containing medium (Fig.
2.4A). To characterize the temporal expression of the SULTs in HepaRG cells as they progressed
through the differentiation process, cells were plated and then harvested every 2-3 days for mRNA
measurements (Fig. 2.4B). Again, CYP3A4 and CYP3A7 mRNA levels were measured for
comparison. CYP3A4 expression was low in the proliferating cultures, increased somewhat during
the confluent phase, and then further increased during the differentiation phase (Fig. 2.4B). By
comparison, CYP3A7 expression was highest during the confluent phase and then decreased
during the differentiation phase (Fig. 2.4B). The SULT2A1 expression profile was comparable to
that for CYP3A4, with highest expression occurring in the differentiated cells (Fig. 2.4B). Most of
the other SULTs were expressed with patterns resembling those for CYP3A7 (i.e., SULT1B1,
SULT1C2, SULT1C3, SULT1C4, and SULT1E1), where expression was highest in the confluent
cultures and then reduced in the differentiated cultures (Fig. 2.4B). The expression of SULT1A1
transcripts and SULT2B1 did not vary
markedly throughout the differentiation process (Fig. 2.4B). SULT1A1 TV1 mRNA was abundant,
while SULT1A1 TV5 and SULT2B1 mRNAs were low.
The protein levels for three of the SULTs (SULT1C2, SULT1E1, and SULT2A1) showing
the two major expression patterns that were observed at the mRNA level were also measured at
several time points. Consistent with the patterns observed at the mRNA level, SULT1C2 and
SULT1E1 protein contents were highest in the confluent cells and then decreased after
differentiation was induced by DMSO, while SULT2A1 protein reached its highest level in the
differentiated HepaRG cells (Fig. 2.5).
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Figure 2.4: Temporal expression of SULTs, CYP3A4, and CYP3A7 in HepaRG cells.
(A) HepaRG differentiation protocol showing proliferating, confluent, and differentiated phases
and times when treatments were begun. (B) HepaRG cells were plated (day 0) and harvested
on the indicated days for measurement of mRNA levels. mRNA levels were normalized to the
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levels measured on day two (i.e., first harvest day). The data show the expression patterns of
eight cytosolic SULTs as well as CYP3A4 and CYP3A7 from the proliferative to the confluent
phase (open bars) and then through the differentiation phase (gray bars). The cycle threshold
(Ct) values for the various genes measured on day 14 (i.e., time of highest expression for
several of the genes) are shown on the graphs as estimations of their relative expression levels.
Data were normalized to GAPDH and are shown as means ± SEM from three independent
experiments. *Significantly different from day 14 mRNA level, p<0.05.
Figure taken with permission from (Dubaisi et al., 2018).
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Figure 2.5: SULT1C2, SULT1E1, and SULT2A1 immunoreactive protein levels in HepaRG
cells harvested at different time points.
HepaRG cells were plated (day 0) and harvested on the indicated days for measurement of
SULT1C2, SULT1E1, and SULT2A1 protein levels by Western blot analysis. b-actin was used
as the loading control. The images shown are from one representative experiment. For each
protein, the last lane contains a standard consisting of whole cell lysate prepared from SULT
cDNA-transfected HEK293 cells (EV, empty vector-transfected HEK293 cells). Band densities
were quantified using image J, and data are shown normalized to the protein levels measured at
day 5. Each bar represents the mean ± SEM from three independent experiments. *Significantly
different from day 14 (P< 0.05).
Figure taken with permission from (Dubaisi et al., 2018).
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2.3.3 Temporal expression of SULTs in a model of intestinal development. We examined the
temporal expression of SULT mRNA at different time points during the process of differentiating
ESCs into HIOs, which mimic fetal intestinal cells (Finkbeiner et al., 2015). Most SULTs, including
SULT1B1, SULT1C2, SULT1C4, SULT1E1. SULT2A1, and SULT2B1 mRNA was readily
detectable in the HIOs (Appendix H). In addition, SULT1C2, SULT1C4, and SULT2B1 expression
was readily detectable in the ESCs and increased during the differentiation process (Appendix
H).
2.3.4 Effects of lipid- and xenobiotic-sensing receptor activators on SULT expression in HepaRG
cells. To identify nuclear signaling pathways that regulate SULT expression in the HepaRG model
of human liver cell differentiation, cells were treated for 48 hours with activators of the AhR and
several lipid- and xenobiotic-sensing nuclear receptors that have been reported to regulate SULT
expression in other human cell systems (Song et al., 2001; Higashi et al., 2004; Fang et al., 2005;
Jiang et al., 2005; Fang et al., 2007; Fu et al., 2011; Rondini et al., 2014; Barrett et al., 2016;
Dubaisi et al., 2016). Both confluent and differentiated HepaRG cells were treated to consider the
possibility that cells in the two stages could differ in their responses due to differences in their
content of transcriptional machinery. However, measurement of marker transcripts for the various
nuclear signaling pathways indicated that all treatments activated their targeted transcription
factors by comparable amounts in confluent and differentiated cells (Figs. 2.6 and 2.7).
As shown in Fig. 2.8, treatment of confluent cells with the AhR agonist TCDD (0.01 μM)
significantly decreased the mRNA levels of all SULTs that were measured, except for SULT1C3,
and decreases of at least 50% were seen for SULT1A1 TV5 (69% decrease), SULT1B1 (51%),
SULT1C4 (77%), SULT1E1 (86%), and SULT2A1 (86%). Treatment with the CAR agonist CITCO
(1 μM) also significantly decreased the mRNA levels of several SULTs (SULT1B1, SULT1C3,
SULT1C4, SULT1E1, and SULT2B1), although these decreases were generally modest and none
exceeded 38%. Treatment with the PXR agonist rifampicin (10 μM) significantly increased
SULT1C4 mRNA content (by 2.8-fold) and decreased the mRNA levels of SULT1B1 (63%
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decrease), SULT1C3 (68%), SULT1E1 (63%), and SULT2A1 (62%). GW3965 treatment (LXR
agonist, 10 μM) significantly increased the amount of SULT1A1 TV5 (by 1.7-fold) and SULT1C4
mRNA (1.9-fold) and decreased the mRNA levels of SULT1C3, SULT1E1, SULT2A1, and
SULT2B1, with the reduction of SULT1C3 mRNA being especially pronounced (>90% decrease).
GW4064 treatment (FXR agonist, 1μM) significantly decreased the expression of several SULTs
(SULT1B1, SULT1C2, SULT1C3, SULT1C4, SULT1E1, SULT2A1), with the largest decreases
seen for SULT1C3 (64%) and SULT2A1 (68%). Treatment with CDCA (50 μM), another FXR
agonist, produced effects that were comparable to those of GW4064, with the largest effects being
reduction of SULT1C3 (60% decrease) and SULT2A1 (55%) mRNA levels. GW7647 treatment
(PPARα agonist, 10 μM) significantly increased SULT1B1 mRNA content, although the increase
was only 1.2-fold, and decreased SULT1C2, SULT1C3, and SULT2B1 mRNA levels, with the
largest reduction seen for SULT1C3 (81%). The PPARγ agonist rosiglitazone (10 μM) had little
effect on SULT expression, other than to decrease SULT1C3 mRNA content (72% decrease).
Treatment with VitD3 (VDR agonist, 0.1 μM) significantly increased the amounts of SULT1C2,
SULT1C4, and SULT2B1 mRNA by 1.4- to 1.8-fold and decreased SULT1A1 TV1, SULT1B1,
SULT1C3, SULT1E1, and SULT2A1 mRNA levels, with the largest reduction seen for SULT1C3
(68% decrease).
Fig. 2.9 shows the effects of the treatments on SULT expression in differentiated HepaRG
cells. Many of the effects were comparable to those seen in the confluent cultures, including: (1)
TCDD treatment decreased the expression of most SULTs; (2) CITCO treatment had relatively
little effect on SULT expression; (3) rifampicin treatment significantly increased SULT1C4 mRNA
content (by 6.3-fold) and decreased SULT1B1, SULT1C3, and SULT2A1 expression; (4) GW3965
treatment significantly increased SULT1A1 TV5 and SULT1C4 mRNA levels and markedly
reduced (by >90%) SULT1C3 mRNA content; levels of SULT2A1 and SULT2B1 mRNA were also
decreased; (5) GW4064 and CDCA treatments significantly decreased the mRNA levels of
several SULTs, including SULT1C2, SULT1C3, SULT1E1, and SULT2A1; (6) GW7647 treatment
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modestly but significantly increased SULT1B1 mRNA content and decreased the amount of
SULT1C3 mRNA; (7) rosiglitazone treatment decreased SULT1C3 expression; and (8) VitD3
treatment significantly increased SULT1C2 and SULT2B1 mRNA levels (SULT1C4 mRNA
content was also ~2-fold higher on average, although this effect was not significant in the
differentiated cells) and decreased SULT1A1 TV1, SULT1B1, SULT1C3, and SULT2A1 mRNA
levels. Differences that were noted between the differentiated and confluent HepaRG cells were:
(1) TCDD treatment significantly decreased SULT1C2 mRNA content only in confluent cells and
increased SULT1C3 mRNA only in differentiated cells; (2) rifampicin treatment significantly
decreased SULT1E1 expression only in confluent cells and induced SULT2B1 in differentiated
cells; and (3) VitD3 treatment significantly decreased SULT1E1 expression only in confluent cells.
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Figure 2.6: Effects of lipid- and xenobiotic-sensing receptor agonists on target gene
expression in confluent HepaRG cells.
Ten days after plating, confluent HepaRG cells were incubated in treatment medium containing
0.1% DMSO, 0.1% ethanol (EtOH), 0.01 µM TCDD (AhR agonist), 1 μM CITCO (CAR), 10 μM
rifampicin (Rif, PXR), 10 μM GW3965 (LXR), 1 μM GW4064 (FXR), 50 µM CDCA (FXR), 10 μM
GW7647 (PPARα), 10 μM rosiglitazone (Rosi, PPARγ), or 0.1 μM VitD3 (VDR) for 48 hr, after
which cells were harvested and the mRNA levels of a known target gene for each agonist and
TATA-box binding protein (used as normalization gene) were measured. Each bar represents
the mean relative mRNA level ± SEM compared to control (0.1% ethanol for VitD3; 0.1% DMSO
for all other agonists) for three independent experiments. Significantly different from control,
*p<0.05, **p<0.01, ***p<001. SREBP1, sterol regulatory element binding protein 1; SHP, short
heterodimer partner; PLIN2, perilipin 2.
Figure taken with permission from (Dubaisi et al., 2018).
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Figure 2.7: Effects of lipid- and xenobiotic-sensing receptor agonists on target gene
expression in differentiated HepaRG cells.
Four weeks after plating, differentiated HepaRG cells were incubated with treatment medium
alone for 72 hour and then treatment medium containing 0.1% DMSO, 0.1% ethanol (EtOH),
0.01 µM TCDD (AhR agonist), 1 μM CITCO (CAR), 10 μM rifampicin (Rif, PXR), 10 μM
GW3965 (LXR), 1 μM GW4064 (FXR), 50 µM CDCA (FXR), 10 μM GW7647 (PPARα), 10 μM
rosiglitazone (Rosi, PPARγ), or 0.1 μM VitD3 (VDR) for 48 hr, after which cells were harvested
and the mRNA levels of a known target gene for each agonist and TATA-box binding protein
(used as normalization gene) were measured. Each bar represents the mean relative mRNA
level ± SEM compared to control (0.1% ethanol for VitD3; 0.1% DMSO for all other agonists) for
four independent experiments. Significantly different from control, *p<0.05, **p<0.01, ***p<001.
SREBP1, sterol regulatory element binding protein 1; SHP, short heterodimer partner; PLIN2,
perilipin.
Figure taken with permission from (Dubaisi et al., 2018).
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Figure 2.8: Effects of lipid- and xenobiotic-sensing receptor activators on SULT mRNA
levels in confluent HepaRG cells.
Ten days after plating, confluent HepaRG cells were incubated in treatment medium containing
0.1% DMSO, 0.1% ethanol, 0.01 µM TCDD, 1 μM CITCO, 10 μM rifampicin (Rif), 10 μM
GW3965, 1 μM GW4064, 50 µM CDCA, 10 μM GW7647, 10 μM rosiglitazone (Rosi), or 0.1 μM
VitD3 for 48 hr, after which cells were harvested and SULT and TATA-box binding protein (used
as normalization gene) mRNA levels were measured. Each bar represents the mean relative
mRNA level ± range (for rosiglitazone treatment only) or SEM compared to control (0.1%
ethanol for VitD3; 0.1% DMSO for all other agonists) for two (for rosiglitazone) or three
independent experiments. *Significantly different from control, p<0.05.
Figure taken with permission from (Dubaisi et al., 2018).
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Figure 2.9: Effects of lipid- and xenobiotic-sensing receptor activators on SULT mRNA
levels in differentiated HepaRG cells.
Four weeks after plating, differentiated HepaRG cells were incubated with treatment medium
alone for 72 hour and then treatment medium containing 0.1% DMSO, 0.1% ethanol, 0.01 µM
TCDD, 1 μM CITCO, 10 μM rifampicin (Rif), 10 μM GW3965, 1 μM GW4064, 50 µM CDCA, 10
μM GW7647, 10 μM rosiglitazone (Rosi), or 0.1 μM VitD3 for 48 hr, after which cells were
harvested and SULT and TATA-box binding protein (used as normalization gene) mRNA levels
were measured. Each bar represents the mean relative mRNA level ± SEM relative to control
(0.1% ethanol for VitD3; 0.1% DMSO for all other agonists) from three independent experiments
(except for SULT1A1/TV1) for the CITCO, GW4064, CDCA, GW7647, and Rosi treatment
groups, where each bar represents mean ± range from two independent experiments).
*Significantly different from control, p<0.05.
Figure taken with permission from (Dubaisi et al., 2018).
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2.3.5

Examining the role of AhR in the regulation of SULTs, CYP3A4, and CYP3A7 mRNA in

differentiating HepaRG cells. Over the past two decades several studies reported that ligandindependent AhR activity regulates physiological processes during development in multiple
tissues, including liver (Mitchell and Elferink, 2009). Our data shown in figures 2.8 and 2.9
indicated that activation of AhR by TCDD suppresses the expression of most SULT1 and SULT2
enzymes in differentiating HepaRG cells. To investigate the role of AhR in the regulation of SULT
expression during liver cell differentiation without any stimulation by exogenous ligand, we defined
the temporal expression profile of several SULTs and CYPs in an AhR KO HepaRG cell line,
where AhR activity is completely absent. We evaluated the expression of SULTs and CYPs that
are primarily expressed in prenatal liver specimens (will be presented in chapter 3) and confluent
HepaRG cells (i.e., SULT1C2, SULT1C4, SULT1E1, CYP3A7) or differentiated cells (i.e.,
SULT2A1 and CYP3A4) as well as CYP1A1, which is a well-known target of AhR. The temporal
expression patterns of SULT1C2, SULT1E1, SULT2A1, CYP3A4, and CYP3A7 in WT and AhR
KO HepaRG cells were comparable (Fig. 2.10). However, the mRNA levels of these genes were
considerably lower in the absence of AhR in the differentiating HepaRG cells, particularly in the
proliferative and confluent stages (between day 5 and 14). Abolishing AhR signaling reduced the
expression of SULT1C2, SULT1C4, SULT1E1, and SULT2A1 by 72-86%, 34-60%, 24-57%, and
69-92%, respectively in the proliferating and confluent cells. CYP3A4 and CYP3A7 mRNA also
decreased by 30-96% and 67-96%, respectively, between days 5 and 14 in the absence of AhR
(Fig. 2.10). The expression of CYP1A1 was relatively the same in AhR KO and WT HepaRG cells
(Fig. 2.10).
2.3.6

The mechanism underlying the transcriptional regulation of SULT1C4 by LXR, PXR, and

VDR. There are currently no known regulators of SULT1C4 expression in human cells. To
examine the mechanism underlying the induction of SULT1C4 mRNA by LXR, PXR, and VDR
(as shown in Fig 2.8 and 2.9), we evaluated fragments from the 5’-flanking region of SULT1C4
for their responsiveness to LXR, PXR, and VDR activation. To determine the transcription start
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site of the SULT1C4 gene, we performed 5’-RACE analysis using RACE-ready cDNA from Caco2 and HepaRG cells and a SULT1C4-specific reverse primer placed within exon 1 (listed in
Appendix G). Using sequence and alignment analysis of 23 5’-RACE clones prepared from
HepaRG and Caco-2, we determined that the 5’-end of most clones started at approximately the
same site. Our analysis indicated that the transcription start site of 5’-RACE clones was 46 bp
downstream of the reported transcription site for NM_006588.3 and NM_001321770.1. The
translation start site was located in exon 1, as previously indicated by Freimuth et al. (Freimuth et
al., 2000). The translation start site was 393 and 191 bp downstream of the transcription start site
for 18 and 4 clones, respectively.
We then transfected a series of constructs containing ~1 or 2 Kb fragments (2.2 Kb and
fragments A to I) from the region upstream of the transcription start site that were attached to the
SULT1C4 core promoter (shown in figure 2.11A) into HepG2 cells, which are relatively easier to
transfect compared to HepaRG cells. To compensate for the low expression of PXR and VDR in
HepG2 cells, we cotransfected the cells with expression plasmids that express one of the two
transcription factors (PXR-pSG5 and VDR-pcDNA3.1, respectively) as well as empty expression
plasmids that were used as controls. LXR activation by 10 µM GW3965 upregulated the luciferase
activity of the positive control SREBP1c-LXRE reporter in HepG2 cells (Fig. 2.11B and 2.12), but
it did not have any effect on the activity of any of the SULT1C4 reporter constructs. Similarly,
treatment with Rif (10µM) or VitD3 (0.1µM) also induced the luciferase activity of the control
CYP3A4-PXRE and SULT1C2-VDRE reporter constructs in HepG2 cells cotransfected with a
PXR and VDR expression plasmid, respectively, without altering the luciferase activity of any of
the SULT1C4 fragments (Fig. 2.11C, 2.11D, 2.13, and 2.14).
Because the effects of LXR and PXR agonist treatments, which produced the most notable
upregulation of SULT1C4 mRNA, were observed in HepaRG cells (Fig. 2.8 and 2.9), we
transfected the SULT1C4 reporter plasmids into HepaRG cells and examined their
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responsiveness to the LXR and PXR agonists. Because SULT1C4 is primarily expressed in
confluent HepaRG cells (Fig. 2.4), the transfections and treatments were done during confluency
(day 9-12). Treatment with 10 µM GW3965 or Rif upregulated the luciferase activity of the control
reporters, SREBP1c-LXRE and CYP3A4-XREM, respectively (Fig. 2.15 and 2.16). However,
neither of the treatments had any effect on the luciferase activity of the SULT1C4 reporter
plasmids (Fig. 2.15 and 2.16).
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Figure 2.10: Temporal expression profiles of SULTs, CYP1A1, CYP3A4, and CYP3A7 in
the absence of AhR signaling in HepaRG cells.
WT and AhR KO HepaRG cells were plated (day 0) and harvested on the days indicated in the
figure for measurement of mRNA levels. mRNA levels were normalized to the levels measured
on day two of the WT cells. The data show the expression patterns of SULT1C2, SULT1C4,
SULT1E1, and SULT2A1 as well as CYP1A1, CYP3A4, and CYP3A7 from the proliferative to
the confluent phase (open bars) and then through the differentiation phase (black bars). Data
were normalized to TBP and are shown as mean ± range from two independent experiments
that were each performed in duplicates (n=4).
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Figure 2.11: The responsiveness of the SULT1C4 2.2Kb reporter construct to LXR, PXR,
(A) Schematic
representation
of the fragments from the 5’-flanking region of SULT1C4 that
and
VDR agonist
in HepG2 cells.
were used in the transfection analysis. HepG2 cells were transiently transfected with the
SULT1C4 2.2 Kb (nt -1819:+350) luciferase reporter construct or an empty pGL4.10 [luc2]. Cells
were also transfected with LXRE/SREBP1c (B), XREM/CYP3A4 (C), and VDRE/SULT1C2 (D)
that were used as positive controls. 24 hours after transfection cells were treated with DMSO
(0.1%), or the nuclear receptor agonist (B) GW3965 (10 µM), (C) rifampicin (Rif; 10 µM), and
(D) VitD3 (0.1 µM) for 48 hours. Cells treated with Rif or VitD3 were cotransfected with a (C)
PXR-pSG5 expression plasmid or empty pSG5 plasmid and (D) VDR-pcDNA3.1 expression
plasmid or empty pcDNA3.1 plasmid. The cells were then harvested for measurement of
luciferase activities. Each column represents the mean± S.D. of normalized (Firefly/Renilla)
luciferase measurements relative to DMSO control (n = 3 wells per treatment) from one cell
culture experiment.
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Figure 2.12: The responsiveness of SULT1C4 reporter constructs to LXR activation in
HepG2 cells.
Cells were transiently transfected with the series of reporter plasmids that contain fragments A
through H that span ~13 Kb region upstream the transcription start site of SULT1C4. Cells were
also transfected with an empty pGL4.10 [luc2], a core promoter, or LXRE/SREBP1c reporter
constructs (used as controls). 24 hours after transfection, cells were treated with GW3965 (10
µM) for 48 hours and then harvested for measurement of luciferase activities. Each column
represents the mean± S.D. of normalized (Firefly/Renilla) luciferase measurements relative to
DMSO control (n = 3 wells per treatment) from one cell culture experiment.
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Figure 2.13: The responsiveness of a series of SULT1C4 reporter constructs to PXR
activation in HepG2 cells.
Cells were transiently transfected with a series of reporter constructs containing fragments A
through I that span ~15 Kb region upstream the transcription start site of SULT1C4. Cells were
also transfected with an empty pGL4.10 [luc2], a core promoter, or XREM/CYP3A4 reporter
constructs (used as controls) and PXR-pSG5 or an empty pSG5 expression plasmid. 24 hours
after transfection, cells were treated with Rif (10 µM) and then harvested for measurement of
luciferase activities. Each column represents the mean± S.D. of normalized (Firefly/Renilla)
luciferase measurements relative to DMSO control (n = 3 wells per treatment) from two cell
culture experiment.
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Figure 2.14: The responsiveness of a series of SULT1C4 reporter constructs to VDR
activation in HepG2 cells.
Cells were transiently transfected with a series of reporter plasmids that contain fragments A
through I that span ~15 Kb region upstream the transcription start site of SULT1C4. Cells were
also transfected with an empty pGL4.10 [luc2], a core promoter, or VDRE/SULT1C2 reporter
constructs (used as controls) and cotransfected with a VDR-pcDNA3.1 or an empty pcDNA3.1
expression plasmid. 24 hours after transfection cells were treated with VitD3 (0.1 µM) and then
harvested for measurement of luciferase activities. Each column represents the mean± S.D. of
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normalized (Firefly/Renilla) luciferase measurements relative to DMSO control (n = 3 wells per
treatment) from one cell culture experiment.

Figure 2.15: The responsiveness of a series of SULT1C4 reporter constructs to LXR
activation in HepaRG cells.
Confluent cells (day 9) were transiently transfected with the series of reporter constructs that
contain fragments A through I, spanning ~15 Kb region upstream from the transcription start site
of SULT1C4. Cells were also transfected with an empty pGL4.10 [luc2], core promoter, or
LXRE/SREBP1c reporter construct (used as controls). 24 hours after transfection, cells were
treated with GW3965 (10 µM) for 48 hours and then harvested for measurement of luciferase
activities. Each column represents the mean± S.D. of normalized (Firefly/Renilla) luciferase
measurements relative to DMSO control (n = 3 wells per treatment) from two cell culture
experiment.
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Figure 2.16: The responsiveness of a series of SULT1C4 reporter constructs to PXR
activation in HepaRG cells.
Confluent cells (day 9) were transiently transfected with the series of reporter plasmids that
contain fragments A through I, spanning ~15 Kb region upstream from the transcription start site
of SULT1C4. Cells were also transfected with an empty pGL4.10 [luc2], core promoter, or
XREM/CYP3A4 reporter construct (used as controls). 24 hours after transfection, cells were
treated with Rif (10 µM) for 48 hours and then harvested for measurement of luciferase
activities. Each column represents the mean± S.D. of normalized (Firefly/Renilla) luciferase
measurements relative to DMSO control (n = 3 wells per treatment) from two cell culture
experiment.
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2.4

Discussion
Xenobiotic-metabolizing enzymes exhibit distinct patterns of developmental expression

(Hines, 2008). Although some detoxification enzymes, such as CYP3A5, CYP3A7, FMO1, and
SULT1E1, were reported to be expressed during early stages of gestation (Lacroix et al., 1997;
Koukouritaki et al., 2002; Stevens et al., 2003; Duanmu et al., 2006), the expression of many
other enzymes matures during later stages of development, including neonatal and postnatal
periods. Previous studies showed that the expression of various phase I, such as CYP1A2,
CYP3A4, CYP2C9, CYP2C19, and phase II enzymes, such as UGT1A4, UGT1A6, and UGT2B7,
increased gradually and reached maximum abundancy during neonatal, infancy, childhood, or
adulthood periods (Sonnier and Cresteil, 1998; Strassburg et al., 2002; Stevens et al., 2003;
Koukouritaki et al., 2004; Bhatt et al., 2018). In this project , we examined the ontogeny of SULT1
and SULT2 enzymes that are expressed in the human liver and are among the most abundant
conjugating enzymes in fetal tissues (Coughtrie, 2015).
There is currently no published information about SULT expression or regulation using in
vitro models of human liver development. In the current investigation, we used cultures of primary
fetal hepatocytes to identify regulators of SULT expression during early stages of liver
development. Placement of fetal hepatocytes into primary culture decreased the expression of
several SULTs. A notable exception was SULT1B1, which is reported to be the third most highly
expressed SULT in adult human liver (Riches et al., 2009). SULT1B1 mRNA content increased
14-fold after the fetal hepatocytes were placed into culture, implying a difference in the
mechanism(s) controlling basal expression of SULT1B1 relative to other SULTs.
To identify mechanisms that regulate SULT expression in human fetal hepatocytes,
primary cultures were treated with several activators of lipid- and xenobiotic-sensing receptors.
Several significant effects and non-significant trends were observed and are discussed in the
context of previous findings. VDR activation significantly increased SULT1C2 as well as CYP3A7
and CYP3A4 mRNA levels. Although liver is not a classical VitD3-responsive organ, VDR is
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expressed in liver (Berger et al., 1988) and its activation has been shown to increase expression
of several cytochromes P450 enzymes, including CYP3A4, in primary cultured adult human
hepatocytes (Drocourt et al., 2002). VDR activation was found to increase SULT1C2 expression
in LS180 colorectal adenocarcinoma cells (Rondini et al., 2014; Barrett et al., 2016). Also,
treatment of fetal hepatocyte cultures with an agonist of PPARα (GW7647) or PPARγ
(rosiglitazone) increased expression of SULT2A1 by approximately 2-fold, whereas treatment
with the FXR agonist GW4064 suppressed SULT2A1 in the cultured fetal hepatocytes. PPARa
and FXR were both previously reported to regulate SULT2A1 expression in primary human
hepatocytes and HepG2 cells, respectively (discussed in chapter 1.5) (Fang et al., 2005; Miyata
et al., 2006).
A novel finding in the cultured fetal hepatocytes was that treatment with the LXR agonist
GW3965 significantly increased expression of SULT1A1 TV5. TV5 is reported to be a rare variant
that contains a distinct 5'-untranslated region and lacks part of the 5'-coding region, and its
transcription start site is located more than 10 Kb upstream from that of other SULT1A1 transcripts
(NCBI information for NM_177536 and SULT1A1 gene). The distinct location of the TV5 promoter
provides a plausible explanation for the unique regulation of this SULT1A1 variant by LXR, which
prompts speculation that SULT1A1 TV5 could play a role in sterol metabolism.
Most studies using HepaRG cells have used differentiated cells as a model to complement
the use of primary cultured human hepatocytes (Josse et al., 2008; Lubberstedt et al., 2011;
Gerets et al., 2012; Klein et al., 2015). However, few studies have evaluated the changes in
xenobiotic-metabolizing enzyme expression that occur as HepaRG cells pass through the stages
of the differentiation process (Aninat et al., 2006; Hart et al., 2010; Ceelen et al., 2011; Tsuji et
al., 2014; Bucher et al., 2016), and no studies have determined expression of the individual
SULTs. We found that SULT1B1, SULT1C2, SULT1C3, SULT1C4, and SULT1E1 mRNA levels
were highest in confluent HepaRG cells, whereas SULT2A1 RNA levels increased throughout the
differentiation process. The temporal trends of gene expression, whereby the SULTs that are
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preferentially expressed in fetal livers and hepatocytes are also preferentially expressed in
confluent HepaRG cells while the SULT that is preferentially expressed in adult liver and
hepatocytes is expressed at the highest level in differentiated HepaRG cells, provide additional
support to the suggestion that HepaRG cells at these stages of the differentiation protocol can
serve as experimental models of human hepatocyte development.
We also evaluated the effects of activators of lipid- and xenobiotic-sensing transcription
factors on SULT expression in HepaRG cells, comparing effects at the confluent and differentiated
stages. More activator-mediated changes in SULT expression were observed in the HepaRG
cells than in the primary cultured fetal hepatocytes. However, while there were marked temporal
changes in SULT expression as the cells underwent differentiation (noted above), most of the
transcription factor activator-mediated changes were comparable in the confluent and
differentiated HepaRG cells, indicating that the evaluated nuclear signaling pathways were
already functional in the confluent cells. As seen in the human fetal hepatocytes, GW3965 and
VitD3 treatment increased SULT1A1 TV5 and SULT1C2 mRNA levels, respectively, while FXR
agonists GW4064 and CDCA suppressed SULT2A1 expression. Treatment with GW4064 or
CDCA also significantly suppressed SULT1E1 expression in confluent HepaRG cells, but
GW4064 only produced a slight reduction of SULT1E1 mRNA content in primary cultured fetal
hepatocytes. These data are consistent with the findings of a recent study that reported the
suppressive effect of FXR on SULT1E1 expression in HepG2 cells (discussed in chapter 1.5)
(Wang et al., 2017).
The effects of the PXR agonist rifampicin differed between HepaRG cells and fetal
hepatocytes. Rifampicin treatment increased SULT1C4 expression and suppressed SULT1E1
and SULT2A1 in HepaRG cells but not in the fetal hepatocytes. We previously reported that
rifampicin-mediated PXR activation suppresses hepatic SULT2A1 expression (Fang et al., 2007),
while the mechanism of PXR-mediated suppression of SULT1E1 was described by Kodama et
al. (2011). Rifampicin treatment also did not increase CYP3A4 or CYP3A7 expression in the
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cultured fetal hepatocytes, suggesting that PXR was not functional in these cells. Our findings
agree with a previous report by Maruyama et al. (2007), who evaluated cytochrome P450
expression in human fetal liver cells prepared from a pool of six normal human fetal livers (average
13 weeks of gestation). These cells expressed CYP3A4 and CYP3A7, and treatment with
dexamethasone, which is an effective agonist of rodent but not human PXR, significantly
increased CYP3A4 and CYP3A7 mRNA levels (Maruyama et al., 2007). However, treatment of
the fetal liver cells with rifampicin did not increase CYP3A4 or CYP3A7 expression, and PXR
mRNA was not detected by RT-PCR (Maruyama et al., 2007). Vyhlidal et al. (Vyhlidal et al., 2006)
have also reported that PXR expression is lower in fetal relative to postnatal livers. These findings
demonstrate that although confluent HepaRG cells model some aspects of the fetal hepatocyte,
the presence of PXR signaling in confluent HepaRG cells and its absence in fetal hepatocytes
indicates that confluent HepaRG cells do not fully recapitulate all aspects of the fetal hepatocyte,
at least at the culture and gestation times that were evaluated.
To date, SULT1C3 mRNA has only been detected in human intestinal tissue and cells
(Duniec-Dmuchowski et al., 2014). In this study, we detected SULT1C3 mRNA in HepaRG cells,
mainly at the confluent stage where the mRNA levels were approximately the same as those for
SULT1C4. SULT1C3 expression was significantly reduced in the HepaRG cells by most of the
treatments that were evaluated, with almost complete suppression by the LXR agonist GW3965.
It seems possible that these suppressive effects contribute to the lack of SULT1C3 expression
that has generally been seen in human liver samples.
TCDD treatment was also found to suppress the expression of most SULTs in HepaRG
cells. This finding is consistent with the suppressive effects of AhR agonist treatments on SULT
expression that we have previously reported in rat hepatocytes (Runge-Morris, 1998) and
MCF10A human breast epithelial cells (Fu et al., 2011). Fu et al. previously showed that the
transcription of SULT1E1 is regulated by confluency in MCF10A cells through a suppressive
action of AhR, which is more active in the preconfluent cells (Fu et al., 2011). Our preliminary data
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presented in the current study we showed that the absence of AhR activity in differentiating
HepaRG cells suppressed, to some extent, SULT1C2, SULT1E1, SULT2A1, CYP3A4, CYP3A7
mRNA, primarily in the proliferating and confluent cells. We are in the process of developing our
own AhR KO HepaRG cell model to further examine the role of AhR in regulating SULT, CYP3A4,
and CYP3A7 expression in the differentiating hepaRG. These results suggest that AhR activity
could be required to achieve maximal expression of some SULTs and CYPs during the early
stages of hepatocyte differentiation.
LXR, PXR, and VDR activation did not have any effect on the luciferase activity of reporter
constructs covering ~15 Kb of the SULT1C4 5’-flanking region, suggesting that response regions
for these receptors are located elsewhere in the SULT1C4 gene.
Several SULTs are expressed in human fetal liver, and thus these enzymes play important
roles during early life, likely in the metabolism of both endogenous and xenobiotic substrates. This
study represents the first effort to define patterns of SULT expression in cell culture models of
human fetal liver and liver cell differentiation and identify signaling pathways that regulate SULT
transcription in these cells. Further studies are warranted to understand the regulation of the
SULTs during human development.
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CHAPTER 3: DEVELOPMENTAL EXPRESSION OF THE CYTOSOLIC
SULFOTRANSFERASES IN HUMAN LIVER
3.1

Introduction
Numerous xenobiotic-metabolizing enzymes that mediate the metabolism of many

endogenous and foreign chemicals are expressed in the liver. The expression profiles of these
enzymes vary markedly during liver development, thereby altering the ability of the liver to detoxify
xenobiotics, bioactivate procarcinogens, and regulate the activity of estrogen and thyroid
hormones as well as other endogenous compounds. The currently available information about
the ontogeny of SULT1 and SULT2 enzymes in the liver is derived from a few studies that
examined the expression of several SULTs using conventional methods, such as non-quantitative
PCR, Western blots, and multi-tissue blots (Her et al., 1997; Sakakibara et al., 1998; Dooley et
al., 2000; Stanley et al., 2005; Duanmu et al., 2006), a recent report by Ekstrom and Rane that
evaluated SULT2A1 expression in fetal and adult liver specimens (Ekstrom and Rane, 2015), and
the limited data that are contained in transcriptomic profiling studies of various adult and fetal
tissues (e.g., GEO DataSet Accession numbers GDS181, GDS833, GDS1096, GDS3113,
GDS3834). To expand our knowledge about the role of SULTs during development, we
characterized the expression patterns of these enzymes at the RNA and protein levels using
human liver specimens and cytosolic fractions from different life stages. To achieve a high level
of rigor in our assessment, we evaluated SULT expression in three independent sets of human
liver specimens using three different methods of measurement, two for mRNA and one for protein.
3.2

Materials and Methods

Materials: Human prenatal (18-19 weeks of gestation, n=10), infant (1-12 months old, n=10), and
adult (18-50 years old, n=10) liver specimens analyzed by reverse transcription-quantitative
polymerase chain reaction (RT-qPCR) were obtained from the University of Maryland National
Institute of Child Health and Human Development Brain and Tissue Bank for Developmental
Disorders (NICHD-BTB, National Institutes of Health Contract Number HHSN275200900011C,
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Ref. No. #N01-HD-9-0011). A separate set of prenatal (weeks 14-16, n=10) and pediatric (0 days
to 17 years, n=52) human liver specimens was analyzed by RNA sequencing (RNA-seq). The
prenatal specimens were obtained from the Central Laboratory for Human Embryology at the
University of Washington (Seattle, WA). The pediatric specimens were obtained from the NICHDBTB and the Liver Tissue Cell Distribution System (National Institutes of Health Contract Number
N01-DK-7-0004/HHSN267200700004C). In addition, 6 samples were generously provided by
Xenotech, LLC (Kansas City, KS). All tissues were maintained at -80ºC prior to use. The use of
these tissues was reviewed and declared non-human subjects research by the University of
Missouri-Kansas City Pediatric Health Sciences Review Board at Children’s Mercy Kansas City
and the institutional review board at Wayne State University. Donor information (age, sex, and
postmortem interval) for the human liver specimens is provided in Appendix I and J.
The library of human liver cytosolic fractions used for measurement of SULT protein levels
(obtained from our collaborator Dr. Hines from the U.S. Environmental Protection Agency,
Research Triangle Park, NC) was previously described (Duanmu et al., 2006). 193 samples from
this library were available for the current analysis. The cytosolic fractions were prepared from
livers at different developmental stages, starting from week 8 of gestation until 18 years, and
include prenatal samples from first trimester (n= 15), second trimester (n=34), and third trimester
(n=13); infants (0-1 years old, n=76); and children (1-18 years old, n= 55). Gender information
was provided for 183 samples with 111 being male and 72 female. Only information about major
diseases, cause of death, and ethnicity as well as the postmortem interval for the prenatal
samples were available. Samples from individuals with disease processes that potentially would
involve liver damage were excluded from the study. Tissues were stored at -80°C and approval
was obtained from the Children’s Hospital of Wisconsin and the Medical College of Wisconsin
Institutional Review Boards. To prepare the liver cytosols, the liver tissues were homogenized in
a buffer containing 100 mM Tris-HCl, pH 7.4, 250 mM sucrose, 5 mM EDTA, 0.1 mM DTT, and
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0.25 mM phenylmethylsulfonyl fluoride. The samples were centrifuged at 105,000 g for 1 hour at
4°C to obtain the cytosolic fractions.
RNA Isolation and Gene Expression Analysis: For the samples analyzed by RT-qPCR, liver
specimens were thawed on ice, and 30-50 mg pieces were dissected and homogenized in QIAzol
Lysis Reagent using a TissueRuptor (Qiagen Inc., Germantown, MD). Total RNA was prepared
using the RNeasy Plus Universal Mini Kit (Qiagen), and RNA quality was determined using a 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA). RNA integrity number (RIN) was used to
assess the quality of the RNA. All prenatal RNA samples had RIN values > 8, whereas most of
the infant and adult RNA samples had RIN values > 5. Three infant and 3 adult liver specimens
yielded RNA with RIN values < 4. These samples were considered extensively degraded and
were excluded from the analysis. RNA samples (3 µg) were reversed transcribed using the High
Capacity cDNA Reverse Transcription Kit, according to the manufacturer’s instructions (Thermo
Fisher Scientific, Waltham, MA). RNA levels of 9 SULTs, CYP3A4, and CYP3A7 were measured
as described in chapter 2.2. Data were normalized to 18S and to the median ΔCT in the prenatal
group to calculate ΔCT and ΔΔCT, respectively, and then the 2−ΔΔCT method was used to
quantify the relative changes in gene expression between the three developmental stages (Livak
and Schmittgen, 2001).
The RNA-seq analysis was performed by our collaborators Drs. Vyhlidal and Gaedigk
(from the Children’s Mercy Kansas City in Kansas City, MO). For these samples, frozen liver
specimens (20-30 mg) were homogenized and total RNA extracted according to the RNeasy
protocol (Qiagen) with on-column DNase I treatment. The quality of the isolated RNA was
assessed using an Experion Automated Electrophoresis Station (Bio-Rad, Hercules, CA) and was
evaluated by the RNA quality indicator (RQI) value. All samples analyzed by RNA-seq had RQIs
> 4.9, with 39 (out of 62) samples having RQIs >8. Libraries were then prepared from 1 µg total
RNA of each sample using the TruSeq Stranded Total RNA Sample Prep Kit (Illumina, San Diego,
CA). Paired-end sequencing (2 x 101 bp) of high output run mode was performed using the HiSeq
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1500 instrument (Illumina, San Diego, CA). The resulting base calling (.bcl) files were converted
to FASTQ files and trimmed RNA-seq reads were mapped to the human genome (GRCh37/hg19).
Transcript assembly and abundance estimation were conducted using the Tuxedo Suite pipeline
and reported in transcripts per kilobase of exon per million fragments mapped (TPM). TPM values
were log-transformed and differences in mRNA expression were compared between age groups.
Age groups were defined as follows: Group 0 (prenatal samples); Group 1 (infants <1 year of
age), Group 2 (children 1-5 years of age), Group 3 (children 6-11 years of age), and Group 4
(adolescents, 12-17 years of age).
SULT protein quantification: Protein concentrations of liver cytosolic fractions were estimated
using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). For each sample, 100 µg of
protein was resolved on a 4-12% Bis-Tris gel (Thermo Fisher Scientific) in duplicate. The region
between 30-40 kDa was excised and proteins were reduced, alkylated, and digested with trypsin
in-gel. Peptides were eluted from the gel pieces and dried. Heavy AQUA peptides, with labels on
C-terminal lysine or arginine residues, were purchased from Thermo Fisher Scientific. Aliquots of
10X stock heavy proteotypic peptides for eight SULTS at 40 fmol/µL were kept frozen at -80°C.
On the day of the assay, peptides were resuspended in 30 µL of 1X heavy peptides in 5%
acetonitrile, 0.1% formic acid, and 0.005% trifluoroacetic acid buffer. Peptides (5 µL) were
separated by reversed-phase chromatography and introduced into a TSQ Vantage triple
quadrupole mass spectrometer (Thermo Fisher Scientific). Transition settings were optimized for
collision energies and peak retention times. Analysis time for each peptide spanned over a 2
minute window during the 20 minute gradient. Instrument settings included full width at half
maximum of 0.7 and cycle time of 1.2 sec. Multiple reaction monitoring (MRM) settings are found
in Appendix K.
Data were imported into Skyline (version 4.1.0; MacCoss Lab, University of Washington).
Integrated peaks were manually validated and those with signal-noise ratios < 3 were excluded.
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Areas-under-the-curve (AUCs) for each transition peak were summed per peptide, and final
calculations for absolute quantitation were as follows:

fmol SULT per mg cytosol = 20 fmol x

(Σ light transition AUCs)
6
x
(Σ heavy transition AUCs) 0.1 mg

Samples were analyzed in duplicate; therefore, results represent the average of two
samples. For the purposes of plotting data and performing statistical analyses, the level of a SULT
protein in a sample with an undetectable level of that protein was given a value of 0. The SULT
protein quantification in liver cytosols was performed in collaboration with Dr. Joseph Caruso at
the Proteomics Core Center at Wayne State University.
Data analysis: Samples were grouped according to age, and scatter and box-and-whisker plots
were prepared for the mRNA and protein data, respectively. Statistical comparisons among
groups were performed using the Kruskal-Wallis non-parametric analysis of variance (ANOVA)
and Dunn’s multiple comparison test, using Prism version 6 (GraphPad Software, La Jolla, CA).
Correlation analyses to perform pairwise comparisons of gene expression were also performed
using Prism.
3.3
3.3.1

Results
Developmental expression of SULT mRNA in human liver. To address the gap in our

knowledge about the developmental expression profiles of ten SULTs, we obtained specimens of
pre- and postnatal human liver and characterized the developmental expression of SULT1 and
SULT2 family genes using RT-qPCR and RNA-seq. While CYP3A7 is established as a gene that
is preferentially expressed during fetal life and remains detectable in many individuals until 2 years
of age, CYP3A4 is known to be primarily expressed in postnatal liver (Lacroix et al., 1997; Stevens
et al., 2003). Therefore, CYP3A7 and CYP3A4 mRNA levels were measured in our tissue sets to
demonstrate that these expected patterns of expression were observed (Fig. 3.1 and 3.2).
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Fig. 3.1 shows the levels of SULT mRNA in prenatal, infant, and adult liver, as measured
by RT-qPCR. As indicated in chapter 2, SULT1A1 mRNA was measured using two different
TaqMan Gene Expression Assays. SULT1A1 (TV1), 1A2, 1B1, 1C2, 1C4, 1E1, and 2A1 mRNAs
were readily detectable (as determined by Ct values <30) in at least one of the developmental
stages, but SULT1A1 (TV5), 1C3, and 2B1 mRNAs were minimally present at all stages (Ct ≥ 33)
(Fig. 3.1). Although not statistically significant, SULT1E1 appeared to be preferentially expressed
in the prenatal liver while SULT2A1 expression was significantly higher in the postnatal
specimens, in agreement with a previous analysis of SULT1E1 and 2A1 immunoreactive protein
in human liver cytosolic fractions that was published by Dr. Runge-Morris’s lab (Duanmu et al.,
2006). Nevertheless, SULT2A1 mRNA levels were relatively high in the prenatal specimens, as
estimated by a median Ct value of 25.5, which was the third lowest (approximately same as
SULT1A1 TV1) after SULT1C4 and 1E1. Like SULT2A1, SULT1A2 mRNA levels were higher in
the postnatal specimens than in the prenatal specimens, while for SULT1B1, mRNA levels were
higher in the adult than either the prenatal or infant specimens. SULT1C2 and 1C4 were
preferentially expressed in the prenatal and infant liver specimens. However, the SULT1C2 and
SULT1C4 expression patterns were not identical, as SULT1C2 mRNA content was highest in the
infant livers, with a median level that was ~ 3-fold and 310-fold higher than it was in the prenatal
and adult specimens, respectively. By contrast, SULT1C4 mRNA content was highest in the
prenatal specimens, with a median level that was ~91 and ~192-fold higher than it was in the
infant and adult specimens, respectively.
A separate set of pre- and postnatal human liver specimens was analyzed by RNA-seq,
and the SULT transcript levels from this dataset were compared to the RT-qPCR findings. While
both tissue sets included prenatal and infant liver specimens, the set used for RNA-seq included
specimens from children 1-17 years of age (evaluated as four age groups: infants <1 year of age,
children 1-5 years, children 6-11 years, and children 12-17 years) but did not include adult
specimens. As for the RT-qPCR data, CYP3A7 and 3A4 displayed the expected patterns of
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predominantly prenatal and postnatal expression, respectively (Fig. 3.2). The SULT1A1, 1A2,
1C2, 1C4, 1E1, and 2A1 developmental expression profiles determined by RNA-seq (Fig. 3.2)
were generally consistent with those observed by RT-qPCR (Fig. 3.1). SULT1A1 was expressed
at a relatively constant level throughout development, with SULT1A1 TV1/2 being the most
abundant transcripts (Table 3.1); SULT1A2 expression did not vary significantly during
development but was generally higher in the postnatal periods (particularly in infants and children
1-11 years old); SULT1C2, SULT1C4, and SULT1E1 were primarily expressed in the prenatal
and infant specimens; and SULT2A1 expression increased after birth (Fig. 3.2). SULT1A1 TVs
3/4 and 5, 1C3, and 2B1 mRNA levels were low throughout development (Table 3.1). SULT1B1
mRNA levels in prenatal liver specimens were not significantly different from those in infant liver,
which is also consistent with the RT-qPCR data, but were higher than they were in the specimens
from children ages 1-5 and 6-11. The higher SULT1B1 mRNA levels that were present in the adult
liver specimens analyzed by RT-qPCR could not be confirmed since the tissue set analyzed by
RNA-seq did not include adult specimens. SULT1A3 mRNA, which was not analyzed by RTqPCR, was also detected in prenatal and postnatal liver by RNA-seq, with highest expression in
the prenatal and infant specimens. Two differences between the tissue sets analyzed by RTqPCR and RNA-seq were that SULT1B1 and 1C4 were the seventh and first most abundant
transcripts in the prenatal samples in Fig. 3.1 (as estimated by Ct values) but were the second
and seventh most abundant transcripts in prenatal samples in Table 3.1 (as estimated by TPM
values).
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Figure 3.1: SULT mRNA Developmental expression profiles in human liver specimens
analyzed by RT-qPCR.
RNA was isolated from human liver specimens from prenatal, infant, and adult donors, and
levels of SULT1A1 (TV1 or TV5), 1B1, 1C2, 1C3, 1C4, 1E1, 2A1, and 2B1 were measured
using TaqMan Gene Expression assays, as described in Materials and Methods. CYP3A4 and
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transcript, data are normalized to the median mRNA level (Ct value) in the prenatal group and
presented as scatter plots, with the horizontal lines representing the median values.
*Significantly different, P< 0.05, **P<0.01, and ***P<0.001.
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Table 3.1: Median Transcript per million (TPM) values for SULTs analyzed by RNA-seq
SULT Transcript

Prenatal

SULT1A1 (TV1/2)
SULT1A1 (TV3/4)

11.01
0.06

1-5 years

6-11 years

12-18 years

14.41
0.00

7.12
0.12

10.98
0.00

17.87
0.22

0.62
1.66
5.40

0.59
4.11
2.91

0.43
4.08
2.40

0.74
4.81
1.44

1.44
2.03
2.18

SULT1B1
SULT1C2

24.07
8.58

17.23
2.63

13.10
0.42

13.13
0.13

16.61
0.21

SULT1C3
SULT1C4
SULT1E1

0.05
4.44
34.63

0.00
0.83
3.63

0.00
0.31
0.95

0.00
0.22
0.60

0.00
0.21
1.31

SULT2A1
SULT2B1

10.03
0.05

68.42
0.02

84.41
0.00

40.07
0.00

150.80
0.02

SULT1A1 (TV5)
SULT1A2
SULT1A3

Infant
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Figure 3.2: SULT mRNA Developmental expression profiles in human liver specimens
analyzed by RNA-seq.
RNA-seq was performed on human liver specimens from prenatal and pediatric (divided into
infant, 1-5 year-old, 6-11 year-old, and 12-18 year-old groups) donors, and TPM values for
SULT1A1 (TV1/2, TV3/4, or TV5), 1A2, 1A3, 1B1, 1C2, 1C3, 1C4, 1E1, 2A1, and 2B1 and
CYP3A4 and 3A7 were determined, as described in Materials and Methods. For each transcript,
data are normalized to the median mRNA level in the prenatal group and presented as scatter
plots, with the horizontal lines representing the median values. Groups not sharing a letter are
significantly different from each other, P< 0.05.
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Because the RT-qPCR and RNA-seq data indicated that several SULTs are expressed in
prenatal liver, we explored the extent to which these genes were coordinately expressed in
individual prenatal liver specimens as a potential clue to shared regulatory mechanisms. We,
therefore, performed pairwise correlation analysis on the RT-qPCR and RNA-seq data for the
genes that were relatively abundant in the prenatal specimens; SULT1A1 (TV 1 to 4), SULT1B1,
SULT1C2, SULT1C4, SULT1E1, SULT2A1, and CYP3A7. In the specimens analyzed by RTqPCR, SULT1C2, SULT1E1, SULT2A1, and CYP3A7 mRNA levels were highly correlated with
each other (Fig. 3.3), but SULT1A1 (TV 1 to 4), SULT1B1, and SULT1C4 mRNA levels did not
significantly correlate with any of the other genes that were examined (Appendix L). For the
specimens analyzed by RNA-seq, SULT1A3 expression correlated with that of SULT1B1,
SULT1C2 expression correlated with that of SULT1C4, and SULT1E1 expression correlated with
that of SULT1A1 (TV1/2) and CYP3A7 (Fig. 3.4).
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Figure 3.3: Correlation among the various SULTs and CYP3A7 mRNA measured by RTqPCR in prenatal liver.
Pairwise correlation analyses were performed on SULT expression data from prenatal samples
(n=10). Each scatter plot shows the expression data of one gene against another gene. The R2
values from the correlation analysis are indicated. Significantly correlated, *p<0.05, ***p<0.005.
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Figure 3.4: Correlation among the various SULTs and CYP3A7 mRNA measured by RNAseq in prenatal liver.
Pairwise correlation analysis was performed on SULT1A1 (TV1/2), SULT1A3, SULT1B1,
SULT1C2, SULT1C4, SULT1E1, SULT2A1, and CYP3A7 expression data in the prenatal liver
(n=10). Each scatter plot shows the expression data of one gene against another. The R2
values from the correlation analysis are indicated. Significantly correlated, *p<0.05, **p<0.01
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3.3.2

SULT protein developmental expression in human liver. Because gene expression at the

mRNA level does not always reflect protein abundancy, we used MRM to measure the protein
levels of SULT1A1, 1A2, 1A3, 1B1, 1C2, 1C4, 1E1, and 2A1 in human liver cytosols isolated from
prenatal, infant (0-12 months-old), and child (1-5, 6-11, and 12-18 years-old) donors. Half of these
SULTs, SULT1A1, 1C2, 1E1, and 2A1, were detected in at least 90% of the samples that were
evaluated, while the others were detected in smaller percentages of the samples (11-69%). Most
SULT proteins were detected in the prenatal period, some as early as 9-10 weeks of gestation,
and their prenatal levels were generally highest at the beginning of the second trimester (14-17
weeks) (Appendix M).
SULT1A1 was detected in all but two of the cytosolic fractions that were analyzed (both
were prenatal samples) and was the most abundant SULT protein regardless of developmental
stage (median levels of 1,130 to 2,681 fmol/mg cytosolic protein among the age brackets).
SULT1A1 protein levels were relatively constant throughout the age groups that were evaluated,
although the levels appeared to trend upward somewhat during later childhood (6-11 and 12-18
years) (Fig. 3.6).
SULT1A2 was detected in most (69%) of the cytosolic fractions that were analyzed, with
the highest frequency of detection in children 12-18 years of age (88%). The median levels of
SULT1A2 protein were highest in the two oldest age groups (195 fmol/mg in children 6-11 years
and 145 fmol/mg in children 12-18 years).
SULT1A3 was detected in only 34% of the samples and was detected more frequently in
samples from some of the earlier age groups [prenatal (60%) and children 1-5 years of age (48%),
although not infant (16%)] than it was in samples from older children (13-19%). The median level
of SULT1A3 in the prenatal samples was 144 fmol/mg.
SULT1B1 was detected in a relatively small percentage of the samples that were analyzed
(38%). The percentage of detection was especially low in the prenatal samples (21%). Detection
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then trended upward, from 36% of infant samples to 75% of children 12-18 years. The median
level of SULT1B1 in children 12-18 was 331 fmol/mg.
SULT1C2 was detected in 95% of the samples that were evaluated. The median levels of
protein were significantly higher in the prenatal samples (61 fmol/mg) than they were in the other
age groups (except infants). Unlike SULT1C2 protein, and unlike the findings for SULT1C4
mRNA, SULT1C4 protein was detected in a small percentage of the samples (11%). The largest
percent detection of SULT1C4 protein occurred in the prenatal samples (27%), and the majority
of this was seen in the earliest ages that were evaluated (~9-16 weeks) (Fig. 3.5). No SULT1C4
protein was detected in children 6-18 years.
SULT1E1 was detected in all samples that were evaluated. SULT1E1 was the second
most abundant SULT protein in prenatal liver cytosolic fractions (873 fmol/mg) and its levels were
lower in the postnatal groups (104-156 fmol/mg).
SULT2A1 was detected in 90% of the samples and was detected at approximately this
frequency in all age groups (87 to 92%). The median levels of SULT2A1 in cytosols from prenatal
donors and children 12-18 were 45 and 158 fmol/mg, respectively.
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Figure 3.5: SULT protein developmental expression profiles in human liver cytosolic
fractions analyzed by MRM.
SULT1A1, 1A2, 1A3, 1B1, 1C2, 1C4, 1E1, and 2A1 protein levels were measured by MRM in a
library of 193 human liver cytosolic fractions from prenatal and pediatric (divided into infant, 1-5
year-old, 6-11 year-old, and 12-18 year-old groups) donors. The data for each developmental
stage are presented as box and whisker plots of femtomole SULT/mg cytosolic protein. *>LD,
greater than the limit of detection = the number of samples in each group with detectable levels
of SULT protein. Groups not sharing a letter are significantly different from each other, P< 0.05.

85
3.4

Discussion
Exposure to drugs and other synthetic chemicals during fetal life can have serious

consequences on the health of the exposed individuals as most of the xenobiotic-metabolizing
enzymes that can protect against such insults are not well-developed during the prenatal period.
Because the metabolic capacity of humans varies during development, the impact of foreign
substances is affected by the combination of the xenobiotic-metabolizing enzymes that are
expressed at the time of exposure by the fetus as well as by the mother and fetus. For example,
the gastroprokinetic drug cisapride was once prescribed to treat gastroesophageal reflux and
other gastrointestinal disorders in neonates and infants. However, due to low CYP3A4 activity,
cisapride treatment of neonates was associated with significant adverse effects on heart rhythm
(Kearns et al., 2003). Therefore, identifying the enzymes that determine the xenobioticmetabolizing capacity of the liver during early stages of development is important, both to
understand the physiological roles of these enzymes in human development and the risks that
are associated with xenobiotic exposures during critical life windows of susceptibility.
To determine the developmental expression patterns of the major SULTs that have been
detected in human liver, we used liver specimens that were mostly obtained from National
Institutes of Health-supported tissue repositories. That human tissue RNA is susceptible to
degradation due to postmortem processes as well as the handling and storage procedures that
are utilized is well known (Holland et al., 2003). Although some of the liver RNA samples we used
for RT-qPCR were partially degraded, we do not believe that this negatively affected our results.
Previous studies have indicated that the effect of RNA quality is minimal when (1) Ct values are
normalized to a reference gene, (2) PCR products are short (<200 bp), and (3) PCR reaction
efficiency is high (Antonov et al., 2005; Fleige et al., 2006; Weis et al., 2007; Gonzalez-Herrera
et al., 2013). In this study, we used TaqMan Gene Expression assays that produce relatively short
amplicons (<200 bp) and have essentially 100% amplification efficiency, and we normalized
mRNA levels to 18S RNA levels, which were relatively stable among the samples that were
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included in the analysis. As for the RNA-seq data, the RQI values and total reads did not
significantly correlate, suggesting that partial degradation of some RNA samples did not adversely
affect the analysis. Additionally, the expression profiles of most SULTs that were determined by
RT-qPCR, RNA-seq, and mass spectrometry were qualitatively similar, suggesting that RNA
quality did not affect our overall conclusions.
Our analyses indicate that SULT1A1 (TV1), 1B1, 1A3, 1C2, 1C4, 1E1, and 2A1 transcripts
are relatively abundant in prenatal human liver. The RT-qPCR and RNA-seq data were generally
consistent, although some discrepancies were noted, such as the above-described differences in
SULT1B1 and 1C4 RNA abundance in the prenatal specimens that were determined by the two
methods. Additionally, the correlation analyses using the data analyzed by RT-PCR and RNAseq we performed, suggested that the expression of several SULTs and CYP3A7 could be
coregulated in prenatal liver. However, the genes that were found to be correlated by analyzing
RT-qPCR data were different from these that were identified from the RNA-seq data. To some
extent, these discrepancies could reflect the small differences in developmental ages of the
prenatal specimens in the two datasets, as the specimens analyzed by RNA-seq were from
subjects at 14-16 weeks of gestation while those analyzed by RT-qPCR were from donors at 1819 weeks of gestation. Differences could also reflect the nature of the two RNA quantification
approaches, where one specifically targets a particular region of a targeted transcript sequence
and the other assembles and aggregates counts of sequence reads that map onto the human
genome. However, the overall consistency of the findings, whereby generally comparable results
were obtained in two independent sets of tissue specimens analyzed by two different mRNA
measurement techniques, supports the validity of our findings.
In chapter 2, we showed that the most abundant SULT mRNAs (as determined by RTqPCR) in primary cultured fetal human hepatocytes (in approximate order of abundancy) were
SULT1C4 > 1E1 > 1A1 ≈ 2A1 > 1C2, which was the same order (as estimated by median Ct
values) that was seen in the prenatal sample set analyzed by RT-qPCR (i.e., using the same
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assays). In the HepaRG model, SULT1B1, 1C2, 1C3, 1C4, and 1E1 temporal expression patterns
are consistent with the developmental expression patterns observed in the liver tissue specimens,
assuming that confluent HepaRG cells represent an early differentiation stage akin to fetal liver,
while differentiated HepaRG cells represent a stage that is more like adult liver.
We also determined the expression profiles of SULT proteins during liver development
using a library of human liver subcellular fractions that has been previously utilized by us and
others to characterize the developmental expression profiles of xenobiotic-metabolizing enzymes,
including flavin-containing monooxygenase 1 and 3 (Koukouritaki et al., 2002), CYP2C9 and
2C19 (Koukouritaki et al., 2004), CYP2E1 (Johnsrud et al., 2003), CYP3A (Stevens et al., 2003),
and SULT1A1, 1E1, and 2A1 (Duanmu et al., 2006). These previous studies used Western blot
and enzymatic activity analyses to demonstrate that xenobiotic-metabolizing enzymes display
three basic patterns of developmental expression (Hines, 2013), and that enzymes belonging to
the same subfamily can have markedly different expression profiles.
In the current investigation, we used MRM to measure SULT protein contents. Mass
spectrometry-based approaches have been used to detect and quantify enzymes and
transporters involved in drug disposition (Groer et al., 2014; Cieslak et al., 2016; Bhatt et al.,
2018). As confirmation of the approach, SULT1A1, 1E1, and 2A1 were found to exhibit the same
expression profiles that we previously reported when the liver cytosolic fractions were analyzed
by Western blot (Duanmu et al., 2006).
SULT1A2 mRNA and protein were detected in the liver specimens, and their levels were
higher in the postnatal liver samples from donors more than 6 years of age than they were in
prenatal or infant samples. These observations are at variance with a previous report that did not
detect SULT1A2 protein in human hepatic or extra-hepatic normal tissue or tumor samples that
were analyzed by Western blot (Nowell et al., 2005). In other earlier studies ,SULT1A2 mRNA
was detected by conventional RT-PCR in some tissues including liver (Zhu et al., 1996; Dooley
et al., 2000), and it was suggested that SULT1A2 mRNA could not be translated into protein
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because of a splicing defect. However, two studies did detect low levels of SULT1A2 protein in
adult human liver (Meinl et al., 2006; Teubner et al., 2007)
Unlike SULT1A2, SULT1A3 was preferentially expressed in prenatal specimens. In
agreement with our analyses, previous studies demonstrated that SULT1A3 mRNA, protein, and
enzymatic activity were detectable in fetal liver, but protein and activity were very low or
undetectable in adult liver (Cappiello et al., 1991; Richard et al., 2001; Stanley et al., 2005; Riches
et al., 2009), although SULT1A3 mRNA was reported to be detectable in adult liver (Wood et al.,
1994; Dooley et al., 2000) and was observed by RNA-seq in the current study with samples from
12-18 year old donors.
As indicated in chapter 1.4.2, SULT1B1 is primarily expressed in the adult liver and it has
been detected in the fetal liver at the mRNA level (Wang et al., 1998; Stanley et al., 2005; Meinl
et al., 2006; Riches et al., 2009). In the current analysis, we determined that SULT1B1 protein
levels increased during development. These findings were consistent with the observed SULT1B1
RNA expression pattern obtained by qPCR, but not RNA-seq. SULT1C2 mRNA and protein were
preferentially expressed during early development, in agreement with previous studies reported
in chapter 1.4.2 (Her et al., 1997; Stanley et al., 2005); one study did report detectable, but very
low levels of mRNA in adult liver (Dooley et al., 2000).
Although SULT1C4 mRNA was relatively abundant in the prenatal liver specimens, its
protein was present at very low levels. This discrepancy appears to be at least partially attributable
to the expression of multiple SULT1C4 transcript variants in liver, some of which do not give rise
to stable protein (to be discussed in chapter 4).
In this report we demonstrated that most of the SULT1 and SULT2 family members are
expressed in the liver during early development, suggesting that SULTs could be involved in the
regulation of physiological processes in the fetus, as well as metabolism of xenobiotics that pass
through the placenta. Further studies are needed to clarify the roles of the SULTs as determinants
of health and disease during gestation and throughout the human life-course.
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CHAPTER 4: DEVELOPMENTAL EXPRESSION OF SULT1C4 TRANSCRIPT VARIANTS IN
HUMAN LIVER
4.1

Introduction
The SULT1Cs are an understudied subfamily of enzymes that were identified and cloned

using extrahepatic tissues (Her et al., 1997; Sakakibara et al., 1998; Duniec-Dmuchowski et al.,
2014). Very little is known about the SULT1Cs in the liver, which is the major site of expression
for most SULTs (Stanley et al., 2005; Riches et al., 2009). Data presented in chapter 2 and 3 and
other previous reports indicated that SULT1C2 and SULT1C4 mRNA is preferentially expressed
during early life stages. SULT1C3 expression was minimal in the hepatic tissues. While the
abundance of SULT1C2 mRNA was reflected at the protein level, the expression of SULT1C4
mRNA and protein did not correlate with each other (as discussed in chapter 3). There are several
transcript variants (TVs) of SULT1C4 indexed in the GenBank database, including the full-length
mRNA containing seven exons (TV1, NM_006588), a variant mRNA lacking exons 3 and 4 (TV2,
NM_001321770), two non-coding RNA variants (TV3, NR_135776 and TV4, NR_135779), and a
predicted transcript variant (TVX1, XM_017003807). The purpose of this study was to identify the
TVs that are expressed in the developing human liver and to determine the TVs that are translated
into protein to gain more insight into the cause of the lack of correlation between SULT1C4 mRNA
and protein expression.
4.2

Materials and Methods

Human Tissues: The human liver specimens that were used in this study are the same tissues
that were analyzed by RT-qPCR and RNA-seq in chapter 3 (described in the methods section of
chapter 3).
RNA isolation and gene expression analysis: Total RNA was isolated from Caco-2 colorectal
adenocarcinoma cells or HepaRG cells using the Purelink RNA Mini Kit (Thermo Fisher
Scientific). RNA was isolated from liver specimens analyzed by qRT-PCR and RNA-seq as
described in chapter 3. RNA was reverse transcribed to cDNA and a primer set that was predicted
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to amplify a 1.2 Kb fragment of the full-length SULT1C4 sequence (NM_006588.3) was used to
evaluate SULT1C4 expression in Caco-2 and HepaRG cells by standard RT-PCR. The 3 resulting
PCR fragments, representing different transcript variants (TVs) were ligated into pGL4.10
(Promega), sequenced, and used as synthetic standards for subsequent RT-qPCR analysis. RTqPCR was performed using SYBR Green, a common forward primer, and reverse primers (Table
4.1) spanning an exon-exon junction that were designed to amplify one of the TVs shown in Fig.
4.2A. A standard curve of Ct versus attomol (amol) plasmid DNA was prepared for each SULT1C4
TV (Fig. 4.2B) by spiking varying amounts of the standard (100 ag to 100 pg) that were prepared
by cloning the fragments shown in Fig. 4.1. For the purpose of plotting the data and calculating
the amounts of each SULT1C4 TV detected in the liver specimens the amounts of each standard
were converted from g to moles. The RNA content of each TV was then calculated using the
following least squares line equations below generated from the standard curve for each TV and
expressed as amol/µg RNA.
Equation 1 (TV1): 𝑦 = −3.639𝑥 + 13.22
Equation 2 (TV2): 𝑦 = −4.229𝑥 + 16.04
Equation 3 (E3DEL): 𝑦 = −3.77𝑥 + 14.91
SULT1C4 TV expression in transfected HEK293 cells was determined using a TaqMan Gene
Expression Assay (Thermo Fisher Scientific). The procedure for RNA-seq analysis was previously
described in chapter 3. Transcript variant information was obtained by analyzing the RNA-seq
data using StringTie analysis software (Pertea et al., 2015).
Western blot analysis:_HEK293 cells were plated into 100 mm dishes and transfected with a
complex consisting of a DDK-tagged pcDNA3.1 expression plasmid containing one of the
SULT1C4 TVs (4 µg), pBluescript II KS+ (16 µg), and Lipofectamine 2000 (50 µl) for 72 hours.
Whole cell lysates were prepared and quantified as previously described in the methods of
chapter 2. Proteins (amounts indicated on the figure) were then resolved on 12.5% sodium
dodecyl sulfate-polyacrylamide gels, transferred to polyvinylidene difluoride membranes, and
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incubated for one hour with blocking buffer [2.5% non-fat dry milk in Tris-buffered saline with
Tween 20 (Sigma-Aldrich)]. The membranes were then incubated overnight at 4°C with mouse
monoclonal anti-DDK antibody (Clone OTI4C5; Origene, Rockville, MD) diluted 1:2000 followed
by a two-hour incubation with horseradish peroxidase-conjugated goat anti-mouse IgG (sc-2005;
Santa Cruz Biotechnology) diluted 1:20,000. The blot was stripped and reprobed with b-actin (as
described in the methods of chapter 2).
Quantification of SULT1C4 TV protein by mass spectrometry: HEK293 cells were plated and
transfected as described in the paragraph above. Whole cell lysates were prepared and quantified
as described in methods of chapter 2. For each sample, 100 µg of protein was resolved on a 412% Bis-Tris gel (Thermo Fisher Scientific) in duplicate. The region between 20-43 kDa was
excised and proteins were reduced, alkylated, and digested with trypsin in-gel. Peptides were
eluted from the gel pieces and dried. The mass spectrometry analysis and quantification of
SULT1C4 transcript variant content in the whole cell lysates was performed as described in
chapter 3. Samples were analyzed in triplicate; therefore, results represent the average of three
samples.
Statistical analysis: Data were analyzed as described in chapter 3.
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Table 4.1: Primers used in the RT-qPCR analysis
Primer Name
Sequence
SULT1C4- 1.2 Kb forward

5’-TAG AGG GCT GGA TAG TGT GGT AGT G-3’

SULT1C4- 1.2 Kb reverse

5’-GAC ATG GAG AGA GGG AAG CTC AAT-3’

SULT1C4- forward

5’-CCT ATC CTA AAG CAG GAA CAA CA-3’

SULT1C4- TV1 reverse

5’-ATG AGC TTG TTC CAA ACC AG-3’

SULT1C4- TV2 reverse

5’-CAG GAG CCC CAG CAC ACA G -3’

SULT1C4- E3DEL reverse

5’-GGA TTT CTT GCT ACA TAG ATT ATC AG -3’
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4.3

Results

4.3.1 Identification of SULT1C4 TVs expressed in human intestinal and hepatic cell lines.
Freimuth et al. is the only report that examined human SULT1C4 cDNA using fetal lung cDNA
and 5’-RACE analysis (Freimuth et al., 2000). In the current analysis we used HepaRG and Caco2 cDNA to investigate the SULT1C4 transcript variants that are expressed in human hepatic and
intestinal cells. Using primers predicted to amplify an approximately 1.2Kb fragment of the fulllength SULT1C4 (TV1) coding region, 1.2 Kb (upper band), 1.1 Kb (middle band), and 1 Kb (lower
band) fragments were detected for both HepaRG and Caco-2 cells (Fig. 4.1). Sequencing of the
fragments and alignment analysis revealed that the middle band represents a transcript that is
missing exon 3 (E3DEL) and that the lower band is missing exons 3 and 4 and aligns with the
TV2 that is reported in GenBank. These data indicated the presence of three potential transcripts
that are co-expressed in human intestinal and liver cells.
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Caco-2 HepaRG
TV1
E3DEL
TV2

Figure 4.1: Amplification of three SULT1C4 TVs from Caco-2 and HepaRG cells.
RNA was isolated from Caco-2 and HepaRG cells and reverse transcribed to cDNA. PCR was
performed using primers predicted to amplify an approximately 1.2Kb fragment of the full-length
SULT1C4 (TV1) coding region. PCR products were resolved on a 1% agarose gel.
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4.3.2 Expression of SULT1C4 TVs in the developing liver. To characterize the developmental
expression patterns of SULT1C4 TVs expressed in the human liver, we used two sets of human
liver specimens that were isolated from prenatal and postnatal donors. Each set of liver
specimens was analyzed separately using either RT-qPCR or RNA-seq analysis.
As shown in figure 4.2C, prenatal, infant, and adult liver specimens analyzed by RT-qPCR
expressed the three SULT1C4 TVs. All three TVs were primarily expressed in prenatal liver and
their expression decreased markedly in the postnatal periods. TV2 was the most abundant
transcript in prenatal, infant, and adult specimens. TV2 mRNA in prenatal liver (6.0 fmol/µg) was
~5-fold higher than that of TV1 (1.3 fmol/ug). Expression of the E3DEL transcript was minimal in
all liver specimens. SULT1C4 transcript variant information generated by analyzing a library of
prenatal and pediatric (i.e., infant and children 1-18 years-old) liver specimens using RNA-seq
identified three TVs expressed in the liver, TV1, TV2, and non-coding TV. These TVs were also
preferentially expressed in the prenatal livers and TV2 was the most abundantly expressed TV
whereas the levels of expression of TV1 and the non-coding RNAs were much lower.
4.3.3 SULT1C4 TV protein abundance. To investigate the reason for the lack of correlation
between SULT1C4 RNA and protein in the developing liver (reported in chapter 3), we examined
the SULT1C4 TV protein content in whole cell lysates prepared from HEK293 cells transfected
with DDK-tagged TV1, TV2, or E3DEL expression plasmid. The results of the Western blot
analysis indicated that only TV1 and TV2 were expressed at the protein level (Fig. 4.3A). Contrary
to our observation at the RNA level, TV1 protein was more abundant that of TV2 (Fig. 4.3A).
When the E3DEL amino acid sequence was computationally examined using SnapGene software
(GSL Biotech, Chicago, IL), we found that deletion of exon 3 causes a frameshift mutation that
introduces a premature stop codon, which explains the absence of E3DEL protein. We also
measured the mRNA levels of the three SULT1C4 transcripts using RT-qPCR to confirm that the
differences in protein levels were not caused by variation in the transfection or transcription
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efficiency. In Fig. 4.3B, we showed that the mRNA levels of TV1, TV2, and E3DEL were relatively
the same (Fig. 4.3B),.
As some factors, such as the binding affinity of the protein to the membrane during transfer
in Western blot analysis, can influence the results obtained from Western blot, we used MRM to
quantify TV1 and TV2 protein in the transfected HEK293 cells. Our results demonstrated that TV1
and TV2 were both expressed in the whole cell lysates prepared from transfected HEK293 cells,
but only TV1 protein level was quantifiable [5.31 fmol/mg] (Table 4.2).
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Figure 4.2: Developmental expression of SULT1C4 TVs in human liver.
(A) Schematic representation of the SULT1C4 TVs that were identified in Caco-2 and HepaRG
cells and the primers designed to detect these transcripts individually. (B) A standard was
prepared for each SULT1C4 transcript by cloning the 3 fragments shown in Fig. 4.1, and
standard curves were prepared to permit quantification of transcript amounts. (C) RNA was
isolated from specimens of prenatal (n=10), infant (n=7), and adult (n=7) human liver, and
SULT1C4 TV levels were measured using RT-qPCR. For each TV, data were grouped
according to developmental stage and are expressed as amol SULT1C4 transcript/μg of RNA.
Data are shown as scatter plots with the horizontal lines representing the median values.
***Significantly different P< 0.001. (D) RNA was isolated from prenatal (n=10) and pediatric
(n=52) human liver specimen samples and analyzed by RNA-seq. Data are shown as scatter
plots with the horizontal lines representing the median values. Groups not sharing a letter are
significantly different from otherone an, p<0.05.
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A

B

Figure 4.3: SULT1C4 protein and mRNA levels after transfection of expression plasmids
for individual TVs into HEK293 Cells.
Whole cell lysates (A) and RNA (B) were prepared from HEK293 cells that were transfected with
DDK-tagged TV1, TV2, or E3DEL expression plasmid and analyzed by RT-qPCR and Western
blot, respectively. The results shown are from one representative experiment. Similar results
were obtained from two additional experiments. EV, empty vector.
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Table 4.2: SULT1C4 TVs’ protein quantification in whole cell lysates of transfected
HEK293 cells by MRM.

Sample
EV
TV1
TV2

Amount (fmol/mg)
N/A
5.31± 0.27
<LD

<LD stands for below limit of detection
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4.4

Discussion
Xenobiotic-metabolizing enzymes that are expressed during early developmental periods

are crucial in determining the influences of xenobiotic exposures on the developing fetus.
Although they generally play a protective role, detoxification enzymes can increase the
mutagenicity of many compounds that enter the body, and could therefore enhance the
susceptibility of the fetuses to cancers in tissues that are exposed to bioactivated procarcinogens
(Banoglu, 2000). Many studies have reported the detection of SULT mRNA, protein, and enzyme
activity in various human tissues isolated from prenatal donors (Hines, 2008), indicating that these
enzymes are involved in xenobiotic metabolism and the regulation of physiological functions
during gestation.
SULT1C4 mRNA was reported to be abundantly expressed in fetal lung and kidney
(Sakakibara et al., 1998). Using two separate sets of human liver specimens isolated from
prenatal and postnatal donors and in vitro models of human liver development (i.e., HepaRG cells
and primary cultures of fetal hepatocytes), we demonstrated that SULT1C4 mRNA is primarily
expressed in prenatal period or undifferentiated hepatocytes, respectively (presented in chapters
2 and 3). Recent studies indicated that SULT1C4 has high sulfonation capacity towards a wide
range of drugs, environmental pollutants, and procarcinogens (Table 1.1). Guidry et al. recently
reported that SULT1C4 can activate various estrogenic compounds, including dietary flavonoids
and environmental estrogens (Guidry et al., 2017). These findings suggested that SULT1C4 could
metabolize exogenous substrates and regulate hormone signaling pathways in human fetuses.
Therefore, it is important to determine the tissue-specific and developmental expression patterns
of SULT1C4 to improve our understanding of its role in modulating the susceptibility of human
tissues to chemical exposures and regulating physiological functions, including hormone activity.
In the current analysis we identified at least four SULT1C4 transcript variants that were coexpressed in human hepatic and intestinal cells and human liver specimens that were analyzed
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by RT-qPCR and RNA-seq. The four SULT1C4 transcripts were preferentially expressed in the
prenatal livers in agreement with our findings in chapter 3, where we determined that SULT1C4
mRNA is preferentially expressed in the prenatal liver using the same two sets of samples that
were analyzed in this study.
Our RT-qPCR and RNA-seq analyses indicated that TV2 is the most abundant transcript in
human livers. By aligning the amino acid sequences of the TV1- and TV2-encoded proteins, also
referred to as isoforms a (NP_006579.2) and b (NP_001308699.1) in the NCBI database, we
determined that isoform b has a 75-amino acid deletion. The deletion does not cause a frameshift
mutation, and thus the remaining amino acid sequence of isoform b aligns perfectly with that of
isoform a (except for a single amino acid change). However, because the active site of SULT1C4
(catalytic histidine residue) is located within exon 3 (personal communication from collaborator,
Dr. Charles Falany, University of Alabama at Birmingham), TV2, which lacks exons 3 and 4,
cannot encode an active sulfotransferase enzyme.
Unlike TV1, the protein encoded by TV1 is more abundant than that of the TV2-encoded
protein. This finding could explain the lack of correlation between SULT1C4 mRNA and protein in
the human liver specimens and cytosolsic fraction, respectively, that was reported in chapter 3.
Sequence changes at the amino acid level can impact enzyme function, activity, stability, binding,
and dissociation (Yue et al., 2005; Capriotti et al., 2012; Bhattacharya et al., 2017). Therefore, it
is plausible that the discrepancy in the abundancy between TV2 mRNA and protein is because of
the decreased stability of the TV2 protein, which could be caused by the deletion of sequences
within exon 3 and 4 that are essential for maintaining the stability of the protein.
The findings of this study suggest that SULT1C4 might not play a major role in the
developing liver, but it is possible that this enzyme could be involved in metabolizing xenobiotics
and endogenous molecules in other tissues, including kidney and lung, where it was previously
detected (Sakakibara et al., 1998). Further investigation is required to understand the functional
implications of SULT1C4 TV expression in hepatic and extra-hepatic human tissues, primarily
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during early developmental periods, and to determine the reason behind the discrepancy between
the expression of TV2 at the mRNA and protein levels.
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CHAPTER 5: TRANSCRIPTIONAL REGULATION OF HUMAN CYTOSOLIC
SULFOTRANSFERASE 1C3 BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORg
IN LS180 HUMAN COLORECTAL ADENOCARCINOMA CELLS
5.1

Introduction
SULT1C3 is one of the least characterized human SULTs. The computationally predicted

SULT1C3 gene consisted of seven protein coding-exons that span 18 Kb and an initial coding
exon (exon 2) that has 3 in-frame ATG translation start sites (Freimuth et al., 2004). SULT1C3
gene was also predicted to have a duplication of exons 7 and 8 that could theoretically be
transcribed and processed into four splice variants containing exons 7a/8a, 7a/8b, 7b/8a, or 7b/8b
(the first TV to be indexed in the NCBI database) that encode isoforms SULT1C3a-d, respectively
(Freimuth et al., 2004). In a later study, SULT1C3d putative cDNA was identified using
computational analysis, suggesting that the this TV is the most favorably expressed SULT1C3 TV
(Meinl et al., 2008a). Substrates of the SULT1C3d enzyme, including benzylic alcohols,
cholesterol, and lithocholic acid, were identified by expressing the recombinant enzyme in
bacteria (Allali-Hassani et al., 2007; Meinl et al., 2008a). Also, a recent study reported that
SULT1C3 had the highest sulfonation capacity of twelve human SULTs tested towards tolvaptan,
which is a selective vasopressin V2-receptor antagonist that possesses a benzylic hydroxy group
(Fang et al., 2015). Previous studies did not detect SULT1C3d, which is encoded by SULT1C3
mRNA reference sequence (NM_001008743), in any of the twenty human tissues that were used
for expression profiling (Freimuth et al., 2004; Meinl et al., 2008a). However, using reverse
transcription-polymerase chain reaction and rapid amplification of cDNA ends (RACE) analysis,
Dr. Kocarek’s lab characterized and detected SULT1C3 mRNA containing exons 7a/8a, encoding
SULT1C3a, in human small intestine and colon and in LS180 colorectal adenocarcinoma cells
(Duniec-Dmuchowski et al., 2014). They also found that SULT1C3 mRNA is up-regulated by
activation of several nuclear receptors, including PPAR α and γ agonists (Rondini et al., 2014).
The purpose of this study was to determine the mechanism responsible for the PPAR-mediated
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transcriptional up-regulation of SULT1C3 in LS180 cells by identifying functional PPRE(s) in a
polymorphic region of the SULT1C3 promoter.
5.2

Materials and Methods

Materials: Ciprofibrate was provided by Sterling Winthrop Pharmaceuticals Research Division
(Rennselaer, NY). 4-[[[2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]methyl]thio]-2methylphenoxyacetic acid (GW0742) was obtained from Tocris. Sources of the following materials
were all listed in the methods section of chapter 2: DMSO, GW3965, GW4064, GW7647,
rosiglitazone, rifampicin, TCDD, cell culture media and supplements, Lipofectamine 2000, and
oligonucleotides. Targets of the agonists used is listed in Appendix E.
Cell culture: LS180 cells were purchased from the American Type Culture Collection (ATCC,
Manassas, VA) and cultured in Eagle’s Minimum Essential Medium (MEM) supplemented with
10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, MEM non-essential amino
acids, 100 U/ml penicillin, and 100 µg/ml streptomycin. HEK293 cells were provided by Dr. YeShih Ho (Wayne State University) and cultured in Dulbecco's Modified Eagle Medium
supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. Cells
were maintained in a humidified atmosphere of 5% CO2 and 95% air at 37°C.
Preparation of SULT1C3 reporter plasmids: Genomic DNA was isolated from MCF10A and LS180
cells using the DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA). Genomic DNA (100 ng),
Herculase II Fusion DNA Polymerase (Agilent Technologies, Santa Clara, CA), and a primer set
that was predicted to amplify a 2.8 Kb fragment of the SULT1C3 5’-flanking region (nt -2780:+38),
as identified by our previous 5’- RACE analysis, were used for PCR (Duniec-Dmuchowski et al.,
2014). The resulting PCR fragments were ligated into the KpnI and XhoI sites of the promoterless
pGL4.10[luc2] firefly luciferase reporter plasmid (Promega Corporation, Madison, WI). The
plasmid containing the 2.8 Kb insert was used as a template to prepare a construct containing ~1
Kb of the SULT1C3 5’-flanking sequence (nucleotides -1008:+38), which was subsequently used
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as a template to prepare a series of deletion constructs that were designed based on the positions
of three PPRE motifs, at nucleotides -769, -446, and -383, that were predicted by computational
analysis using MatInspector (Genomatix, Ann Arbor, MI) (Quandt et al., 1995; Cartharius et al.,
2005). All primer sequences are shown in Table 5.1. The sequences of all SULT1C3 clones were
confirmed using the services of the Applied Genomics Technology Center at Wayne State
University.
Site-directed mutagenesis of PPRE motifs: Mutations were introduced into the three predicted
PPREs using the wild-type or singly mutated (at the -446 PPRE) SULT1C3 1 Kb construct as
template and the QuikChange II Site-Directed Mutagenesis Kit according to the manufacturer’s
instructions (Agilent Technologies, Santa Clara, CA). The mutagenic primers are listed in Table
5.1.
Transient transfection analysis and treatments: Approximately 250,000 LS180 cells/well in 1 ml
of supplemented MEM were plated into 12-well plates. Cells were transfected 48 to 72 hours after
seeding with a complex containing 4 μl Lipofectamine 2000, 1.6 μg of a firefly luciferase reporter
plasmid, and 1 ng pRL-CMV (Promega) per well diluted in 400 μl Opti-MEM (Life Technologies).
24 hours after transfection, fresh supplemented MEM was added containing either DMSO (0.1%
final concentration) or a transcription factor activator (at concentrations indicated in the text below
and figure legends). Treatment medium was changed after 24 hours. Cells were lysed, collected,
and analyzed as described in chapter 2.2.
PPARγ in vitro binding assay: A PPARγ expression plasmid (pTR151) was provided by Dr. Todd
Leff (Wayne State University). HEK293 cells were plated into 100 -mm dishes and transiently
transfected with a complex containing 50 μl Lipofectamine 2000, 4 µg of PPARγ expression
plasmid, 0.8 µg of a Tet-off plasmid, and 15.2 µg of pBluescript II KS+ (Agilent Technologies).
Forty-eight hours after transfection, cells were harvested and nuclear extracts were prepared
using the NucBuster Protein Extraction Kit (Millipore, Billerica, MA). Competitive binding
experiments were performed using the TransAM PPARγ Kit (Active Motif, Carlsbad, CA), an
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ELISA-based assay. Each well in the 96-well plate contained an immobilized biotinylated
oligonucleotide probe that included a consensus PPRE sequence. Competitor oligonucleotides
containing the wild-type or mutated SULT1C3 PPRE (at nt -769) or CYP4A1 PPRE as positive
control (Aldridge et al., 1995) were designed (sequences are shown in Table 5.1), purchased,
and annealed by heating at 95ºC for 5 minutes followed by slowly cooling to room temperature.
Binding assays were performed according to the manufacturer’s instructions. Incubations
included 5 µg of nuclear protein extract and 0, 30, or 100 pmol of competitor oligonucleotide, and
were performed for one hour. PPARγ binding to the biotinylated probe was determined by
colorimetric analysis using a microplate reader (CLARIOstar, BMG LABTECH, Cary, NC) at
wavelengths of 450 and 655 nm.
RNA interference: LS180 cells were plated into 12-well plates and cotransfected with 1.6 μg of
the SULT1C3 1 Kb reporter plasmid and 20 pmol of an siRNA pool targeting PPARα, PPARδ, or
PPARγ mRNA (ON-TARGETplus SMARTpool siRNA; Dharmacon, Lafayette, CO) or a negative
control siRNA pool (ON-TARGETplus non-targeting control siRNA, Dharmacon). Cells were
transfected using 4 μl Lipofectamine 2000 and 1 ng pRL-CMV per well. Twenty-four hours after
transfection, cells were treated with DMSO (final concentration of 0.1%), rosiglitazone (1 μM),
GW7647 (10 μM), or GW0742 (10 μM). Treatment medium was changed after 24 hours. After 48hour treatments, cells were collected to measure firefly and Renilla luciferase activities as
described above. A luciferase reporter containing the PPRE from the promoter of the CYP4A1
gene was used as a positive control for detection of PPAR knockdown (Kocarek and MercerHaines, 2002).
Genotyping analysis: Genomic DNA used for the genotyping analysis was isolated from human
liver samples (n = 77). 100 ng of genomic DNA, HotStarTaq Plus DNA Polymerase, and two
primer sets (listed in table 5.1 and shown in Fig. 5.6A) were used to PCR amplify the SULT1C3
alleles in the liver samples. The primer set A and B amplifies the full-length allele (1174 bp) or the
deleted allele (328 bp) whereas the primer set B and C amplifies only the full-length allele (645
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bp). The PCR products were sequenced and aligned to the 2.8 Kb fragment from the promoter
region of the SULT1C3.
Statistical analysis: Statistical analysis was performed using GraphPad Prism (version 6;
GraphPad, La Jolla, CA). Data were analyzed using one-way analysis of variance (ANOVA)
followed by the Neuman-Keuls post-hoc test. p<0.05 was considered significantly different. Data
are presented as means ± SD relative to DMSO-treated control. In each experiment, all treatments
were performed in triplicate. Each experiment was repeated three times.
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Table 5.1: Primers used to prepare reporter constructs and for genotyping analysis and
oligonucleotides used in the PPARγ in vitro binding assay
Primer Name

Sequence

SULT1C3- TSS Reverse*

5’-GGG CTC GAG GCT CCA GGA CAC TGT GCA AGC AA-3’

SULT1C3-2.8Kb Forward

5’-GGG GGT ACC TCT GGT CCT CCT TCA TTC CCG SUCAA-3’

SULT1C3- 1Kb Forward

5’-GGG GGT ACC ATG CTC TAC ATA ATT CAC GTC-3’

SULT1C3-DEL1 Forward

5’-GGG GGT ACC ACA GAG GAC AGA CAA TGT AAA T-3’

SULT1C3-DEL2 Forward

5’-GGG GGT ACC TTT TAT TAC AGG CCT TGT GGT-3’

SULT1C3-DEL3 Forward

5’-GGG GGT ACC TTT CTA CAG GGT CAA AGG GA-3’

SULT1C3-DEL4 Forward

5’-GGG GGT ACC AAC AGG ATG AAA TAA TTG TGC-3’

SULT1C3- MUT#1 Sense

5’-GGA GTT AAG TAA ATA TTG TAC AGA AGG TAT TGT TAA AAT
TCC ATA TAT TTA CAT TGTT CTG TCC TCT GTT TTG CAA-3’

SULT1C3- MUT#2 Sense

SULT1C3- WT PPRE Sense

5’-CCG TAG TTA AAA TTG GTG TAG AAG AAA AAG CTT TTT AGG
AAA CCA CAA GGC CTGT TAA AAC-3’
5’-ACT TGC ACA ATT ATT TCA TCC TGT TCC CTG GAT CCC TGT
AGA AAA TAT ATT CTA TTG CCT CT-3’
5’-AAC AAT GAA CTC TGT ACA ATA TTT -3’

SULT1C3- MUT PPRE Sense

5’-AAC AAT ACC TTC TGT ACA ATA TTT -3’

CYP4A1- WT PPRE Sense

5’-GAA ACT AGG GTA AAG TTC AGT GAG -3’

CYP4A1- MUT PPRE Sense

5’-GAA ACT CGG AGC ACG TTA AGT GAG -3’

SULT1C3- Forward primer A

5’-AGC CAA GTG TAA TGA TGA TAT GAA CC-3’

SULT1C3- Reverse primer B

5’-TTG CTG CCT TTA GTC AAA CTG CT-3’

SULT1C3- Forward primer C

5’-CGA CAT TCT TGC CCT GAA ATA CAC A-3’

SULT1C3- MUT#3 Sense

*The same reverse primer was used to prepare the 2.8Kb, 1.9Kb, 1Kb, DEL1, DEL2, and DEL3
SULT1C3 fragments.
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5.3

Results

5.3.1 Evaluation of the SULT1C3 5’-flanking region for responsiveness to transcription factor
activators. Dr. Kocarek’s lab previously reported that SULT1C3 mRNA levels in LS180 cells were
increased by treatments with several transcription factor activators, including ciprofibrate
(PPARα), rosiglitazone (PPARγ), GW4064 (FXR), GW3965 (LXR), rifampicin (PXR), and TCDD
(AhR) (Rondini et al., 2014). To determine the mechanisms underlying the regulation of SULT1C3
by these transcription factor activators, luciferase reporter constructs containing portions of the
5’-flanking region of SULT1C3 were prepared. While attempting to amplify a 2.8 Kb fragment (2789: +36) using human genomic DNA from two different sources, LS180 cells and the MCF10A
mammary epithelial cell line, both the expected 2.8 Kb fragment and a 1.9 Kb fragment were
generated from LS180 cells, while only the 1.9 Kb fragment was amplified from MCF10A cells
(Fig. 5.1A). Sequencing of the two fragments revealed that the 1.9 Kb fragment had an internal
deletion of 863 nt (-1008: -146) relative to the 2.8 Kb fragment (Fig. 5.1A). LS180 cells were
transiently transfected with a reporter plasmid containing the 2.8 Kb or 1.9 Kb fragment and then
treated for 48 hourhours with 100 µM ciprofibrate, 10 µM rosiglitazone, 1 µM GW4064, 10 µM
GW3965, 30 µM rifampicin, or 0.01 µM TCDD. Of these treatments, ciprofibrate, rosiglitazone,
GW3965, and GW4064 significantly increased luciferase activity from the 2.8 Kb reporter
construct, while rifampicin and TCDD had no effect. However, the GW3965 and GW4064
treatments also increased luciferase activity from the empty reporter plasmid, indicating that these
treatments did not activate elements within the 2.8 Kb SULT1C3 5’-flanking region. Ciprofibrate
and rosiglitazone did not increase the activity of the 1.9 Kb reporter construct (Fig. 5.1B),
suggesting that the 863 nt deletion region contained essential elements for PPAR-mediated
activation of SULT1C3 transcription. Rosiglitazone treatment also significantly activated a
reporter construct containing only the 863 nt deletion and more proximal promoter region (1 Kb
construct; nt -1008: +36), further supporting the importance of the 863 nt deletion region for
PPAR-mediated SULT1C3 transcriptional activation (Fig. 5.2A).
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5.3.2 Concentration-dependent effects of PPARα, PPARδ, and PPARγ agonists on SULT1C3
transcriptional activation. To evaluate the SULT1C3 863 nt deletion region further for its
responsiveness to PPAR activation, we determined the concentration-dependent effects of
agonists for the three PPARs on SULT1C3 reporter activity. For these studies, LS180 cells were
transfected with the 1 Kb reporter construct and then treated with varying concentrations (0.1-10
µM) of rosiglitazone (PPARγ), GW7647 (PPARα), or GW0742 (PPARδ). Rosiglitazone treatment
maximally increased reporter activity at the lowest concentration tested, which is consistent with
its high potency for PPARγ (Fig. 5.2B). While GW7647 and GW0742 also increased reporter
activity, the sub-micromolar concentrations that would reflect the high reported potencies of these
compounds for their respective receptors had little or no effect, while the higher concentrations
that might reflect cross-activation of another PPAR produced concentration-dependent increases
that reached ~3-fold at 10 μM, which is comparable to the magnitude of increase produced by
rosiglitazone (Fig. 5.2B). Treatment with 10 µM GW7647 and GW0742 also induced luciferase
activity from the reporter containing the longer 2.8 KB region but not the 1.9 Kb construct lacking
the 863 nt fragment (Fig. 5.2C), as was seen for ciprofibrate and rosiglitazone (Fig. 5.1B).
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Figure 5.1: Impact of a deletion in the 5’-flanking region of the SULT1C3 gene on its
regulation by transcription factor activators.
(A) PCR was performed with primers designed to amplify a 2.8 Kb fragment of the SULT1C3 5’flanking region using genomic DNA from MCF10A or LS180 cells. The PCR products were
resolved on a 1% agarose gel. A schematic representation of the 2.8, 1.9, and 1 Kb SULT1C3
5’-flanking fragments is shown adjacent to the gel image. (B) LS180 cells were transiently
transfected with the SULT1C3-2.8 Kb or 1.9 Kb luciferase reporter plasmid or with the pGL4.10
[luc2] empty reporter vector and then treated with DMSO (0.1%), ciprofibrate (PPARα agonist,
100 μM), GW3965 (LXR, 10 μM), GW4064 (FXR, 1 μM), rifampicin (PXR, 30 μM), rosiglitazone
(PPARγ, 10 μM), or TCDD (AhR, 0.01 μM) for 48 hours. The cells were then harvested for
measurement of luciferase activities. Each column represents the mean ± S.D. of normalized
(Firefly/Renilla) luciferase measurements relative to DMSO control (n=3 wells per treatment)
from one cell culture experiment. Similar data were obtained in two additional independent
experiments. *, **, ***Significantly different from DMSO-treated controls at P< 0.05, 0.01, and
0.001, respectively.
Figure taken with permission from (Dubaisi et al., 2016)
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Figure 5.2: Effects of PPAR agonists on transcription of SULT1C3 reporter constructs.
(A) LS180 cells were transiently transfected with a luciferase reporter plasmid containing either
the 2.8 Kb or 1.9 Kb SULT1C3 5’-flanking region fragment, with the 1Kb reporter containing the
deleted region, or with control empty vector. 24 Hours after transfection the cells were treated
with DMSO (0.1%) or rosiglitazone (10 µM) for 48 hours. (B) LS180 cells transfected with the 1
Kb reporter were treated with DMSO (0.1%) or with 0.1 to 10 µM rosiglitazone (PPARγ agonist),
GW7647 (PPARα), or GW0742 (PPARδ) for 48 hours. (C) LS180 cells transfected with the 2.8
Kb, 1.9 Kb, or 1 Kb reporter or with control empty vector were treated with DMSO (0.1%),
GW7647 (10 µM), or GW0742 (10 µM). The cells were then harvested for measurement of
luciferase activities. Each column represents the mean ± S.D. of normalized (Firefly/Renilla)
luciferase measurements relative to the corresponding DMSO control (n=3 wells per treatment)
from one cell culture experiment. Similar data were obtained in two additional independent
experiments. *, **, ***Significantly different from DMSO-treated control at P< 0.05, 0.01, and
0.001, respectively.
Figure taken with permission from (Dubaisi et al., 2016)
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5.3.3 Identification of a functional PPRE within the 863 nt deletion region of the SULT1C3 gene.
Computational analysis identified three putative PPREs within the 1 Kb reporter fragment (-1008:
+36) located -769, -446, and -383 nt upstream from the transcription start site. To determine the
functionality of these predicted PPREs, we first prepared four reporter constructs that
progressively deleted the three PPREs from the 1 Kb fragment and transfected them into LS180
cells. Treatment with rosiglitazone (1 μM), GW7647 (10 μM), or GW0742 (10 μM) for 48 hours
increased the luciferase activity of the 1 Kb construct and deletion construct containing all three
PPREs (-808:+36) by 3- to 5- fold relative to DMSO-treated controls, but did not increase the
activity of the three reporters that lacked the first PPRE at -769 (Fig. 5.3A). These data implicate
the PPRE at nt -769 as an essential element for obtaining PPAR-mediated SULT1C3
transactivation.
To confirm the importance of the PPRE at -769 and determine the involvement of the other
two predicted PPREs in the transcriptional activation of SULT1C3, mutations were introduced into
each of the PPREs. LS180 cells were transfected with reporters containing either the wild-type 1
Kb fragment or the 1Kb fragment with one or two mutated PPREs. Mutation of the distal PPRE
(at nt -769) eliminated the response of the 1 Kb reporter to rosiglitazone, GW7647, and GW0742
treatments (Fig. 5.3B). However, the PPAR agonists were all able to produce significant activation
of reporters in which one or both of the more proximal PPREs (at nt -446 and -383) were mutated
(Fig. 5.3B). These data indicate that only the PPRE at -769 is essential for obtaining PPARmediated activation of SULT1C3 transcription.
A competitive ELISA-based in vitro DNA-binding assay was used to determine the ability of
PPARγ to bind directly to the distal PPRE. As shown in Fig 5.4, addition of 30 or 100 pmol of a
double-stranded competitor oligonucleotide containing the wild-type SULT1C3 PPRE, but not the
mutated SULT1C3 PPRE, significantly decreased the amount of PPARγ that bound to a
biotinylated capture probe. This level of inhibition was approximately the same as that produced
by a competitor containing the CYP4A1 PPRE
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A

Figure 5.3: Evaluation of three computationally predicted PPREs within the deleted
region of the SULT1C3 5’-flanking region.
LS180 cells were transiently transfected with a series of reporter plasmids with progressive 5’deletions from the 1 Kb SULT1C3 reporter plasmid that were designed based on the positions
of computationally predicted PPREs (A) or with the 1 Kb SULT1C3 reporter plasmid containing
either the wild-type sequence or site-directed mutations at one or two of the predicted PPREs
(B). Transfected cells were treated with DMSO (0.1%), rosiglitazone (1 μM), GW7647 (10 μM),
or GW0742 (10 μM) for 48 hours and then harvested for measurement of luciferase activities.
Each column represents the mean ± S.D. of normalized (Firefly/Renilla) luciferase
measurements relative to the DMSO-treated, empty vector-transfected group (n=3 wells per
treatment) from one cell culture experiment. Similar data were obtained in two additional
independent experiments. *, **, ***Significantly different from DMSO-treated controls at P< 0.05,
0.01, and 0.001, respectively.
Figure taken with permission from (Dubaisi et al., 2016)
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Figure 5.4: In vitro binding of PPARγ to the predicted SULT1C3 PPRE at nt -769.
In vitro binding was determined by incubating a biotinylated oligonucleotide containing a
consensus PPRE with PPARγ-containing nuclear extract in the absence or presence of
unbiotinylated competitor oligonucleotide (30 or 100 pm) containing wild-type or mutated
CYP4A1 or SULT1C3 PPRE, as described in Methods. Each column represents the mean ±
S.D. absorbance relative to the control absorbance (no competitor added; n=4). ***Significantly
different from control at P<0.001.
Figure taken with permission from (Dubaisi et al., 2016)
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5.3.4 Predominance of PPARγ in the transcriptional regulation of SULT1C3. Rosiglitazone,
GW7647, and GW0742 are potent and selective agonists of PPARγ, PPARα, and PPARδ,
respectively, although each agonist can cross-activate non-target PPAR receptors at sufficiently
high concentrations. As shown in Fig. 5.2, while rosiglitazone increased SULT1C3 reporter
expression at low concentrations consistent with PPARγ activation, the effects of GW7647 and
GW0742 were only evident at relatively high concentrations, suggesting that these compounds
might have increased SULT1C3 transcription by cross-activating PPARγ rather than by activating
their target receptors. To test this possibility, we assessed the impact of siRNA-mediated
knockdown of each PPAR on activation of the 1Kb reporter construct by 1 μM rosiglitazone, 10
μM GW7647, and 10 μM GW0742. The knockdown of PPARγ decreased activation of the positive
control CYP4A1-PPRE reporter and the SULT1C3 1 Kb reporter by almost 90%, not only by
rosiglitazone, but also by GW7647 and GW0742 (Fig 5.5A). However, knockdown of PPARα or
PPARδ had little to no effect on reporter activation by rosiglitazone, GW7647, or GW0742 (Fig
5.5B and 5.5C). These data indicate that the effects of all three PPAR agonists on SULT1C3
transcription can mainly be attributed to the activation of PPARγ.
5.3.5 Genotyping for the full-length and variant SULT1C3 alleles in the human genome. To verify
the existence of the deletion (863 nt) in the genome of normal individuals, we genotyped for the
SULT1C3 alleles in human liver specimens (in collaboration with Dr. Erin Scheutz at the St. Jude
Children’s Research Hospital). Our preliminary experiments showed that primer set A and B
preferentially amplified a fragment from the variant allele (328 bp) over a fragment from the fulllength allele (1174 bp), and thus the individuals that carry both alleles could not be identified using
this primer set. To identify heterozygotes, we designed a forward primer that was placed within
the deleted region (primer C). The primer set C and B exclusively amplified a fragment from the
full-length allele (645 bp). Fig. 5.6B is a representative gel image that shows the genotype for the
SULT1C3 gene in the genome of some individuals. The 1174 bp (upper panel) and 645 bp (lower
panel) were detected in homozygotes for the full-length allele, as shown in specimens with ID

117
numbers 443, 637, 675, and 765. Only a 328 bp band (upper panel) was detected in homozygotes
for the variant SULT1C3 allele, as shown in specimens with ID numbers 350, 432, 482, 663, and
740. Two bands were amplified in heterozygotes, the 385 bp fragment (upper panel) and the 645
bp fragment (lower panel), as shown in specimen ID numbers 433, 619, 623, 638, 656, 674, 684,
686, 727, 744, and 769.
Overall, there were 18 homozygotes for the full-length allele, 15 homozygotes for the variant
allele, and 44 heterozygotes and the calculated frequency for the deleted allele was 0.48 (Fig.
5.6C). The sequencing of the PCR products and alignment of these products to the full-length
fragment indicated that the variant allele has 863 nt deleted and an additional 18 nt inserted at
the site of the deletion.
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Figure 5.5: Effect of PPAR knockdowns on SULT1C3 transcriptional activation by
different classes of PPAR agonist.
LS180 cells were transiently cotransfected with either the SULT1C3 1Kb or the CYP4A1 PPRE
reporter plasmid (positive control) and 20 pmol of either non-targeting (NT) siRNA or siRNA
targeting PPARγ (A), PPARα (B), or PPARδ (C). 24 Hours after transfection cells were treated
with DMSO (0.1%), rosiglitazone (1 μM), GW7647 (10 μM), or GW0742 (10 μM) for 48 hours
and then harvested for measurement of luciferase activities. Each column represents the mean
± S.D. of normalized (Firefly/Renilla) luciferase measurements (3 wells per treatment). Similar
data were obtained in two additional independent experiments. *, **, ***Significantly different
from DMSO-treated controls at P< 0.05, 0.01, and 0.001, respectively.
Figure taken with permission from (Dubaisi et al., 2016)

119
A

1174 bp
645 bp

328 bp

B

C
Genotypes

Observed #

Homozygote reference

18

Heterozygote

44

Homozygote variant

15

Variant allele frequency

0.48*

Figure 5.6: Genotyping analysis for full-length and variant alleles in the 5’-flanking region
of SULT1C3 gene in human liver.
(A) Schematic representation demonstrating the locations of the primers used for the
genotyping analysis and the expected sizes of the PCR products. (B) PCR was performed with
primers designed to genotype SULT1C3 5’-flanking region using genomic DNA prepared from
human liver specimens (n=77). The PCR products were resolved on a 1% agarose gel. (C) A
table presenting the number of observed homozygotes for full-length and variant alleles and
heterozygotes as well as the overall frequency of the variant allele.
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5.4

Discussion
The intestine is a major portal of entry for many drugs, environmental chemicals, and other

xenobiotics, and the intestine is therefore equipped with many xenobiotic-metabolizing enzymes,
including several SULTs. The intestine is the major site of expression for SULT1A3, SULT1B1,
and SULTE1, relative to the kidney, liver, and lung (Riches et al., 2009). SULT1A1, SULT1A3,
and SULT1B1 are abundantly expressed throughout the gastrointestinal tract, while SULT1E1
and SULT2A1 are expressed in the jejunum, ileum, and cecum (Teubner et al., 2007; Riches et
al., 2009). SULT1C enzymes are also expressed in the gastrointestinal tract (as shown in Table
1.2) as well as several human intestinal cell lines, including LS180 and Caco-2 cells (Sakakibara
et al., 1998; Dooley et al., 2000; Meinl et al., 2008b; Rondini et al., 2014).
Rondini et al. previously reported that SULT1C3 expression in LS180 cells is induced by AhR,
FXR, LXR, PPARα, PPARγ, and PXR agonists (Rondini et al., 2014). However, we report here
that only PPAR agonists activated SULT1C3 transcription through sequence information
contained within a 2.8 Kb fragment (-2789: +36) of the gene’s 5’-flanking region. This finding
implies that the cis-elements controlling SULT1C3 expression by the other transcription factors
are located in other regions of the SULT1C3 gene, possibly further upstream or within the 7.1 Kb
intron that separates non-coding exon 1 from exon 2 (Duniec-Dmuchowski et al., 2014).
While attempting to amplify a 2.8 Kb fragment of the SULT1C3 5’-flanking region, we found
that amplicons of two different sizes were generated from LS180 genomic DNA; the expected 2.8
Kb fragment and a smaller fragment with an internal 863 nt deletion, from -1008 to -146 relative
to the transcription start site. However, only the smaller fragment was detected in MCF10A cells
indicating that there was variability in the SULT1C3 5’-flanking sequence among sources of
genomic DNA. We also detected a variant allele that has the same 863 nt deleted in the genome
of 59 individuals. This sequence variability appears to be attributable to a deletion polymorphism
because the 1000 Genomes Project includes this structural variant in its database (esv3591922)
(Genomes Project et al., 2012). Since this deletion region contains a functional PPARγ binding
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site, it is plausible that SULT1C3 expression may vary among individuals depending on whether
they carry the variant allele.
The three PPARs are expressed in fetal and adult human intestine (Abbott et al., 2010), and
we have shown that PPARα and PPARγ are expressed in LS180 cells (PPARδ was not evaluated)
(Rondini et al., 2014). In the current investigation we found that rosiglitazone, a potent and
selective PPARγ agonist, significantly increased the activities of luciferase reporter plasmids
containing the deletion region of the SULT1C3 5’-flanking region (i.e., the 2.8 Kb and 1 Kb
reporters). Although the luciferase activity of these reporters was also increased by PPARα and
PPARδ agonist treatments, these effects were probably attributable to cross-activation of PPARγ
since (1) relatively high concentrations of the PPARα and PPARδ agonists were needed to induce
the reporter activity and (2) siRNA targeting PPARγ abolished reporter activation by all PPAR
agonists while siRNA targeting PPARα or PPARδ had little effect. These data indicate that PPARγ
is the predominant PPAR that regulates SULT1C3 transcription in LS180 cells.
PPARγ is highly expressed in the various regions of human intestine, at levels that are
comparable to those detected in adipocytes, and this transcription factor could play a role in
gastrointestinal morphogenesis during fetal development (Fajas et al., 1997; Huin et al., 2000;
Abbott, 2009; Abbott et al., 2010). In human intestine, PPARγ signaling has been linked to growth
arrest, apoptosis, and differentiation (Gupta et al., 2001; Gupta et al., 2003; Thompson, 2007). In
human colon cancer cells, PPARγ-regulated genes have been classified into three functional
categories: regulation of lipid metabolism, signal transduction, and motility and adhesion (Chen
et al., 2006; Bush et al., 2007; Su et al., 2007). SULT1C3 could play a role in intestinal physiology
by metabolizing one or more endogenous molecules that function in the regulation of these
PPARγ-regulated processes.
In summary, we have identified a functional PPRE in the 5’-flanking region of the SULT1C3
gene, thereby establishing SULT1C3 as a direct PPARγ target in intestinal cells. This finding
implies that SULT1C3 could play a role in PPARγ-regulated processes associated with intestinal
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development and function. Since the PPRE is located within a polymorphic region of the
SULT1C3 gene, our findings also provide a mechanistic rationale to hypothesize that there could
be considerable differences among individuals in the intestinal expression of SULT1C3. Further
studies are needed to establish the genotype-phenotype relationship between the presence of
the PPRE and intestinal SULT1C3 expression. The findings of our genotyping analysis and the
reports in 1000 Genomes Database indicated that the structural variant lacking the PPRE appears
to be a fairly common polymorphism (the overall allele frequency of esv3591922 in the 1000
Genomes Database is 0.3329). The data from the 1000 Genome Database demonstrated that
the frequency of this polymorphism varied among the different populations (frequencies of
esv3591922 for African, Ad Mixed American, East Asian, European, and South Asian super
populations of 0.2852, 0.3329, 0.1091, 0.4394, and 0.5184, respectively). It is possible that interindividual differences in intestinal SULT1C3 expression could have pharmacological and
toxicological implications, for example by modifying the risk for intestinal bioactivation of
procarcinogenic molecules.
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CHAPTER 6: FINAL CONCLUSIONS AND FUTURE DIRECTIONS
Eugen Baumann was the first to discover the process of sulfonation in 1876 (Baumann, 1876),
and since then a large number of xenobiotics and endogenous molecules have been found to be
conjugated with a sulfonate group, thereby modulating the activity of these molecules. SULT1
and SULT2 expression was detected in prenatal hepatic and extrahepatic tissues, suggesting that
these enzymes are responsible for the biotransformation of xenobiotics during fetal life (Barker et
al., 1994; Stanley et al., 2005; Duanmu et al., 2006). However, none of these studies performed
a comprehensive analysis of SULT expression that includes the understudied SULTs, such as
the SULT1Cs, or identified signaling pathways that regulate the expression of these enzymes in
differentiating hepatocytes or intestinal cells. For this reason, we (1) examined the role of lipidand xenobiotic-sensing transcription factors in the regulation of SULT expression using in vitro
models of human liver development, (2) determined the expression profiles of SULT1 and SULT2
mRNA and protein in prenatal and postnatal liver specimens and cytosolic fractions, (3) examined
the expression profile of SULT1C4 TVs in the developing human liver, and (4) determined the
mechanism involved in the transcriptional regulation of SULT1C3 by PPARγ.
Based on previous studies, we hypothesized that (1) most SULT1 and SULT2 mRNA and
protein are expressed in the immature liver and that these enzymes are expressed with class I,
II, and III expression patterns (described in chapter 1) and (2) SULT1 and SULT2 expression is
regulated by lipid- and xenobiotic-sensing transcription factors. Our data demonstrated that
SULTs, primarily SULT1A1, SULT1C2, SULT1C4, SULT1E1, and SULT2A1, were abundantly
expressed in primary cultures of fetal hepatocytes, confluent HepaRG cells, and prenatal liver
specimens. We also classified the expression of individual SULTs into the three classes of
developmental expression patterns. Our results also indicated that SULT1 and SULT2 expression
was regulated by lipid- and xenobiotic-sensing nuclear receptors as well as AhR. These findings
suggest that SULT1 and SULT2 enzymes are part of regulatory networks that are involved in
mediating the effects of xenobiotics and endogenous molecules during early development, and
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further implicate SULT1 and SULT2 enzymes in the regulation of essential cellular functions in
the immature liver. To further confirm these observations, future work should examine the
regulation of the individual SULTs in models of human liver development that undergo a complex
differentiation process resembling that of human liver cells in vivo. Induced pluripotent stem cells
that can be induced to differentiate into hepatocyte-like cells and humanized mouse models that
express human SULT genes are models that can be used to investigate the regulatory
mechanisms controlling SULT expression and to study their role in hepatocyte differentiation. It
will also be interesting to determine some of the substrates that are metabolized by SULT1 and
SULT2 enzymes in the differentiating liver cells to help us understand the physiological
importance of these enzymes.
Current evidence suggests that SULT1C4 is primarily expressed in fetal tissues (Sakakibara
et al., 1998). In this project we found that SULT1C4 mRNA is abundantly expressed in primary
fetal hepatocytes, confluent HepaRG cells, and prenatal liver specimens, but the protein levels
are very low throughout development. Based on our data, we believe that the inconsistency
between SULT1C4 mRNA and protein levels is due to the low translation efficiency or decreased
stability of the protein made from SULT1C4 TV2, which is the most abundant TV at the mRNA
level. Future experiments should include examining the stability of the SULT1C4 TV1 and TV2
protein that could explain the lack of correlation in the abundance of TV1 and TV2 mRNA and
protein. We are currently working on developing an ELISA assay that will allow us to examine
TV1 and TV2 protein stability by pulse labeling with a non-radiolabeled modified amino acid. Since
our findings suggest that SULT1C4 does not play an important metabolic role in the liver, further
studies using extrahepatic tissues is needed to examine the role of SULT1C4 in other tissues.
Finally, our work on SULT1C3 suggests that this enzyme is involved in regulating intestinal
processes that are controlled by PPARγ. Our data also indicate that a genetic variation in the
SULT1C3 promoter region affects the regulation of SULT1C3 by PPARγ. To identify the biological
pathways that are regulated by SULT1C3, future studies should focus on identifying target genes
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and substrates that are regulated by SULT1C3 expression using human intestinal in vitro models,
tissue specimens, and humanized mouse models. Experiments examining the correlation
between SULT1C3 genotype and phenotype in human intestinal tissues could also elucidate the
impact of this allelic variation on SULT1C3 expression.
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APPENDIX D: CHARACTERISTICS OF FETAL HEPATOCYTES DONORS

Tissue ID

Gestational Age

Sex

Hepatocyte Viability
at Isolation

HFet#100

12 Weeks

Female

90%

HFet#101

14 Weeks

Female

90%

HFet#104

18 Weeks

Female

87%

HFet#105

18 Weeks

Female

90%

HFet#106

22 Weeks

Male

88%

permission from (Dubaisi et al., 2018)

Table taken with
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APPENDIX E: TARGETS AND TREATMENT CONSENTRATIONS OF AGONISTS USED IN
CHAPTERS 2 AND 5

Agonist

Target Pathway

TCDD

AhR

CITCO
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GW3965

LXR

Rifampicin

PXR

CDCA

FXR

GW4064

FXR

Ciprofibrate

PPARa

GW7647

PPARa

GW0742

PPARd

Rosiglitazone

PPARg

VitD3

VDR

TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; AhR, aryl hydrocarbon receptor; CITCO, 6-(4chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime; CAR,
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farnesoid X receptor; GW7647, 2-[[4-[2-[[(cyclohexylamino)carbonyl](4cyclohexylbutyl)amino]ethyl]phenyl]thio]-2-methylpropanoic acid; GW0742, 4-[[[2-[3-fluoro-4(trifluoromethyl)phenyl]-4-methyl-5-thiazolyl]methyl]-thio]-2-methylphenoxyacetic acid; PPAR,
peroxisome proliferator-activated receptor; VDR, vitamin D receptor; VitD3, 1α,25dihydroxyvitamin D3
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APPENDIX F: TAQMAN GENE EXPRESSION ASSAYS USED IN CHAPTERS 2 AND 3.

Gene

TaqMan Assay ID

CYP1A1

Hs00153120_m1

CYP2B6

Hs04183483_g1

CYP3A4

Hs00604506_m1

CYP3A7

Hs00426361_m1

PLIN2

Hs00605340_m1

SHP

Hs00222677_m1

SREBP1

Hs01088679_g1

SULT1A1- TV5

Hs00738644_m1

SULT1A1- TV1

APFVK4A1

SULT1A1- TV1 to 4

Hs00742033_mH

SULT1B1

Hs00234899_m1

SULT1C2

Hs00602560_m1

SULT1C3

Hs01371045_m1

SULT1C4

Hs00923769_m1

SULT1E1

Hs00193690_m1

SULT2A1

Hs00234219_m1

SULT2B1

Hs00190268_m1

18S

4319413E

GAPDH

4326317E

TBP

4310891E

Table taken with permission from (Dubaisi et al., 2018)
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APPENDIX G: PRIMERS USED FOR THE RACE ANALYSIS AND TO PREPARE SULT1C4
REPORTER CONSTRUCTS

Primer name

Sequence

RACE Reverse

5’-TCC AAG CCA AGC CTG ATG ACC TGC T-3’

2.2 Kb Forward

5’-GGC AGT TTA AAT TCA AAC CCA-3’

2.2 Kb Reverse

5’-GTG GTA GTG TGG TGG ATA GAG TGC T-3’

Fragment A Forward

5’-GAG CTC GCT AGC CTC GAG CTT CCT CTT GCT TCG GTT TCA AGT -3’

Fragment A Reverse

5’-GGA TCT GAA TCT CTC GAG GTG ATC TTG ACT ACA AAC ACT GCT C-3’

Fragment B Forward
Fragment B Reverse

5’-GAG CTC GCT AGC CTC GAG CAC AGT GAG AAG CCT GTA CTA AGG GA3’
5’-GGA TCT GAA TCT CTC GAG GGA GAG TGA GCT AAG CCT GTG T-3’

Fragment C Forward

5’-GAG CTC GCT AGC CTC GAG ACC CAT GTG GTT CCT TGT AAC ACT -3’

Fragment C Reverse

5’-GGA TCT GAA TCT CTC GAG GTG CTG CCT GTC TAT CAT GGG TC-3’

Fragment D Forward

5’-GAG CTC GCT AGC CTC GAG AAT CCG AAC ACC AGA CTC TTC TGA-3’

Fragment D Reverse

5’-GAG CTC GCT AGC CTC GAG GGG AAA TGG TCC TGG GTA TGT GT -3’

Fragment E Forward

5’-GAG CTC GCT AGC CTC GAG AGT GAG ATC ACA CCC CAT GAA G -3’

Fragment E Reverse

5’-GGA TCT GAA TCT CTC GAG TGG AGA TTC AAA GTG TCT CAA AGT-3’

Fragment F Forward

5’-GAG CTC GCT AGC CTC GAG GGC ATG TCT TTC TAT ATG GAT GTG G-3’

Fragment F Reverse

5’-GGA TCT GAA TCT CTC GAG AGC CAG GTA ATT GGG AAT TGG T -3’

Fragment G Forward

5’-GAG CTC GCT AGC CTC GAG TGT GAT AAA TGC AAG TGA GGT TGG-3’

Fragment G Reverse

5’-GAG CTC GCT AGC CTC GAG GGG AGA GGC AAT GCT TTA AAT TTG T-3’

Fragment H Forward

5’-GAG CTC GCT AGC CTC GAG TCT AAA GGA GAG GAC AGA GGA AGA -3’

Fragment H Reverse

5’-GAG CTC GCT AGC CTC GAG GCT TCC TTA GAG AAG GGG ATT TCA-3’

Fragment I Forward

5’-GAG CTC GCT AGC CTC GAG TGG CAC TAC AAT GGC TTC TAA TCA-3’

Fragment I Reverse

5’-GAG CTC GCT AGC CTC GAG AGA TCT GAG ATT CCC CTT GCT TTT-3’

Note: The sequences in bold were added to all primers that were used with the In-Fusion HD
Cloning Kit to PCR amplify and fuse the fragments with the linearized PGL4.10 reporter plasmid
containing the core promoter.
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APPENDIX H: EXPRESSION OF SULT mRNA IN THE DIFFERENTIATING HIOs

Temporal expression of SULTs during the differentiation of ESCs into HIOs. Cells were
harvested on the indicated time points for measurement of mRNA levels. mRNA levels were
normalized to the levels measured in the HIOs. The data show the expression patterns of seven
cytosolic SULTs from the ESCs, DE, HG (treated with FGF for 4 and 6 days), and HIOs. The
cycle threshold (Ct) values for the various genes are shown below the x-axis. 3 wells were
pooled together for the ESCs, DE, and HG samples and multiple HIOs were pooled in 1 sample.
Data were normalized to GAPDH. Similar results were obtained from a second experiment.
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APPENDIX I: DONOR INFORMATION FOR SAMPLES ANALYZED BY RT-QPCR

Developmental
Stage

Prenatal

Infant

Adult

Sample ID
34
40
42
235
246
276
317
893
1330
1390
75
82
83
326
1102
1472
1490
289
602
819
1021
1028
1539
5611

Sex
Female
Female
Female
Female
Male
Male
Male
Female
Female
Female
Male
Male
Male
Female
Male
Female
Female
Male
Male
Male
Male
Male
Female
Female

Prenatal Age

Postnatal Age

18 weeks
18 weeks
18 weeks
19 weeks
19 weeks
18 weeks
19 weeks
19 weeks
18 weeks
18 weeks
96 days
137 days
69 days
66 days
119 days
118 days
70 days
24 years, 362 days
27 years, 42 days
18 years, 217 days
19 years, 242 days
39 years, 11 days
33 years, 177 days
50 years, 183 days

Postmortem
Interval
(hours)
1
1
1
1
1
1
1
2
2
1
36
37
27
19
22
19
23
5
15
28
14
14
23
15
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APPENDIX J: DONOR INFORMATION FOR SAMPLES ANALYZED BY RNA-SEQ

Developmental
Stage

Prenatal

Infant

Child

Sample ID
20636
21248
21251
21432
21601
21605
21806
21883
21949
21978
86
432
435
569
759
774
780
825
1055
1157
1281
1296
1325
1547
64
346
617
677
689
792
872
885
1860
8902
8906
8910
8917
8920
8924
8925
8926
8935
9003
9006
9011
9013
9023
9027
9032

Sex
Male
Female
Male
Male
Male
Male
Female
Male
Female
Female
Male
Male
Male
Male
Male
Male
Male
Male
Male
Female
Male
Male
Female
Male
Male
Male
Female
Male
Female
Male
Male
Male
Male
Male
Male
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Male

Prenatal Age

Postnatal Age

14.7 weeks
14.7 weeks
14.7 weeks
16.1 weeks
16.4 weeks
14.7 weeks
16.4 weeks
16.4 weeks
16.1 weeks
15.6 weeks
56 days
4 days
274 days
133 days
35 days
273 days
0 days
334 days
96 days
20 days
206 days
98 days
182 days
259 days
15 years
3 years
1 year, 347 days
1 year, 353 days
5 years
4 years
2 years
17 years
8 years, 2 days
7 years
12 years
14 years
6 years
11 years
9 years
8 years
1 year, 304 days
17 years
7 years
10 years
3 years, 183 days
11 years
2 years, 213 days
12 years
14 years

Postmortem
Interval (hours)
<2
<2
<2
<2
<2
<2
<2
<2
<2
<2
11
2
10
16
7
10
13
11
12
14
6
16
18
10
13
11.17
9
13
19.5
14.5
14.5
12.5
5
Surgical specimen
Surgical specimen
Surgical specimen
Surgical specimen
Surgical specimen
Surgical specimen
Surgical specimen
Surgical specimen
Surgical specimen
Surgical specimen
Surgical specimen
Surgical specimen
Surgical specimen
Surgical specimen
Surgical specimen
Surgical specimen
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9036
9101
9127
9608
9609
9611
9612
70898
70994
71000
71008
71058
71281

Female
Male
Male
Male
Male
Male
Male
Male
Male
Male
Male
Female
Male

5 years
2 years
15 years
4 years
4 years
9 years
3 years
7 years
16 years
6 years
13 years
10 years
16 years

Surgical specimen
Surgical specimen
Surgical specimen
Surgical specimen
Surgical specimen
Surgical specimen
Surgical specimen
Not recorded
24
12
24
15
15
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APPENDIX K: MULTIPLE REACTION MONITORING (MRM) SETTINGS FOR SULT
PROTEINS

Parent
Protein

Peptide

SULT1A1
SULT1A1
SULT1A1
SULT1A1
SULT1A1
SULT1A1
SULT1A2
SULT1A2
SULT1A2
SULT1A2
SULT1A2
SULT1A2
SULT1A3
SULT1A3
SULT1A3
SULT1A3
SULT1A3
SULT1A3
SULT1A3
SULT1A3
SULT1B1
SULT1B1
SULT1B1
SULT1B1
SULT1B1
SULT1B1
SULT1C2
SULT1C2
SULT1C2
SULT1C2
SULT1C2
SULT1C2
SULT1C4

VHPEPGTWDSFLEK
VHPEPGTWDSFLEK
VHPEPGTWDSFLEK
VHPEPGTWDSFLEK
VHPEPGTWDSFLEK
VHPEPGTWDSFLEK
VYPHPGTWESFLEK
VYPHPGTWESFLEK
VYPHPGTWESFLEK
VYPHPGTWESFLEK
VYPHPGTWESFLEK
VYPHPGTWESFLEK
AHPEPGTWDSFLEK
AHPEPGTWDSFLEK
AHPEPGTWDSFLEK
AHPEPGTWDSFLEK
AHPEPGTWDSFLEK
AHPEPGTWDSFLEK
AHPEPGTWDSFLEK
AHPEPGTWDSFLEK
NLNDEILDR
NLNDEILDR
NLNDEILDR
NLNDEILDR
NLNDEILDR
NLNDEILDR
IVQETSFEK
IVQETSFEK
IVQETSFEK
IVQETSFEK
IVQETSFEK
IVQETSFEK
IVHYTSFDVMK

Collision
Energy
(%)
23
16
23
16
35
35
19
12
19
19
12
19
24
15
15
15
24
15
15
15
19
21
19
19
21
19
18
16
14
18
16
14
20

Transition

Label

m/z

z

Fragment

m/z

z

light
light
heavy
heavy
light
heavy
light
light
light
heavy
heavy
heavy
light
light
light
light
heavy
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light

547.935
547.935
550.606
550.606
821.399
825.406
563.947
563.947
563.947
566.619
566.619
566.619
538.591
538.591
538.591
538.591
541.263
541.263
541.263
541.263
551.280
551.280
551.280
556.285
556.285
556.285
540.782
540.782
540.782
544.789
544.789
544.789
447.229

3
3
3
3
2
2
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
3

b2
y6
b2
y6
b2
b2
y5
y12
y10
y5
y12
y10
b2
y5
b7
y6
b2
y5
b7
y6
b2
y3
y7
b2
y3
y7
y5
y6
y7
y5
y6
y7
y2

237.135
738.367
237.135
746.381
237.135
237.135
623.340
714.351
1193.584
631.354
718.358
1201.598
209.103
623.340
690.321
738.367
209.103
631.354
690.321
746.381
228.134
403.230
874.426
228.134
413.238
884.435
611.304
740.346
868.405
619.318
748.360
876.419
278.153

1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1

138
SULT1C4
SULT1C4
SULT1C4
SULT1C4
SULT1C4
SULT1E1
SULT1E1
SULT1E1
SULT1E1
SULT1E1
SULT1E1
SULT2A1
SULT2A1
SULT2A1
SULT2A1
SULT2A1
SULT2A1

IVHYTSFDVMK
IVHYTSFDVMK
IVHYTSFDVMK
IVHYTSFDVMK
IVHYTSFDVMK
KPSEELVDR
KPSEELVDR
KPSEELVDR
KPSEELVDR
KPSEELVDR
KPSEELVDR
DEDVIILTYPK
DEDVIILTYPK
DEDVIILTYPK
DEDVIILTYPK
DEDVIILTYPK
DEDVIILTYPK

23
13
20
23
13
22
26
26
22
26
26
19
18
19
19
18
19

light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy
light
light
light
heavy
heavy
heavy

447.229
447.229
449.900
449.900
449.900
536.785
536.785
536.785
541.789
541.789
541.789
653.350
653.350
653.350
657.358
657.358
657.358

3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2

b3
y4
y2
b3
y4
y8
y7
y8
y8
y7
y8
y6
y7
y8
y6
y7
y8

350.219
492.249
286.167
350.219
500.263
472.738
847.416
944.468
477.742
857.424
954.477
734.445
847.529
946.597
742.459
855.543
954.611

1
1
1
1
1
2
1
1
2
1
1
1
1
1
1
1
1
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APPENDIX L: CORRELATION ANALYSES FOR RNA-SEQ DATA FROM CHAPTER 3

Correlation between SULT1A1, SULT1B1, and SULT1C4 expression measured by RT-PCR
in prenatal liver. SULT1A1, SULT1B1, and SULT1C4 expression from the prenatal samples
(n=10) were analyzed using using pairwaise correlation analysis. Each scatter plot shows the
expression data of one gene against another. The R2 values from the correlation analysis are
indicated.
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APPENDIX M: PROTEIN QUANTIFICATION DATA FROM CHAPTER 3 PRESENTED AS
SCATTER PLOTS
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SULT1C4

150

150

150

100

0

Fmol/mg

200

50

100
50
0

8 11 14 17 20 23 26 29 32 35 38 41
EGA (weeks)

3

6
9
PNA (months)

0

12

4000

4000

4000

3000
2000

1000

1000

0

0

8 11 14 17 20 23 26 29 32 35 38 41
EGA (weeks)

Fmol/mg

5000

2000

0

3

6
9
PNA (months)

0

12

0

3

SULT2A1

900

Fmol/mg

900

Fmol/mg

900

600
300
0

6
9
12
PNA (years)

15

18

15

18

SULT2A1
1200

8 11 14 17 20 23 26 29 32 35 38 41
EGA (weeks)

18

2000

1200

0

15

1000

SULT2A1

300

9
12
PNA (years)

3000

1200

600

6

SULT1E1

5000

3000

3

SULT1E1

5000

Fmol/mg

Fmol/mg

100
50

SULT1E1

Fmol/mg

SULT1C4

200

Fmol/mg

Fmol/mg

SULT1C4
200

600
300

0

3

6
9
PNA (months)

12

0

0

3

6
9
12
PNA (years)

Developmental expression of SULT protein in human liver cytosols analyzed by MRM.
SULT protein contents (fmol/mg) are shown as scatter plots against age of the donor. Age was
divided into three groups: prenatal [estimated gestational age (EGA) in weeks (left)], infant
[postnatal age (PNA) in months (middle)], and 1-18 years-old (PNA in years, right).
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APPENDIX N: PERMISSION TO REPUBLISH FIGURES AND TABLES IN CHAPTER 5
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SULTs are conjugation enzymes that can modify the activity of a myriad of foreign and
endogenous molecules. SULT expression was detected in various human tissues, including liver,
small intestine, and colon. There are 13 human SULT genes that are classified into 4 families,
SULT1, SULT2, SULT4, and SULT6. In humans, SULT1 and SULT2 families include 11 genes
that are further divided into 6 subfamilies. In addition to their role in xenobiotic detoxification and
regulation of physiological processes, SULT enzymes were implicated in the bioactivation of
procarcinogens. Previous studies detected the expression of most SULT1 and SULT2 enzymes
during early development, as early as the embryonic stage. There is limited information about the
developmental expression profiles and regulation of SULT1 and SULT2 enzymes in the liver and
intestine. The objective of this study was to gain more insight into the roles of SULT1 and SULT2
enzymes during prenatal and postnatal periods in the two main metabolic organs, liver and
intestine. To learn more about the regulation of SULT mRNA in differentiating liver cells, we first
characterized their expression in primary cultures of human fetal hepatocytes and the HepaRG
model of liver cell differentiation, and then examined the effect of treatment with activators of lipidand xenobiotic-sensing receptors on SULT expression in these in vitro models. Using RT-qPCR
analysis we demonstrated that SULT1A1 (transcript variants 1, TV1), SULT1C2, SULT1C4,
SULT1E1, and SULT2A1 mRNA was the most abundant in human fetal hepatocytes. In HepaRG

178
cells, SULT1C2 and SULT1E1 mRNA and protein increased during the transition from
proliferation to confluency and then decreased as the cells underwent further differentiation
whereas SULT2A1 mRNA and protein increased during differentiation. Like SULT1C2, SULT1C3,
SULT1C4, and SULT1B1 mRNA levels were highest in the confluency stage. SULT1A1 and
SULT2B1 mRNA levels remined relatively constant. Treatment of fetal hepatocytes as well as
confluent and differentiating HepaRG cells with activators of aryl hydrocarbon receptor,
constitutive androstane receptor, liver X receptor, peroxisome proliferator-activated receptors
(PPARs), pregnane X receptor, and vitamin D receptor indicated that SULT1 and SULT2 mRNA
is regulated by xenobiotic stimuli.
We also determined the developmental expression profiles of SULT expression in libraries of
human liver specimens and cytosols that were collected from prenatal and postnatal (i.e. infants,
children 1-18 years-old, and adults) donors using RT-PCR and RNA-seq analysis to measure
SULT mRNA and multiple monitoring reaction (MRM) analysis for SULT protein quantification. In
this dissertation we reported that SULT1A1 expression did not vary substantially during
development; SULT1A3, SULT1C2, SULT1C4, and SULT1E1 expression was highest in prenatal
and/or infant specimens; SULT1A2 and SULT2A1 expression was highest postnatally; and
SULT1B1 mRNA, as determined by RT-qPCR analysis and protein appears to be highest in
children and adults. SULT1A1 (TV5), SULT1C3, and SULT2B1 mRNA levels were low regardless
of developmental stage. SULT1C4 mRNA was most abundant in the prenatal livers, but the
protein levels were very low. To investigate the reason for this discrepancy we measured the
mRNA levels of SULT1C4 TVs in the same human liver specimens described above and
determined whether the individual variants can be translated into protein. Using RT-qPCR and
RNA-seq analyses we detected at least four SULT1C4 transcript variants, including TV1, TV2,
E3DEL, which were detected in the intestinal and hepatic cell lines we examined. These TVs were
preferentially expressed in prenatal liver and TV2 was the most abundant of all. Using Western
blot analysis we found that only TV1 and TV2 are translated into protein, but TV2 protein was
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much lower than that of TV1. This finding suggests that TV2 is either less efficiently translated
into protein than is TV1 or that the TV2 protein is more rapidly degraded, and thus could explain
the lack of correlation between SULT1C4 mRNA and protein level. Therefore, we conclude that
SULT1 and SULT2 expression is modulated by xenobiotics and that most of these enzymes play
an important role in hepatic metabolism, especially during early life stages.
Lastly, we examined the mechanism underlying the transcriptional regulation of SULT1C3,
which is one of the least studied SULTs, by PPARg. While attempting to amplify a 2.8 Kb fragment
from different sources of human genomic DNA, a 1.9 Kb fragment was sometimes co-amplified
with the expected 2.8 Kb fragment. When aligning the 1.9 Kb fragment sequence to the published
SULT1C3 5’-flanking sequence an 863 nt deletion (nt -146 to -1008 relative to the transcription
start site) was revealed. Transfection of reporter plasmids containing the 2.8 and 1.9 Kb fragments
into LS180 cells followed by treatment with PPARα, δ, and γ induced the luciferase expression of
the 2.8 but not the 1.9 Kb construct and indicated that the 863 nt deletion region was sufficient to
confer PPAR-inducible reporter expression. Three putative PPAR-response elements (PPRE)
were identified by computational analysis. Serial deletions, site-directed mutations, and RNA
interference analysis demonstrated that only the distal PPRE (at nt -769) was required to mediate
PPARg transcriptional activation of SULT1C3. Genotyping analysis revealed that a similar
deletion exist in the human genome. These findings suggest that SULT1C3 play a role in the
regulation of PPARg-controlled pathways.
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